ifosfamide and Sarcoma, Epithelioid
ifosfamide has been researched along with Sarcoma, Epithelioid in 496 studies
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"The results of the association of doxorubicin plus ifosfamide in the treatment of locally advanced and/or metastatic adult soft tissue sarcomas as reported in the literature from 1986 up to the present time are reviewed." | 10.17 | Doxorubicin (or epidoxorubicin) combined with ifosfamide in the treatment of adult advanced soft tissue sarcomas. ( Palumbo, R; Santi, L; Sogno, G; Toma, S; Venturino, A, 1992) |
"This randomised phase II/III trial aimed to determine whether perioperative chemotherapy with gemcitabine plus docetaxel (GD) is non-inferior to the standard Adriamycin plus ifosfamide (AI) in terms of overall survival (OS) in patients with soft tissue sarcoma (STS)." | 9.51 | Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306. ( Abe, S; Akisue, T; Asanuma, K; Emori, M; Fukuda, H; Furuta, T; Hatano, H; Hiraga, H; Hiraoka, K; Hiruma, T; Iwamoto, Y; Katagiri, H; Kataoka, T; Kawai, A; Kawano, M; Kawashima, H; Machida, R; Matsumoto, Y; Morii, T; Nagano, A; Nakayama, R; Nishida, Y; Okuma, T; Outani, H; Ozaki, T; Suehara, Y; Takenaka, S; Takeyama, M; Tanaka, K; Toguchida, J; Tsukushi, S; Watanuki, M; Yamamoto, T; Yonemoto, T, 2022) |
"This prospective single-arm phase II clinical trial aimed to evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) combined with ifosfamide (IFO) as the first-line treatment for patients with advanced or metastatic soft-tissue sarcoma (STS)." | 9.51 | Pegylated Liposomal Doxorubicin Combined with Ifosfamide for Treating Advanced or Metastatic Soft-tissue Sarcoma: A Prospective, Single-arm Phase II Study. ( Chen, H; Chen, Y; Huang, M; Jiang, S; Liu, X; Luo, Z; Miao, J; Wang, C; Wang, H; Wang, J; Wu, X; Xia, J; Xu, Y; Yan, W; Yao, W; Yu, L; Zhang, X, 2022) |
"Pazopanib and gemcitabine have shown good tolerability, albeit modest single-agent activity in pretreated soft tissue sarcoma." | 9.41 | Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial. ( Crysandt, M; Cygon, F; Egerer, G; Eigendorff, E; Heißner, K; Kasper, B; Kessler, T; Kopp, HG; Kunitz, A; Lindner, LH; Mayer-Steinacker, R; Meinert, F; Niederwieser, D; Petersen, I; Reichardt, P; Rüssel, J; Schmoll, HJ; Steighardt, J; Stein, A, 2021) |
"EORTC-1506-STBSG was a prospective, multicentric, randomised, open-label phase 2 trial to assess the efficacy and safety of second-line nintedanib versus ifosfamide in patients with advanced, inoperable metastatic soft tissue sarcoma (STS)." | 9.41 | Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC- ( Bovée, JVMG; Brahmi, M; Charon-Barra, C; Cousin, S; de Haan, J; De Meulemeester, L; Domènech, M; Dudzisz-Śledź, M; Estival, A; Gelderblom, H; Karavasilis, V; Litière, S; Marquina, G; Marreaud, S; Olungu, C; Schöffski, P; Steeghs, N; Toulmonde, M; Wozniak, A, 2021) |
" This phase II trial was performed to evaluate the activity and the safety of NPLD and ifosfamide combination in patients with metastatic soft tissue sarcoma." | 9.20 | Non-pegylated liposomal doxorubicin plus ifosfamide in metastatic soft tissue sarcoma: results from a phase-II trial. ( Basso, U; Bertuzzi, A; Colombo, P; Comandone, A; De Sanctis, R; Giordano, L; Lutman, RF; Marchetti, S; Marrari, A; Santoro, A, 2015) |
" Patients aged 18 years and older with metastatic soft-tissue sarcomas, an Eastern Cooperative Oncology Group performance status of 0-2, and who had previously received treatment with anthracycline and ifosfamide were randomly assigned (1:1) to intravenous infusion of ombrabulin 25 mg/m(2) plus cisplatin 75 mg/m(2) or intravenous infusion of placebo plus cisplatin 75 mg/m(2) every 3 weeks." | 9.20 | Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial. ( Babovic, N; Blay, JY; Bompas, E; Chawla, SP; Cohen, P; Cupissol, D; Demetri, GD; Franke, FA; Isambert, N; Italiano, A; Le-Guennec, S; López-Pousa, A; Pápai, Z; Penel, N; Saâda-Bouzid, E; Santoro, A; Staddon, AP; Tolcher, AW, 2015) |
"Doxorubicin and ifosfamide (AI) is standard therapy for high-risk soft tissue sarcoma (STS) but often causes severe toxicities resulting in hospitalisation." | 9.20 | A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma. ( Baker, LH; Biermann, JS; Chugh, R; Davis, EJ; Feng, M; Jacobson, J; Lucas, DR; Metko, G; Reinke, D; Schuetze, SM; Wong, SL; Zalupski, MM; Zhao, L; Zyczynski, L, 2015) |
"This phase I trial assessed safety, pharmacokinetics (PK), dose limiting toxicity (DLT), maximum tolerated dose and recommended dose (RD) of the combination of sorafenib plus ifosfamide in patients with advanced sarcoma." | 9.19 | Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study. ( Brendel, E; Broto, JM; Cubedo, R; del Muro, XG; Gallego, O; López-Pousa, A; Martín-Liberal, J; Tirado, OM, 2014) |
"Effective targeted treatment is unavailable for most sarcomas and doxorubicin and ifosfamide-which have been used to treat soft-tissue sarcoma for more than 30 years-still have an important role." | 9.19 | Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. ( Alcindor, T; Blay, JY; dei Tos, AP; Fisher, C; Gelderblom, H; Hartmann, JT; Hermans, C; Hogendoorn, PC; Hohenberger, P; Judson, I; Kerst, JM; Krarup-Hansen, A; Litière, S; Marreaud, S; Schöffski, P; Sufliarsky, J; van der Graaf, WT; Verweij, J; Whelan, J, 2014) |
" Perioperative chemotherapy with adriamycin plus ifosfamide is the current standard treatment for T2bN0M0 high-grade non-round cell soft tissue sarcoma." | 9.19 | A randomized phase II/III trial of perioperative chemotherapy with adriamycin plus ifosfamide versus gemcitabine plus docetaxel for high-grade soft tissue sarcoma: Japan Clinical Oncology Group Study JCOG1306. ( Araki, N; Fukuda, H; Hiraga, H; Iwamoto, Y; Kataoka, K; Kawai, A; Kimura, A; Matsumine, A; Matsunobu, T; Mizusawa, J; Oda, Y; Tanaka, K, 2014) |
"The objective of this Phase I dose escalation study was to explore the safety and tolerability of eltrombopag, an oral, nonpeptide, thrombopoietin receptor agonist, in patients with advanced soft tissue sarcoma (STS) and thrombocytopenia due to treatment with doxorubicin and ifosfamide (AI) combination chemotherapy." | 9.17 | Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide. ( Chawla, SP; Hendifar, A; Kamel, YM; Messam, CA; Patwardhan, R; Staddon, A, 2013) |
"This multicenter, phase II trial evaluated the efficacy and safety of everolimus, an mTOR inhibitor, in patients with metastatic or recurrent bone and soft-tissue sarcoma after the failure of anthracycline- and ifosfamide-containing regimens." | 9.17 | Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide. ( Ahn, JH; Kim, TM; Kim, YJ; Lee, HJ; Lee, J; Lee, KH; Park, KH; Rha, SY; Yoo, C, 2013) |
"Doxorubicin and ifosfamide are highly active drugs for the treatment of high-grade sarcomas, but little is known on the optimal management of young patients who develop such malignancies during pregnancy." | 9.16 | Doxorubicin and ifosfamide for high-grade sarcoma during pregnancy. ( Berrada, N; Bonvalot, S; Boulet, B; Cioffi, A; Domont, J; Le Cesne, A; Lokiec, F; Mir, O; Terrier, P; Trichot, C, 2012) |
"Adjuvant chemotherapy with doxorubicin and ifosfamide in resected soft-tissue sarcoma showed no benefit in relapse-free survival or overall survival." | 9.16 | Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. ( Azzarelli, A; Bonvalot, S; Bramwell, VH; Hoekstra, HJ; Hogendoorn, PC; Hohenberger, P; Le Cesne, A; Leahy, M; Marreaud, S; Ouali, M; Reichardt, P; Van Coevorden, F; Verweij, J; Woll, PJ, 2012) |
"Ifosfamide and doxorubicin combination is an active regimen for patients with advanced soft tissue sarcomas (STS) but is burdened by high toxicity." | 9.15 | Optimizing clinical care in patients with advanced soft tissue sarcoma: a phase II study of a new schedule of high-dose continuous infusion ifosfamide and doxorubicin combination. ( Boni, C; Boselli, S; Catania, C; de Braud, F; De Pas, T; Delmonte, A; Frustaci, S; Noberasco, C; Radice, D; Rosati, G; Scalamogna, R; Spitaleri, G; Toffalorio, F; Tucci, A; Vecchio, F, 2011) |
"This phase II clinical trial aims to evaluate the efficacies and toxicities of pre- and postoperative chemotherapy with adriamycin plus ifosfamide on the patients with soft-tissue high-grade sarcomas." | 9.14 | Preoperative and postoperative chemotherapy with ifosfamide and adriamycin for adult high-grade soft-tissue sarcomas in the extremities: Japan Clinical Oncology Group Study JCOG0304. ( Fukuda, H; Iwamoto, Y; Kawamoto, H; Saito, I; Tanaka, K; Yoshimura, K, 2009) |
"To assess the progression-free survival (PFS) and antitumor response to standard-dose doxorubicin compared with sequential dose-dense doxorubicin and ifosfamide in first-line treatment of advanced soft tissue sarcoma." | 9.14 | Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas. ( Andrés, R; Balañá, C; Buesa, JM; Casado, A; Cruz, J; Cubedo, R; de la Cruz, JJ; de Las Peñas, R; Del Muro, XG; Fra, J; Gallego, O; Gómez, MA; López-Pousa, A; Martín, J; Martínez-Trufero, J; Maurel, J; Poveda, A; Rubió, J; Rubio-Viqueira, B; Sevilla, I, 2009) |
"The aim of this study was to evaluate the maximum tolerated dose (MTD) and safety of the combination of non- pegylated liposomal doxorubicin (Myocet) and ifosfamide in patients with metastatic soft tissue sarcomas." | 9.14 | Phase I study of non-pegylated liposomal doxorubicin in combination with ifosfamide in adult patients with metastatic soft tissue sarcomas. ( Barbato, A; Bertuzzi, A; Di Comite, G; Lutman, RF; Mussi, C; Santoro, A; Stroppa, E, 2010) |
"Ifosfamide is a cornerstone of chemotherapy in bone and soft-tissue sarcoma." | 9.14 | Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients. ( Alexandre, J; Anract, P; Billemont, B; Camps, S; Coriat, R; Goldwasser, F; Larousserie, F; Leconte, M; Mir, O; Ropert, S, 2010) |
"The objective of this study is to assess the effect of anthracyclines/ifosfamide-based adjuvant chemotherapy for soft tissue sarcoma (STS) and provide a relative ranking of regimens for STS." | 9.12 | Effect of anthracyclines/ifosfamide-based adjuvant chemotherapy for soft tissue sarcoma: a conventional and network Meta-analysis. ( Hua, Q; Xu, G; Zhang, T; Zhao, L, 2021) |
"High-dose ifosfamide plus doxorubicin is an active regimen for all subtypes of gynecological sarcomas." | 9.12 | Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas. ( Cerny, T; Dietrich, D; Fey, M; Honegger, HP; Jundt, G; Leyvraz, S; Lissoni, A; Sessa, C; Zweifel, M, 2006) |
"To determine clinical activity and toxic effects of ifosfamide when used to treat cats with vaccine-associated sarcoma (VAS)." | 9.12 | Results of a phase II clinical trial on the use of ifosfamide for treatment of cats with vaccine-associated sarcomas. ( Chaffin, K; Khanna, C; Kristal, O; Page, RL; Rassnick, KM; Rodriguez, CO; Rosenberg, MP, 2006) |
"In the prospective high-risk sarcoma (HIRISA) Phase II trial HIRISA1, pediatric patients with high-risk sarcomas received 3 cycles of intensive vincristine, ifosfamide, etoposide, cyclophosphamide, and doxorubicin (VACIE) before radiotherapy and/or surgery began at Week 9 with concurrent vincristine, cyclophosphamide, and doxorubicin (Week 9) and vincristine and ifosfamide (Week 12)." | 9.12 | Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience. ( Billups, CA; Cain, AM; Furman, WL; Hale, GA; Merchant, TE; Navid, F; Pappo, AS; Rao, BN; Santana, VM; Spunt, SL, 2006) |
"Based on the promising results of a Phase I study with a combination of gemcitabine and DTIC performed in advanced soft tissue sarcoma (ASTS) patients, and due to the limited efficacy of second or third line therapies in those patients, we designed a Phase II study to determine the activity of this new regimen." | 9.12 | Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. ( Buesa, JM; Del Muro, JG; Escudero, P; Esteban, E; Fra, J; Gión, M; Goitia, A; López-Pousa, A; Losa, R; Maurel, J; Nadal, R; Sierra, M; Uña, E, 2007) |
"This phase I study evaluated the toxicity of first-line combined pegylated liposomal doxorubicin (Caelyx) and ifosfamide in patients with advanced and/or metastatic soft tissue sarcomas." | 9.12 | Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas. ( Blay, J; Christensen, TB; Daugaard, S; Hermans, C; Judson, I; Marreaud, S; Nielsen, OS; Pink, D; Reichardt, P; van Glabbeke, M, 2006) |
"Having determined in a phase I study the maximum tolerated dose of high-dose ifosfamide combined with high-dose doxorubicin, we now report the long-term results of a phase II trial in advanced soft-tissue sarcomas." | 9.12 | Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies. ( Cerny, T; Christinat, A; Dietrich, D; Fey, MF; Guillou, L; Herrmann, R; Honegger, HP; Leyvraz, S; Pestalozzi, B; Sessa, C; Wernli, M, 2006) |
"This randomized prospective multicenter phase III trial was designed to compare progression-free survival of patients with advanced soft tissue sarcoma receiving either regimen of standard doxorubicin 75 mg/m2 every 21 days, ifosfamide 9 g/m2 over 3 days continuous infusion, or ifosfamide 3 g/m2 per day in 3 hours over 3 days." | 9.12 | Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. ( Blay, JY; Hogendoorn, PC; Kirkpatrick, A; Le Cesne, A; Leahy, MG; Lorigan, P; Papai, Z; Radford, JA; Rodenhuis, S; Van Glabbeke, MM; Verweij, J, 2007) |
"Combinations of high-dose ifosfamide (IF; 10-12 g/m2) plus doxorubicin (DX; 50-90 mg/m2) have been administered to patients with advanced soft tissue sarcoma (ASTS) in an attempt to improve therapeutic efficacy." | 9.11 | Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS). ( Balañá, C; Buesa, JM; Casado, A; de las Peñas, R; Fra, J; García del Muro, X; López-Pousa, A; Martín, J; Martínez-Trufero, J; Maurel, J, 2004) |
"5 g m(-2), carboplatin 100 mg m(-2) and etoposide 150 mg m(-2), days 1-4, q 28 days, G-CSF 5 microg kg(-1) starting from day 6) alone and in combination with regional hyperthermia (RHT) in soft tissue sarcoma (STS) refractory to previous standard doxorubicin-ifosfamide-based chemotherapy." | 9.11 | Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults. ( Abdel-Rahman, S; Fahn, W; Fiegl, M; Issels, RD; Schlemmer, M; Wendtner, CM, 2004) |
"Children with recurrent/refractory sarcoma were treated with ifosfamide (1,800 mg/m2/day on day 0-4), carboplatin (400 mg/m2/day on day 0-1), etoposide (100 mg/m2/day on day 0-4) and either rhG-CSF (10 microg/kg/day vs." | 9.11 | Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience. ( Anderson, B; Angiolillo, A; Cairo, MS; Cheung, YK; Davenport, V; Krailo, M; Reaman, G; Van Winkle, P, 2005) |
"The relative value of increasing ifosfamide dose in combination chemotherapy for patients with soft tissue sarcoma (STS) is unclear." | 9.11 | Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. ( Baker, LH; Biermann, JS; Chugh, R; Leu, KM; McGinn, CJ; Sondak, VK; Taylor, JM; Worden, FP; Zalupski, MM, 2005) |
"Ifosfamide and doxorubicin are the most effective agents in the treatment of sarcomas, although their contributions to survival are usually limited." | 9.11 | High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas. ( Akbulut, H; Buyukcelik, A; Demirkazik, A; Icli, F; Pamir, A; Utkan, G; Yalcin, B, 2004) |
"To describe the response rate and survival of children and adolescents with unresected or metastatic nonrhabdomyosarcomatous soft tissue sarcomas (NRSTS) treated with vincristine, ifosfamide, and doxorubicin." | 9.11 | Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study. ( Devidas, M; Gebhardt, M; Grier, HE; Jenkins, J; Marcus, R; Pappo, AS; Pratt, C; Rao, B; Thomas, P, 2005) |
"Doxorubicin and ifosfamide are the two most active agents used to treat soft tissue sarcomas." | 9.11 | Alternating sequential chemotherapy with high-dose ifosfamide and doxorubicin/cyclophosphamide for adult non-small round cell soft tissue sarcomas. ( Abe, S; Araki, N; Beppu, Y; Hasegawa, T; Ihara, K; Ishii, T; Isu, K; Kawai, A; Ozaki, T; Sugiura, H; Tsugane, S; Umeda, T; Wada, T; Yabe, H, 2005) |
"The anthracycline/ifosfamide combination is the most effective chemotherapy in soft tissue sarcoma." | 9.11 | Ifosfamide/liposomal daunorubicin is a well tolerated and active first-line chemotherapy regimen in advanced soft tissue sarcoma: results of a phase II study. ( Deckert, PM; Hütter, G; Keilholz, U; Schmittel, A; Siehl, JM; Szelényi, H; Thiel, E, 2005) |
"This randomized study compared the efficacy of epirubicin-based adjuvant chemotherapy on the disease-free interval (DFI) and overall survival of patients with high-risk soft-tissue sarcomas." | 9.10 | Adjuvant epirubicin with or without Ifosfamide for adult soft-tissue sarcoma. ( Civitelli, S; Coratti, A; Correale, P; D'Aniello, C; Francini, G; Grimaldi, L; Marsili, S; Marzocca, G; Messinese, S; Petrioli, R; Pirtoli, L; Tanzini, G, 2002) |
"The aim of this phase II study was to evaluate the efficacy and toxicity of two regimens of ifosfamide in metastatic soft tissue sarcoma patients given as first- and second-line chemotherapy." | 9.10 | Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. ( Dombernowsky, P; Hermans, C; Judson, I; Krzemieniecki, K; Mouridsen, HT; Nielsen, OS; Spooner, D; Svancarova, L; Van Glabbeke, M; van Oosterom, AT; Verweij, J, 2002) |
"The addition of ifosfamide and etoposide to a standard regimen does not affect the outcome for patients with metastatic disease, but it significantly improves the outcome for patients with nonmetastatic Ewing's sarcoma, primitive neuroectodermal tumor of bone, or primitive sarcoma of bone." | 9.10 | Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. ( Dickman, PS; Donaldson, SS; Fryer, CJ; Gebhardt, MC; Grier, HE; Krailo, MD; Link, MP; Meyers, PA; Miser, JS; Moore, S; Perlman, EJ; Pritchard, DJ; Rausen, AR; Tarbell, NJ; Vietti, TJ, 2003) |
"We conducted our study to determine the pharmacokinetics (PK) and clinical efficacy of oral mesna in patients receiving ifosfamide for soft tissue sarcoma." | 9.10 | Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide. ( Baker, LH; Bernardy, H; Demetri, G; Junge, K; Keohan, ML; Mace, JR; Mueller, U; Niebch, G; Romeis, P; Thoma, A; Wagner, T, 2003) |
"Between March 1994 and October 1997, 20 women and 19 men with primary extremity or limb girdle high-grade soft tissue sarcomas were registered to a study of preoperative ifosfamide, mitomycin, doxorubicin, cisplatin (IMAP) plus granulocyte macrophage-colony-stimulating factor (GM-CSF) followed by preoperative irradiation and subsequent limb-sparing surgery." | 9.10 | Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor. ( Buckner, JC; Edmonson, JH; Foo, ML; Gunderson, LL; Haddock, MG; Mahoney, MR; Maples, WJ; O'Connor, MI; Petersen, IA; Pritchard, DJ; Rock, MG; Shives, TC; Sim, FH; Stafford, SL, 2002) |
"To determine whether a prolonged 12-day continuous infusion allows the administration of high-dose ifosfamide (IFO) with an acceptable toxicity profile when combined with full-dose doxorubicin (Adriamycin; ADM) as first-line chemotherapy in patients with advanced soft tissue sarcomas." | 9.10 | Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas. ( Boni, C; Catania, C; Comandone, A; Curigliano, G; de Braud, F; De Pas, T; Marrocco, E; Masci, G; Pagani, O; Tucci, A, 2002) |
"This phase II study was designed to verify the activity and safety of an intensive epirubicin/ifosfamide schedule in untreated soft tissue sarcoma (STS) patients by using both the agents at the identified maximal tolerated doses." | 9.09 | Dose-intensive first-line chemotherapy with epirubicin and continuous infusion ifosfamide in adult patients with advanced soft tissue sarcomas: a phase II study. ( Bertero, G; Cosso, M; Neumaier, C; Palumbo, R; Pastorino, M; Raffo, P; Spadini, N; Toma, S; Valente, S; Villani, G, 1999) |
"The aim of this study was to assess the pharmacology, toxicity and activity of high-dose ifosfamide mesna +/- GM-CSF administered by a five-day continuous infusion at a total ifosfamide dose of 12-18 g/m2 in adult patients with advanced sarcomas." | 9.09 | Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK). ( Boddy, AV; Brunner, J; Cerny, T; Honegger, P; Küpfer, A; Leyvraz, S; Schaad, R; Schmitz, SF; Sessa, C; von Briel, T, 1999) |
"In this phase II study the effect of high-dose ifosfamide (HDI) given as a 3-day continuous infusion at a dose of 12 g/m2 repeated every 4 weeks with adequate mesna protection and hydration was evaluated in patients with advanced soft tissue sarcomas." | 9.09 | Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. ( Blay, JY; Hermans, C; Judson, I; Keizer, HJ; Krzemienlecki, K; le Cesne, A; Nielsen, OS; Oosterhuis, JW; Radford, JA; Svancárová, L; van Glabbeke, M; van Hoesel, Q; van Oosterom, A; Verweij, J, 2000) |
"The Soft Tissue and Bone Sarcoma Group (STBSG) of the EORTC ran a phase II study to assess the therapeutic activity of high-dose ifosfamide in patients with advanced soft tissue sarcomas by means of response rate (RR)." | 9.09 | Radiologist review versus group peer review of claimed responses in a phase II study on high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the EORTC Soft Tissue and Bone Sarcoma Group. ( Gwyther, SJ; Judson, IR; Nielsen, OS; van Glabbeke, M; Verweij, J, 2000) |
"The efficacy and feasibility of a novel sequential schedule of high-dose ifosfamide (HD-IFO) and full-dose epirubicin (EPI) with granulocyte colony-stimulating factor (G-CSF) was evaluated in adult patients with soft tissue sarcomas (STS)." | 9.09 | A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule. ( Cognetti, F; Gamucci, T; Nardi, M; Serrone, L; Zeuli, M, 2001) |
"The Epirubicin (EPI) and ifosfamide (IFO) combination has been widely tested in soft tissue sarcomas, even though the optimal schedule of drug administration has still to be defined." | 9.09 | Ifosfamide and epirubicin combination in untreated sarcomas: two treatment schedules. ( Cognetti, F; Nardoni, C; Pacetti, U; Papaldo, P; Serrone, L; Zeuli, M, 2001) |
"Patients with locally advanced or metastatic soft tissue sarcoma refractory to treatment with anthracyclines and ifosfamide were enrolled into the present phase II study." | 9.09 | Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial. ( Amann, G; Attems, Y; Brodowicz, T; Fiebiger, WC; Hejna, M; Köstler, WJ; Krainer, M; Tomek, S; Wiltschke, CH; Zielinski, CC, 2001) |
"The population pharmacokinetics and pharmacodynamics of the cytostatic agent ifosfamide and its main metabolites 2- and 3-dechloroethylifosfamide and 4-hydroxyifosfamide were assessed in patients with soft tissue sarcoma." | 9.09 | Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide and metabolites after a 72-h continuous infusion in patients with soft tissue sarcoma. ( Beijnen, JH; Keizer, HJ; Kerbusch, T; Mathĵt, RA; Ouwerkerk, J; Rodenhuis, S; Schellens, JH, 2001) |
"The study was designed to assess the toxicity and activity of high-dose ifosfamide (HDI) administered by continuous infusion at a dose of 4 g/m2/d over 3 days every 4 weeks in adult patients with advanced soft tissue sarcomas (ASTS) pretreated with doxorubicin and/or a standard-dose ifosfamide (SDI)-containing regimen." | 9.08 | High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. ( Antoine, E; Brain, E; Fontaine, F; Genin, J; Janin, N; Kayitalire, L; Le Cesne, A; Le Chevalier, T; Spielmann, M; Toussaint, C, 1995) |
"Ifosfamide, an oxazaphosphorine analogue, is now commonly used in first-line anthracycline-containing regimens for advanced soft tissue sarcomas, based on its demonstrated single-agent activity in previously treated patients." | 9.08 | High-dose ifosfamide in the treatment of advanced soft tissue sarcomas. ( Tursz, T, 1996) |
" ifosfamide (5 g/m2), carboplatin (300 mg/m2), and etoposide given with WBH, as well as, day 2 and 3 post-WBH (100 mg/m2) for adult patients with refractory sarcoma." | 9.08 | Ifosfamide, carboplatin and etoposide (ICE) combined with 41.8 degrees C whole body hyperthermia in patients with refractory sarcoma. ( Crahé, R; Deeken, M; Eleftheriadis, S; Gutsche, S; Katschinski, DM; Mentzel, M; Robins, HI; Storer, B; Wagner, T; Weiss, C; Wiedemann, GJ, 1996) |
"To evaluate the efficacy and feasibility of high-dose ifosfamide (HDI) at a total dose of 14 g/m2 per cycle with mesna in combination with granulocyte colony-stimulating factor (G-CSF) in adult patients with sarcomas." | 9.08 | High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. ( Benjamin, RS; Burgess, MA; Hays, C; Papadopolous, N; Patel, SR; Plager, C; Vadhan-Raj, S, 1997) |
"This Phase I/II study investigates increasingly high doses of ifosfamide combined with full dose doxorubicin chemotherapy supported with peripheral blood stem cells (PBSC) and granulocyte-colony stimulating factor (G-CSF) in patients with metastatic soft tissue sarcoma (STS)." | 9.08 | A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. ( Arseniev, L; Bokemeyer, C; Franzke, A; Hartmann, JT; Kanz, L; Link, H; Metzner, B; Schmoll, HJ; Schöber, C, 1997) |
"The purpose of this study was to evaluate tumour response and toxicity to ifosfamide and continuous infusion etoposide in metastatic or locally advanced soft tissue sarcoma, with dose escalations under G-CSF (granulocyte colony-stimulating factor) support." | 9.08 | Ifosfamide and continuous infusion etoposide in advanced adult soft tissue sarcoma. A Scandinavian Sarcoma Group Phase II Study. ( Alvegård, TA; Erlanson, M; Hannisdal, E; Klepp, R; Monge, OR; Raabe, N; Saeter, G; Söderberg, M; Solheim, OP; Strander, H; Turesson, I; Wist, E, 1997) |
"Ifosfamide has important activity in pretreated soft tissue sarcomas (STS), and recent data support a clinically significant dose-response relationship for this agent." | 9.08 | Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas. ( Antimi, M; Gatti, C; Palmeri, S; Palumbo, R; Raffo, P; Toma, S; Villani, G, 1997) |
"The authors evaluate the efficacy and feasibility of dose-intensive doxorubicin and ifosfamide combination chemotherapy in patients with sarcomas." | 9.08 | Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. ( Benjamin, RS; Burgess, MA; Jenkins, J; Papadopolous, N; Patel, SR; Plager, C; Vadhan-Raj, S, 1998) |
"The agent Ifosfamide (IFOS) is active against soft tissue sarcomas (STS), and patients who progress to IFOS at doses < or = 10 g/m2 show remissions when exposed to high-dose ifosfamide (HDI) (i." | 9.08 | Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS) ( Antón, A; Arranz, F; Bellmunt, J; Buesa, JM; Casado, A; Escudero, P; García del Muro, J; López-Pousa, A; Martín, J; Menéndez, D; Poveda, A; Valentí, V, 1998) |
"Ifosfamide and doxorubicin are the most active agents in the treatment of sarcomas and are characterized by a marked dose-response relationship." | 9.08 | Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK). ( Bacchi, M; Bressoud, A; Cerny, T; Hermann, R; Leyvraz, S; Lissoni, A; Sessa, C, 1998) |
"Adriamycin (ADM) and ifosfamide (IFO) are the two most active agents in the treatment of soft tissue sarcomas (STS) with a clear dose-response relationship." | 9.08 | High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible? ( Aapro, MS; De Braud, F; De Pas, T; Fazio, N; Goldhirsch, A; Munzone, E; Nolè, F; Orlando, L; Zampino, MG, 1998) |
"Ifosfamide is an active chemotherapeutic agent in the treatment of soft tissue sarcoma." | 9.07 | Ifosfamide and etoposide in the treatment of advanced soft tissue sarcomas. ( Baker, LH; Blair, SC; Zalupski, MM, 1994) |
"The purpose of this review is to characterize the nephrotoxicity noted in newly diagnosed patients under 21 years of age after treatment with ifosfamide-containing chemotherapy regimens and local irradiation for localized gross residual rhabdomyosarcoma or undifferentiated sarcoma." | 9.07 | Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor. ( Ensign, LG; Foreman, J; Khan, F; Maurer, H; Newton, W; Ortega, J; Ragab, A; Raney, B; Wharam, M; Wiener, E, 1994) |
"5 g/m2 mesna was administered for 7 days, both by continuous infusion, in combination with 50 mg/m2/d oral etoposide for 8 days in 21 patients with sarcomas or other solid tumors." | 9.07 | Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas. ( Hamdan, H; Skubitz, KM; Thompson, RC, 1993) |
"To evaluate the feasibility, toxicity and efficacy of the combination of (IFO) ifosfamide and epirubicin (EPI) given at conventional doses for monochemotherapy, we started a phase II study in advanced/metastatic soft tissue sarcoma patients." | 9.07 | Epirubicin and ifosfamide in advanced soft tissue sarcomas. ( Buonadonna, A; Carbone, A; Crivellari, D; De Paoli, A; Foladore, S; Frustaci, S; Monfardini, S; Morassut, S; Sorio, R, 1993) |
"This three-armed phase III study in adults with advanced soft tissue sarcomas was planned as a comparison of objective regression rates, toxicity, and survival of patients receiving doxorubicin alone, ifosfamide plus doxorubicin, and mitomycin plus doxorubicin plus cisplatin." | 9.07 | Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. ( Blum, RH; Brooks, JS; Edmonson, JH; Frytak, S; Parkinson, DR; Ryan, LM; Shiraki, M, 1993) |
"Doxorubicin alone or with dacarbazine (DTIC; AD) is considered the best available therapy for metastatic adult sarcomas." | 9.07 | An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. ( Antman, K; Balcerzak, SP; Barlogie, B; Cooper, RM; Crowley, J; Elias, A; Natale, RB; Rivkin, SE; Trump, DL; Weiss, GR, 1993) |
"The objective of this phase II trial was to assess the therapeutic activity and toxicity of doxorubicin plus ifosfamide in previously untreated patients with advanced soft-tissue sarcoma." | 9.07 | Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma. ( Blackledge, G; Dombernowsky, P; Mouridsen, HT; Santoro, A; Schütte, J; Somers, R; Steward, W; Thomas, D; van Oosterom, AT; Verweij, J, 1993) |
"A total of 51 patients with large, primary, high-grade soft-tissue sarcomas of the extremities were treated at our institute with two preoperative and three postoperative cycles of doxorubicin plus ifosfamide/mesna." | 9.07 | Preoperative doxorubicin plus ifosfamide in primary soft-tissue sarcomas of the extremities. ( Azzarelli, A; Casali, P; Fissi, S; Montalto, F; Quagliuolo, V; Santoro, A, 1993) |
"The Southwest Oncology Group (SWOG) performed a phase II trial of a combination of ifosfamide/mesna/cisplatin in patients with metastatic soft-tissue sarcoma who had previously received one chemotherapeutic regimen." | 9.07 | Phase II trial of ifosfamide and cisplatin in the treatment of metastatic sarcomas: a Southwest Oncology Group study. ( Balcerzak, SP; Budd, GT; Fabian, C; Metch, B; Stephens, RL; Weick, JK; Weiss, SA, 1993) |
"On the basis of ifosfamide's demonstrated single-agent activity in adult soft-tissue sarcoma, the Eastern Cooperative Oncology Group (ECOG) tested whether ifosfamide would add to the efficacy of doxorubicin in a three-regimen, controlled phase III trial." | 9.07 | Efficacy of ifosfamide in combination with doxorubicin for the treatment of metastatic soft-tissue sarcoma. The Eastern Cooperative Oncology Group. ( Blum, RH; Edmonson, J; Pelletier, L; Ryan, L, 1993) |
"A total of 37 adult patients with locally advanced or metastatic soft-tissue sarcoma (STS) entered a pilot study of combination chemotherapy based on the CYVADIC (cyclophosphamide, vincristine, doxorubicin, and dacarbazine) regimen, in which cyclophosphamide was replaced by ifosfamide and mesna (1 g/m2 ifosfamide given daily on days 1-5 as 2-h infusions, 1." | 9.07 | Ifosfamide, vincristine, doxorubicin and dacarbazine in adult patients with advanced soft-tissue sarcoma. ( Blomqvist, CP; Elomaa, I; Virolainen, M; Wiklund, TA, 1992) |
"Doxorubicin and ifosfamide are the two most active agents used in the treatment of advanced inoperable soft-tissue sarcoma, but their use in combination produces dose-limiting myelosuppression." | 9.07 | Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma Group. ( Blackledge, G; Clavel, M; Greifenberg, B; Soedirman, J; Somers, R; Steward, WP; Thomas, D; Van Glabbeke, M; Van Oosterom, AT; Verweij, J, 1991) |
"European and American investigators have reported response rates of 38% to 83% for ifosfamide alone in pretreated sarcomas." | 9.06 | Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. ( Antman, KH; Elias, A; Grier, HE; Ryan, L; Sherman, D, 1989) |
"In this phase II trial, 105 eligible patients with no prior chemotherapy and advanced sarcoma received doxorubicin, ifosfamide, and dacarbazine (DTIC) with mesna uroprotection (MAID)." | 9.06 | Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. ( Aisner, J; Antman, KH; Collins, J; Elias, A; Ryan, L; Sulkes, A, 1989) |
"Between April 1986 and March 1987, 42 patients with advanced sarcoma were entered in this multi-institutional trial evaluating ifosfamide plus doxorubicin." | 9.06 | Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase II trial. ( Braun, TJ; Hainsworth, JD; Loehrer, PJ; Martelo, OJ; Nicaise, C; Omura, G; Sledge, GW; Usakewicz, J, 1989) |
"The regimen of doxorubicin (DOX), ifosfamide (IFF), and dacarbazine (DTIC) (AID) for previously untreated inoperable or metastatic sarcoma has acceptable toxicity with significant activity." | 9.06 | Doxorubicin, ifosfamide, and dacarbazine (AID) with mesna uroprotection for advanced untreated sarcoma: a phase I study. ( Antman, KH; Elias, AD, 1986) |
"One hundred and seventy-one patients with advanced soft tissue sarcoma entered a randomized crossover phase II study comparing cyclophosphamide (CYCLO) with a new analogue, ifosfamide (IFOS), both administered as 24 h i." | 9.06 | Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas. ( Blackledge, G; Bramwell, VH; Mouridsen, HT; Santoro, A; Somers, R; Sylvester, R; Thomas, D; Van Oosterom, A, 1986) |
"Ifosfamide and Mesna are currently given to patients for 14 days continuous home-based infusion for the treatment of soft tissue sarcoma." | 8.93 | Evaluation of the stability profile of anticancer drugs: A review of Ifosfamide and Mesna regimen for the treatment of metastatic soft tissue sarcoma. ( Barton, S; Nabhani-Gebara, S; Peron, JM; Salman, D; Swinden, J, 2016) |
"Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma." | 8.91 | Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. ( Kremer, LC; Langer, T; Mulder, RL; Paulides, M; van Dalen, EC, 2015) |
"Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma." | 8.88 | Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. ( Kremer, LC; Langer, T; Mulder, RL; Paulides, M; van Dalen, EC, 2012) |
"Independent favourable prognostic factors for overall survival (OS) were good performance status, female gender, low histological grade, extremity primary tumour site and locally advanced disease; for progression-free survival (PFS), the combination of doxorubicin and ifosfamide, locally advanced disease, and tumour entity with a lower risk to progress for synovial sarcoma patients compared to leiomyosarcoma." | 8.86 | Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Tr ( Blay, JY; Hogendoorn, PC; Krarup-Hansen, A; Le Cesne, A; Ouali, M; Rodenhuis, S; Sleijfer, S; van Glabbeke, M; Verweij, J, 2010) |
"Ifosfamide is a chemotherapeutic prodrug used in the treatment of several tumor entities, including bone and soft-tissue sarcoma." | 8.86 | Palifosfamide, a bifunctional alkylator for the treatment of sarcomas. ( Jung, S; Kasper, B, 2010) |
"Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma." | 8.86 | Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. ( Kremer, LC; Langer, T; Mulder, RL; Paulides, M; van Dalen, EC, 2010) |
"This meta-analysis examines the role of ifosfamide-based combination chemotherapy in patients with advanced soft tissue sarcoma." | 8.84 | Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma. ( Blackstein, M; Haynes, AE; Stys-Norman, D; Verma, S; Younus, J, 2008) |
"Ifosfamide and anthracyclines are the only active agents in advanced soft tissue sarcomas." | 8.82 | Ifosfamide in the adjuvant therapy of soft tissue sarcomas. ( Berretta, M; Bidoli, E; Boz, G; Buonadonna, A; De Paoli, A; Frustaci, S; Gherlinzoni, F; La Mura, N, 2003) |
"The current study was performed to evaluate the toxicity profile of therapeutic doses of ifosfamide (IFX) given concurrently with full-dose external beam radiotherapy (EBRT) in patients with soft tissue and bone sarcomas." | 8.81 | Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma. ( Ballo, MT; Benjamin, RS; Burgess, MA; Cormier, JN; Feig, BW; Herzog, CE; Hunt, KK; Patel, SR; Pisters, PW; Raney, RB; Zagars, GK, 2001) |
"Ifosfamide is one of the three most active agents in the treatment of soft tissue sarcomas." | 8.79 | Ifosfamide in the treatment of soft tissue sarcomas. ( Budd, GT; Connelly, EF, 1996) |
"Ifosfamide is an alkylating agent with clinical activity in the treatment of sarcomas, and data support a dose-response relationship in this disease." | 8.79 | High-dose ifosfamide in the treatment of sarcomas of soft tissues and bone. ( Demetri, GD, 1996) |
"We have used ifosfamide to treat patients with sarcomas in four completed single-agent protocols and one pilot study since 1985." | 8.78 | Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience. ( Benjamin, RS; Legha, SS; Nicaise, C; Patel, SR, 1993) |
"Doxorubicin and ifosfamide are currently the two main drugs for the treatment of soft tissue sarcomas in adults." | 8.78 | Perspectives on anthracyclines plus ifosfamide in advanced soft tissue sarcomas. ( Azzarelli, A; Bertulli, R; Casali, P; Devizzi, L; Pastorino, U; Santoro, A; Zucchinelli, P, 1993) |
"Ifosfamide is an analogue of cyclophosphamide that has been extensively investigated in sarcomas." | 8.78 | The role of ifosfamide in the treatment of adult soft tissue sarcomas, Ewing's sarcoma, and osteosarcoma: a review. ( Dirix, LY; Van Oosterom, AT, 1990) |
"The alkylating agent ifosfamide has demonstrated significant activity against advanced sarcomas." | 8.77 | The role of ifosfamide in the treatment of sarcomas. ( Dirix, LY; Van Oosterom, AT, 1989) |
"We conducted a multi-institutional retrospective study, identifying sarcoma patients who received anthracyclines and/or ifosfamide during pregnancy." | 8.12 | Pregnancy outcomes related to the treatment of sarcomas with anthracyclines and/or ifosfamide during pregnancy. ( Agulnik, M; Davis, LE; Godbole, S; Hirbe, AC; Livingston, JA; Miller, D; Park, Y; Parkes, A; Posey, K; Robinson, SI; Skubitz, K; Van Tine, BA, 2022) |
"To investigate the value of contrast-enhanced computed tomography (CECT) radiomics features in predicting the efficacy of epirubicin combined with ifosfamide in patients with pulmonary metastases from soft tissue sarcoma." | 8.12 | Prediction of the therapeutic efficacy of epirubicin combined with ifosfamide in patients with lung metastases from soft tissue sarcoma based on contrast-enhanced CT radiomics features. ( Jiang, X; Li, M; Ma, ST; Miao, L; Wang, YM; Zhang, HH, 2022) |
"To compare long-term outcomes of high-grade, primary soft-tissue-sarcoma (STS), using Ifosfamide-Doxorubicin vs local therapy alone, in histology-specific sarcomas." | 8.02 | The role of Ifosfamide-doxorubicin chemotherapy in histology-specific, high grade, locally advanced soft tissue sarcoma, a 14-year experience. ( Burchette, RJ; Goy, BW; Helmstedter, CS; Padmanabhan, A; Syed, S, 2021) |
"For Ewing sarcoma, interval-compressed vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide administered every 2 weeks rather than every 3 weeks has been shown to improve event-free survival in pediatric patients." | 7.96 | Feasibility of Treating Adults with Ewing or Ewing-Like Sarcoma with Interval-Compressed Vincristine, Doxorubicin, and Cyclophosphamide Alternating with Ifosfamide and Etoposide. ( Bassale, S; Davis, LE; Lim, JY; Lu, E; Ryan, CW, 2020) |
"We compared the outcomes in soft tissue sarcoma (STS) treated with olaratumab and doxorubicin (OD) versus doxorubicin, ifosfamide, and mesna (AIM) to assess whether OD could supersede AIM in STS therapy." | 7.96 | Doxorubicin and Olaratumab Versus Doxorubicin, Ifosfamide, and Mesna for Treatment of Advanced Soft Tissue Sarcomas. ( Copeland, VC; Cranmer, LD; Hammer, KJ; Loggers, ET; Pollack, SM; Wagner, MJ, 2020) |
"The objective of this study was to analyze outcomes for patients with soft tissue sarcoma of the extremities using neoadjuvant ifosfamide-based chemotherapy and hypofractionated reduced dose radiotherapy, followed by limb-sparing surgery." | 7.88 | Long-term Outcomes With Ifosfamide-based Hypofractionated Preoperative Chemoradiotherapy for Extremity Soft Tissue Sarcomas. ( Bernthal, NM; Bukata, SV; Chmielowski, B; Dry, SM; Eckardt, JJ; Eilber, FC; Eilber, FR; Federman, N; Kalbasi, A; Kamrava, M; Luu, M; Nelson, SD; Pennington, JD; Reed, JP; Selch, MT; Singh, AS; Steinberg, ML; Wang, PC, 2018) |
"A retrospective search of the Royal Marsden Sarcoma Unit Database was performed to identify patients initially treated with ifosfamide (as single agent or in combination) and who were subsequently rechallenged with single-agent ifosfamide." | 7.88 | Successful Ifosfamide Rechallenge in Soft-Tissue Sarcoma. ( Benson, C; Constantinidou, A; Jones, RL; Judson, I; Messiou, C; Miah, A; Noujaim, J; Thway, K, 2018) |
"Anthracycline and ifosfamide-based chemotherapy represents a widely used regimen both in early and advanced settings in soft tissue sarcoma (STS)." | 7.85 | Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR). ( Amadori, D; Bongiovanni, A; De Vita, A; Di Iorio, V; Foca, F; Ibrahim, T; Liverani, C; Mercatali, L; Miserocchi, G; Monti, M; Recine, F; Riva, N, 2017) |
"We retrospectively reviewed outcomes of treatment with VIP (combination of etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma (STS)." | 7.85 | VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma. ( Baek, SW; Choi, YS; Jo, DY; Kim, S; Lee, HJ; Moon, JY; Ryu, H; Song, IC; Yun, HJ, 2017) |
"Ifosfamide is an alkylating agent, frequently used in the treatment of sarcoma." | 7.77 | Ifosfamide nephropathy in patients with sarcoma. ( Keikhaei, M; Mashhadi, MA; Sanadgol, H, 2011) |
"We retrospectively examined the incidence, severity, and risk factors of ifosfamide encephalopathy in 61 Japanese patients with bone and soft tissue sarcomas at our institution." | 7.76 | Ifosfamide encephalopathy associated with chemotherapy for musculoskeletal sarcomas: incidence, severity, and risk factors. ( Kikuchi, S; Konno, S; Tajino, T; Takeda, A; Yamada, H, 2010) |
"To report two cases of recurrent uterine sarcoma that developed ifosfamide-induced encephalopathy (IIE) with successful management." | 7.76 | Ifosfamide-induced encephalopathy in patients with uterine sarcoma. ( Chang, FW; Liu, YL; Tsai, SH; Yu, MH, 2010) |
"Ifosfamide is currently used to treat pediatric sarcomas and increasing its dosage may be associated with a better response rate." | 7.76 | Prolonged 14-day continuous infusion of high-dose ifosfamide with an external portable pump: feasibility and efficacy in refractory pediatric sarcoma. ( Casanova, M; Cefalo, G; Favini, F; Ferrari, A; Luksch, R; Massimino, M; Meazza, C; Podda, M, 2010) |
"To report the experience of a single institution in the south of Israel with doxorubicin and ifosfamide-mesna in patients with advanced/recurrent uterine sarcomas." | 7.73 | Doxorubicin and ifosfamide-mesna in advanced and recurrent uterine sarcomas. ( Piura, B; Rabinovich, A, 2005) |
"To assess the impact of different factors on response rate (RR), time to tumor progression (TTP), and overall survival time (OS) in patients with locally advanced or metastatic soft tissue sarcoma (ASTS), included in three protocols with high-dose ifosfamide (HDIF)." | 7.72 | Salvage surgical resection after high-dose ifosfamide (HDIF) based regimens in advanced soft tissue sarcoma (ASTS): a potential positive selection bias--a study of the Spanish group for research on sarcomas (GEIS). ( Balañá, C; Buesa, J; Casado, A; de Las Peñas, R; del Muro, XG; López-Pousa, A; Martín, J; Martínez-Trufero, J; Maurel, J; Quintana, MJ, 2004) |
"Adriamycin, dacarbazine and ifosfamide are three effective chemotherapy drugs in treating progressive soft tissue sarcoma." | 7.71 | [Continuous-infusion high dose ifosfamide as salvage treatment for pre-treated soft tissue sarcoma]. ( Chen, LK; Liang, Y; Liu, JL; Teng, XY; Xu, GC; Zhou, XM, 2002) |
"Ifosfamide is a leading drug in soft tissue sarcoma therapy." | 7.70 | Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas. ( Bergnolo, P; Boglione, A; Bumma, C; Colussi, AM; Comandone, A; Dal Canton, O; Frustaci, S; Leone, L; Monteleone, M; Oliva, C, 1998) |
"Our objective was to assess the efficacy of a standard dose ifosfamide and doxorubicin containing regimen in the treatment of advanced soft tissue sarcomas." | 7.70 | Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy. ( Altundağ, K; Baltali, E; Barişta, I; Celik, I; Firat, D; Güler, N; Güllü, I; Kars, A; Ozişik, Y; Tekuzman, G; Türker, A; Uner, A; Yalçin, S; Zengin, N, 2000) |
"Between 1992 and 1999, 13 consecutive patients with completely resected moderate- to high-grade uterine sarcoma received three cycles of adjuvant ifosfamide (1." | 7.70 | Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma. ( Belinson, JL; Kennedy, AW; Kushner, DM; Markman, M; Rybicki, LA; Webster, KD, 2000) |
"A total of 33 patients (median age, 44 years) with high-grade, adult soft-tissue sarcoma were treated with etoposide given at 600 mg/m2 in a 72-h continuous infusion and ifosfamide given at 1500 mg/m2 per day for 3 days every 3 weeks." | 7.69 | Treatment of advanced, high-grade soft-tissue sarcoma with ifosfamide and continuous-infusion etoposide. ( Saeter, G; Solheim, OP; Talle, K, 1995) |
"Four patients with metastatic ovarian mixed Müllerian sarcoma (2 homologous, 2 heterologous) were treated with mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) chemotherapy." | 7.69 | Mesna, doxorubicin, ifosfamide, and dacarbazine chemotherapy for ovarian mixed müllerian sarcoma: report of four cases. ( Greenberg, S; Patsner, B, 1995) |
"Twenty patients with advanced sarcomas entered a pilot study with ifosfamide (IF) and mercaptoethane sulfonate sodium (Mesna) as a second-line treatment for six planned cycles." | 7.69 | High-dose ifosfamide by infusion with Mesna in advanced refractory sarcomas. ( Alkiş, N; Baltali, E; Barişta, I; Celik, I; Güler, N; Güllü, I; Kars, A; Tekuzman, G; Yalçin, S; Zengin, N, 1996) |
"From January 1990 to December 1995 we treated 35 patients (pts) with bone and soft tissue sarcoma with ifosfamide (IFM)." | 7.69 | [The effects of high-dose ifosfamide in the treatment of bone and soft tissue sarcomas]. ( Ishii, T; Kitoh, M; Satoh, T; Tatezaki, S; Umeda, T; Yonemoto, T, 1997) |
"A total of 64 courses of ifosfamide (IFM) treatments for sarcoma patients were evaluated for toxic effects." | 7.68 | [Toxic effects of ifosfamide in the treatment of bone and soft tissue sarcomas]. ( Ishii, T; Kitoh, M; Satoh, T; Tatezaki, S; Umeda, T, 1993) |
"Between 1982 and 1986, 38 patients with soft-tissue sarcomas were treated with the combination doxorubicin/dacarbazine (group A); between 1986 and 1990, another 46 patients received doxorubicin/ifosfamide (group B); and between 1990 and 1991, 11 patients received an alternating regimen of doxorubicin and ifosfamide (group C)." | 7.68 | Treatment results obtained in metastatic soft-tissue sarcoma with a combination of doxorubicin and dacarbazine or doxorubicin and ifosfamide. ( Agarwal, K; Dietel, M; Hossfeld, DK; Schwarz, R; Weh, HJ; Zornig, C, 1993) |
"Two trials using ifosfamide-based combination chemotherapy for advanced soft-tissue sarcoma have been completed." | 7.68 | Ifosfamide combination regimens for soft-tissue sarcoma. ( Bell, DR; Dalley, D; Levi, J; Simes, RJ; Stuart-Harris, R; Wiltshaw, E, 1993) |
"The response of ifosfamide-based chemotherapeutic regimens was retrospectively analyzed in adult patients with advanced soft-tissue sarcoma who were treated at the West German Tumor Center, Essen, between 1978 and 1990." | 7.68 | Ifosfamide in the treatment of soft-tissue sarcomas: experience at the West German Tumor Center, Essen. ( Kellner, R; Schütte, J; Seeber, S, 1993) |
"Currently, anthracyclines and ifosfamide are the most effective drugs for the treatment of disseminated soft-tissue sarcoma." | 7.68 | A pilot study of rapidly alternating epirubicin/dacarbazine and ifosfamide as first-line therapy for metastatic soft-tissue sarcoma in adults. ( Anagnou, J; Bokemeyer, C; Harstrick, A; Knipp, H; Köhne-Wömpner, CH; Neumann, S; Poliwoda, H; Schmoll, HJ; Schöffski, P; Wipperman, B, 1993) |
"A total of 46 consecutive patients were entered into this study to assess the efficacy and toxicity of an epirubicin/ifosfamide combination in treating locally advanced and/or metastatic adult sarcomas (38 soft-tissue sarcomas and 7 bone sarcomas in 45 evaluable patients)." | 7.68 | Ifosfamide plus epirubicin at escalating doses in the treatment of locally advanced and/or metastatic sarcomas. ( Albanese, E; Barisone, A; Canavese, G; Cantoni, E; Palumbo, R; Reggiardo, G; Rosso, R; Santi, L; Toma, S, 1993) |
"Twenty-eight patients with non-pretreated metastatic soft tissue sarcomas were entered on a treatment protocol of rapidly alternating epirubicin/dacarbazine and ifosfamide: Epirubicin 100 mg/m2 d1, dacarbazine 500 mg/m2 d1 + d2, ifosfamide 6000 mg/m2 24-h infusion d15; repeated d29." | 7.68 | Epirubicin/dacarbazine rapidly alternated with ifosfamide in the treatment of metastatic soft tissue sarcomas. ( Bokemeyer, C; Harstrick, A; Köhne-Wömpner, CH; Poliwoda, H; Schmoll, HJ; Schöffski, P, 1992) |
"From July 1986 to 1990, 65 patients with deep-seated, advanced sarcomas (43 soft-tissue sarcomas, 12 Ewing's sarcomas, 7 chondrosarcomas and 3 osteosarcomas) were entered in a protocol involving regional hyperthermia (RHT) combined with systemic ifosfamide and etoposide." | 7.68 | Improvement of local control by regional hyperthermia combined with systemic chemotherapy (ifosfamide plus etoposide) in advanced sarcomas: updated report on 65 patients. ( Denzlinger, C; Gerl, A; Issels, RD; Mittermüller, J; Ortmaier, A; Sauer, H; Simon, W; Wilmanns, W, 1991) |
"The mesna, doxorubicin, ifosfamide, dacarbazine regimen produced a 47% response rate (including 10% complete responses) in 105 eligible adults with advanced sarcoma." | 7.68 | Mesna, doxorubicin, ifosfamide, dacarbazine (MAID) regimen for adults with advanced sarcoma. ( Aisner, J; Antman, KH; Elias, A; Ryan, L, 1990) |
"From July 1986 to July 1989, 40 patients (92% pretreated) with deep-seated, advanced soft tissue sarcomas (STS, 25 patients), Ewing's sarcomas (ES, eight patients), osteosarcomas (OS, three patients) and chondrosarcomas (ChS, four patients) were treated at the University of Munich in a protocol involving regional hyperthermia (RHT) combined with ifosfamide plus etoposide." | 7.68 | Ifosfamide plus etoposide combined with regional hyperthermia in patients with locally advanced sarcomas: a phase II study. ( Berger, H; Boehm, E; Denecke, H; Issels, RD; Jauch, KW; Nagele, A; Peter, K; Prenninger, SW; Sauer, H; Wilmanns, W, 1990) |
"The objective of this phase II trial was to assess the therapeutic activity and toxicity of doxorubicin plus ifosfamide in previously untreated patients with advanced soft tissue sarcoma." | 7.68 | Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group. ( Blackledge, G; Dombernowsky, P; Mouridsen, HT; Santoro, A; Schütte, J; Somers, R; Stewart, W; Thomas, D; van Oosterom, AT; Verweij, J, 1990) |
"The combination of ifosfamide (IFO) and epirubicin (EPI) has been found to be an effective regimen in the treatment of metastatic tumours and shows remarkable activity in heavily pretreated breast cancer patients." | 7.68 | Epirubicin and ifosfamide in patients with refractory breast cancer and other metastatic solid tumours. ( Hoffmann, W; Könner, J; Migeod, F; Seeber, S; Weidmann, B, 1990) |
"Forty-three adult patients with locally advanced or metastatic soft tissue sarcoma entered a pilot study of combination chemotherapy comprising 50 mg of doxorubicin/m2 by intravenous bolus, 850 mg of dacarbazine/m2 by 1-hour infusion, and 5 g of ifosfamide/m2 by 24-hour infusion with mesna uroprotection." | 7.67 | Combination chemotherapy with doxorubicin, dacarbazine, and ifosfamide in advanced adult soft tissue sarcoma. Canadian Sarcoma Group--National Cancer Institute of Canada Clinical Trials Group. ( Bramwell, V; Eisenhauer, E; Knowling, M; Quirt, I; Verma, S; Warr, D; Young, V, 1989) |
"Early results with ifosfamide plus mesna in soft tissue sarcoma showed an initial response rate of 38% in 42 patients." | 7.67 | Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma. ( Fisher, C; Harmer, C; McKinna, A; Westbury, G; Wiltshaw, E, 1986) |
"One hundred twenty-four children and young adults with recurrent tumors, predominantly sarcomas, were treated with the combination of ifosfamide, etoposide, and the uroprotector, mesna (2-mercaptoethane sulphonate), in a phase II trial." | 7.67 | Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. ( Forquer, R; Jarosinski, P; Kinsella, TJ; Magrath, I; Miser, JS; Triche, TJ; Tsokos, M; Wesley, R, 1987) |
"Fifty-four patients with advanced soft tissue sarcoma were treated with a combination of ifosfamide (5 g/m2) and adriamycin (40-60 mg/m2) at 3 weekly intervals." | 7.67 | A phase I-II study of ifosfamide in combination with adriamycin in the treatment of adult soft tissue sarcoma. ( Fisher, C; King, M; MacMillan, S; Mansi, JL; Stuart-Harris, R; Wiltshaw, E, 1988) |
"We have evaluated the activity of ifosfamide in 75 patients with recurrent sarcomas and pediatric solid tumors." | 7.67 | A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people. ( Arasi, V; Magrath, I; Miser, J; Raynor, A; Rosenberg, S; Sandlund, J, 1986) |
" Hemorrhagic cystitis was not observed in patients treated with 400-500 mg of mesna iv every 4 hours during ifosfamide treatment." | 7.67 | Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. ( Antman, KH; Montella, D; Rosenbaum, C; Schwen, M, 1985) |
"In a phase II study, 42 patients with advanced soft-tissue sarcoma were treated with ifosfamide by 24-h infusion and mesna by 4-h IV bolus, repeated every 3 weeks." | 7.66 | High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma. ( Gowing, NF; Harper, PG; Kaye, SB; Mooney, CA; Parsons, CA; Stuart-Harris, RC; Wiltshaw, E, 1983) |
"The efficacy of ifosfamide combination chemotherapy was studied in 164 patients, 94 with advanced testicular carcinoma and 70 with metastatic sarcoma." | 7.66 | Ifosfamide in combination chemotherapy for sarcomas and testicular carcinomas. ( Cremer, M; Niederle, N; Scheulen, ME; Schmidt, CG; Schütte, J; Seeber, S, 1983) |
"Patients with Stage III non-round cell soft tissue sarcomas in the extremities were eligible." | 6.80 | Perioperative chemotherapy with ifosfamide and doxorubicin for high-grade soft tissue sarcomas in the extremities (JCOG0304). ( Araki, N; Chuman, H; Fukuda, H; Hatano, H; Hiruma, T; Iwamoto, Y; Mizusawa, J; Morioka, H; Ozaki, T; Takahashi, M; Tanaka, K; Tsuchiya, H, 2015) |
"Ifosfamide is a chemotherapeutic agent that requires cytochrome P450 3A (CYP3A) for bioactivation and metabolism." | 6.73 | Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma. ( Baker, LH; Chugh, R; Griffith, KA; Leu, KM; Taylor, JM; Thomas, DG; Wagner, T; Worden, FP; Zalupski, MM, 2007) |
" Samples for pharmacokinetic analysis were obtained after the MTD was reached." | 6.72 | Phase I trial and pharmacokinetic analysis of ifosfamide in cats with sarcomas. ( Beaulieu, BB; Kristal, O; Lewis, LD; Moore, AS; Northrup, NC; Page, RL; Rassnick, KM, 2006) |
"Prognosis of patients with metastatic soft tissue sarcomas (MSTS) is poor even after response to doxorubicin-based chemotherapy." | 6.72 | Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas. ( Abdel-Rahman, S; Baumert, J; Falk, M; Hentrich, M; Hiddemann, W; Issels, RD; Licht, T; Salat, C; Schlemmer, M; Straka, C; Wendtner, CM, 2006) |
"Etoposide monotherapy was successful in 8%; the effectiveness of cisplatin was 5-23%." | 6.69 | The efficacy of a combination of etoposide, ifosfamide, and cisplatin in the treatment of patients with soft tissue sarcoma. ( Bodoky, G; Eckhardt, S; Láng, I; Pápai, Z; Poller, I; Rahóty, P; Szántó, J; Szendroi, M, 2000) |
"Gemcitabine was administered as a 360 min infusion on days 1, 8 and 15 of a 28 day cycle." | 6.69 | Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. ( Dietzmann, A; Genvresse, I; Grunewald, R; Koschuth, A; Possinger, K; Späth-Schwalbe, E, 2000) |
"Patients with non-resectable soft tissue sarcomas of the extremities do not live longer if they are treated by amputation or disarticulation." | 6.69 | Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. ( Bejkos, D; Bischof-Delaloye, A; Chassot, PG; Chiolero, R; Genton, A; Guillou, L; Landry, M; Lejeune, FJ; Leyvraz, PF; Leyvraz, S; Liénard, D; Mirimanoff, RO; Mosimann, F; Pujol, N; Raffoul, W, 2000) |
"In advanced soft tissue sarcomas of adults, single-agent doxorubicin is still the standard chemotherapy against which more intensive or new drug treatments should be compared." | 6.68 | Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. ( Buesa, J; Casali, P; Mouridsen, H; Rankin, E; Santoro, A; Somers, R; Spooner, D; Steward, W; Tursz, T; Verweij, J, 1995) |
" No clinical evidence of renal failure was attributed to the high dosage of the drug in the course of assays of biochemical components of the blood, blood- and urine-beta-2-microglobulins, N-acetyl-D-hexoaminidase (NAG) level in urine, creatinine clearance and complex renoscintigraphy data." | 6.68 | [High-dose ifosfamide in the treatment of patients with soft tissue sarcoma]. ( Averinova, SG; Garin, AM; Kashkadaeva, AV; Liubimova, NV; Romanova, LF; Shiriaev, SV; Sidorova, NI; Tiuliandin, SA, 1996) |
"Ifosfamide (5 g/m2) was compared with its parent analogue cyclophosphamide (1." | 6.67 | Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group. ( Blackledge, G; Bramwell, VH; Dombernowsky, P; Mouridsen, HT; Onsrud, M; Santoro, A; Somers, R; Sylvester, R; Thomas, D; Verweij, J, 1993) |
"Ifosfamide dosage was not increased." | 6.67 | Epirubicin and ifosfamide in advanced soft tissue sarcoma: a phase II study. ( Chevallier, B; Facchini, T; Fargeot, P; Leyvraz, S; Olivier, JP; Vo Van, ML, 1993) |
"For high-risk soft tissue sarcomas (HR-STS) of adults, new treatment strategies are needed to improve outcome with regard to local control and overall survival." | 6.42 | Ifosfamide with regional hyperthermia in soft-tissue sarcomas. ( Issels, RD; Schlemmer, M; Wendtner, CM, 2003) |
"The results of the association of doxorubicin plus ifosfamide in the treatment of locally advanced and/or metastatic adult soft tissue sarcomas as reported in the literature from 1986 up to the present time are reviewed." | 6.17 | Doxorubicin (or epidoxorubicin) combined with ifosfamide in the treatment of adult advanced soft tissue sarcomas. ( Palumbo, R; Santi, L; Sogno, G; Toma, S; Venturino, A, 1992) |
"Thoracic sarcomas are rare malignancies, with limited data for unresectable/advanced scenarios." | 5.91 | Epirubicin, cisplatin plus ifosfamide versus standard chemotherapeutic regimens for advanced/unresectable primary thoracic sarcomas. ( Alatorre-Alexander, JA; Carrasco-CaraChards, S; Cruz-Zermeño, M; de Jesús Rodríguez-Zea, I; Godina-Flores, A; Green-Renner, D; Guzmán-Casta, J; Guzmán-Huesca, J; Imaz-Olguin, V; Juarez-Vignon Whaley, JJ; Martínez-Barrera, LM; Riera-Sala, R; Rodriguez-Cid, JR; Sánchez-Domínguez, G; Sánchez-Ríos, CP; Santillán-Doherty, PJ; Seidman-Sorsby, A; Sosa-Sánchez, R, 2023) |
"This randomised phase II/III trial aimed to determine whether perioperative chemotherapy with gemcitabine plus docetaxel (GD) is non-inferior to the standard Adriamycin plus ifosfamide (AI) in terms of overall survival (OS) in patients with soft tissue sarcoma (STS)." | 5.51 | Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306. ( Abe, S; Akisue, T; Asanuma, K; Emori, M; Fukuda, H; Furuta, T; Hatano, H; Hiraga, H; Hiraoka, K; Hiruma, T; Iwamoto, Y; Katagiri, H; Kataoka, T; Kawai, A; Kawano, M; Kawashima, H; Machida, R; Matsumoto, Y; Morii, T; Nagano, A; Nakayama, R; Nishida, Y; Okuma, T; Outani, H; Ozaki, T; Suehara, Y; Takenaka, S; Takeyama, M; Tanaka, K; Toguchida, J; Tsukushi, S; Watanuki, M; Yamamoto, T; Yonemoto, T, 2022) |
"This prospective single-arm phase II clinical trial aimed to evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) combined with ifosfamide (IFO) as the first-line treatment for patients with advanced or metastatic soft-tissue sarcoma (STS)." | 5.51 | Pegylated Liposomal Doxorubicin Combined with Ifosfamide for Treating Advanced or Metastatic Soft-tissue Sarcoma: A Prospective, Single-arm Phase II Study. ( Chen, H; Chen, Y; Huang, M; Jiang, S; Liu, X; Luo, Z; Miao, J; Wang, C; Wang, H; Wang, J; Wu, X; Xia, J; Xu, Y; Yan, W; Yao, W; Yu, L; Zhang, X, 2022) |
"Olaratumab (OLA), a monoclonal antibody against platelet-derived growth factor receptor alpha (PDGFRα), has recently been used against soft-tissue sarcoma (STS) combined with doxorubicin (DOX), with limited efficacy." | 5.51 | Olaratumab combined with doxorubicin and ifosfamide overcomes individual doxorubicin and olaratumab resistance of an undifferentiated soft-tissue sarcoma in a PDOX mouse model. ( Bouvet, M; Hayashi, K; Higuchi, T; Hoffman, RM; Igarashi, K; Kimura, H; Miwa, S; Miyake, K; Oshiro, H; Razmjooei, S; Singh, SR; Sugisawa, N; Tsuchiya, H; Yamamoto, N; Zhang, Z, 2019) |
"Pazopanib and gemcitabine have shown good tolerability, albeit modest single-agent activity in pretreated soft tissue sarcoma." | 5.41 | Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial. ( Crysandt, M; Cygon, F; Egerer, G; Eigendorff, E; Heißner, K; Kasper, B; Kessler, T; Kopp, HG; Kunitz, A; Lindner, LH; Mayer-Steinacker, R; Meinert, F; Niederwieser, D; Petersen, I; Reichardt, P; Rüssel, J; Schmoll, HJ; Steighardt, J; Stein, A, 2021) |
"EORTC-1506-STBSG was a prospective, multicentric, randomised, open-label phase 2 trial to assess the efficacy and safety of second-line nintedanib versus ifosfamide in patients with advanced, inoperable metastatic soft tissue sarcoma (STS)." | 5.41 | Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC- ( Bovée, JVMG; Brahmi, M; Charon-Barra, C; Cousin, S; de Haan, J; De Meulemeester, L; Domènech, M; Dudzisz-Śledź, M; Estival, A; Gelderblom, H; Karavasilis, V; Litière, S; Marquina, G; Marreaud, S; Olungu, C; Schöffski, P; Steeghs, N; Toulmonde, M; Wozniak, A, 2021) |
"As adjuvant chemotherapy (AC) for soft tissue sarcomas is controversial, we performed a retrospective analysis of patients seen at Washington University in St." | 5.40 | Risk-stratified patients with resectable soft tissue sarcoma benefit from epirubicin-based adjuvant chemotherapy. ( Adkins, DR; Luo, J; Montgomery, L; Morgensztern, D; Schenone, AD; Van Tine, BA, 2014) |
"Ifosfamide is an alkylating agent with well-demonstrated efficacy against STS, and dose-dependent activity." | 5.37 | High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients. ( Baek, KK; Chang, MH; Han, B; Lee, J; Lee, SH; Lim, T; Park, JO, 2011) |
"Breast stromal sarcoma is very rare, accounting for less than 1% of mammary neoplasms, and the treatment strategy is not well established, especially regarding chemotherapy." | 5.37 | Stromal sarcoma of the breast with lung metastases showing a clinical complete response to doxorubicin plus ifosfamide treatment: report of a case. ( Inoue, K; Iwase, H; Kuriwaki, K; Sueta, A; Yamamoto, Y, 2011) |
"This study was aimed at determining whether patients with high-risk soft tissue sarcoma (STS), as identified using the nomogram Sarculator, benefitted from adjuvant chemotherapy in the EORTC-STBSG 62931 randomised controlled trial (RCT), which failed to detect an impact for adjuvant doxorubicin plus ifosfamide (Adj) over observation (Obs)." | 5.30 | The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial. ( Casali, PG; Dei Tos, AP; Gelderblom, H; Gronchi, A; Judson, I; Kasper, B; Litiere, S; Marreaud, S; Pasquali, S; Pizzamiglio, S; Stacchiotti, S; Touati, N; Verderio, P; Woll, PJ, 2019) |
" So we compared VAC protocol and ifosfamiide for toxic effects." | 5.30 | Toxicity of chemotherapeutical protocols in the treatment of uterine sarcomas (Vincristine, actinomycin D, Cyclophosphamide VAC versus ifosfamide). ( Erman, O; Simşek, T; Trak, B; Uner, M; Zorlu, GC, 1998) |
"Ifosfamide was escalated from 5 to 10 g/m2 with a fixed carboplatin dose of 480 mg/m2." | 5.29 | Ifosfamide and carboplatin combined with 41.8 degrees C whole-body hyperthermia in patients with refractory sarcoma and malignant teratoma. ( Bucsky, P; d'Oleire, F; Eleftheriadis, S; Feddersen, S; Geisler, J; Klouche, M; Knop, E; Mentzel, M; Schmucker, P; Wiedemann, GJ, 1994) |
"From November 1990 to September 1991, 23 adults with high-risk, nonmetastatic sarcomas (20 soft-tissue sarcomas and 3 chondrosarcomas) were entered in a pilot protocol (RHT-91) involving regional hyperthermia combined with systemic chemotherapy followed by surgery." | 5.29 | Preoperative systemic etoposide/ifosfamide/doxorubicin chemotherapy combined with regional hyperthermia in high-risk sarcoma: a pilot study. ( Abdel-Rahman, S; Berger, H; Bosse, D; Issels, RD; Jauch, KW; Panzer, M; Peter, K; Sauer, H; Starck, M; Stiegler, H, 1993) |
"The model systems were human breast carcinoma (MX1/3) and human sarcoma (S117) grown in nude mice." | 5.28 | Local hyperthermia enhances cyclophosphamide, ifosfamide and cis-diamminedichloroplatinum cytotoxicity on human-derived breast carcinoma and sarcoma xenografts in nude mice. ( Biersack, A; Roszinski, S; Wagner, T; Weiss, C; Wiedemann, G, 1992) |
"Between 1982 and 1986, 38 patients with soft tissue sarcomas were treated with a combination of ADM/DTIC (group A), another 45 (group B) received ADM/IFO between 1986 and 1990." | 5.28 | Chemotherapy of metastatic soft tissue sarcoma with a combination of adriamycin and DTIC or adriamycin and ifosfamide. ( Dietel, M; Hossfeld, DK; Schwarz, R; Weh, HJ; Wingberg, D; Zornig, C; Zügel, M, 1990) |
"The European Organization for Research and Treatment of Cancer (EORTC) 62012 study was a Phase III trial of doxorubicin versus doxorubicin-ifosfamide chemotherapy in 455 patients with advanced soft tissue sarcoma (STS)." | 5.24 | Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study. ( Collin, F; Daugaard, S; Fisher, C; Gronchi, A; Grünwald, V; Hogendoorn, PCW; Judson, I; Lia, M; Litière, S; Mechtersheimer, G; Messiou, C; Sciot, R; van der Graaf, W; Wardelmann, E; Young, RJ, 2017) |
"Patients with high-grade soft tissue sarcomas were treated with 2 cycles of ifosfamide, mitomycin, doxorubicin, and cisplatin plus GM-CSF subcutaneous followed by 45 Gy irradiation with concurrent 2 cycles of mitomycin, doxorubicin, and cisplatin followed by surgery +/- intraoperative radiation or brachytherapy." | 5.22 | Chemotherapy, Irradiation, and Surgery for Function-preserving Curative Therapy of Primary Extremity Soft Tissue Sarcomas: Initial Treatment With I-MAP and Inhalation GM-CSF During Preoperative Irradiation and Postoperatively. ( Haddock, M; Mahoney, M; Maples, W; Markovic, SN; O'Connor, MI; Okuno, S; Petersen, I; Shives, T; Sim, F, 2016) |
" This phase II trial was performed to evaluate the activity and the safety of NPLD and ifosfamide combination in patients with metastatic soft tissue sarcoma." | 5.20 | Non-pegylated liposomal doxorubicin plus ifosfamide in metastatic soft tissue sarcoma: results from a phase-II trial. ( Basso, U; Bertuzzi, A; Colombo, P; Comandone, A; De Sanctis, R; Giordano, L; Lutman, RF; Marchetti, S; Marrari, A; Santoro, A, 2015) |
" Patients aged 18 years and older with metastatic soft-tissue sarcomas, an Eastern Cooperative Oncology Group performance status of 0-2, and who had previously received treatment with anthracycline and ifosfamide were randomly assigned (1:1) to intravenous infusion of ombrabulin 25 mg/m(2) plus cisplatin 75 mg/m(2) or intravenous infusion of placebo plus cisplatin 75 mg/m(2) every 3 weeks." | 5.20 | Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial. ( Babovic, N; Blay, JY; Bompas, E; Chawla, SP; Cohen, P; Cupissol, D; Demetri, GD; Franke, FA; Isambert, N; Italiano, A; Le-Guennec, S; López-Pousa, A; Pápai, Z; Penel, N; Saâda-Bouzid, E; Santoro, A; Staddon, AP; Tolcher, AW, 2015) |
"Doxorubicin and ifosfamide (AI) is standard therapy for high-risk soft tissue sarcoma (STS) but often causes severe toxicities resulting in hospitalisation." | 5.20 | A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma. ( Baker, LH; Biermann, JS; Chugh, R; Davis, EJ; Feng, M; Jacobson, J; Lucas, DR; Metko, G; Reinke, D; Schuetze, SM; Wong, SL; Zalupski, MM; Zhao, L; Zyczynski, L, 2015) |
"This phase I trial assessed safety, pharmacokinetics (PK), dose limiting toxicity (DLT), maximum tolerated dose and recommended dose (RD) of the combination of sorafenib plus ifosfamide in patients with advanced sarcoma." | 5.19 | Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study. ( Brendel, E; Broto, JM; Cubedo, R; del Muro, XG; Gallego, O; López-Pousa, A; Martín-Liberal, J; Tirado, OM, 2014) |
"To study feasibility, safety and activity of the combination of high-dose long-infusion ifosfamide (HLI) and radiotherapy (RT) as preoperative treatment for resectable localised retroperitoneal sarcoma (RPS)." | 5.19 | Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: a phase I-II study from the Italian Sarcoma Group. ( Bertola, G; Bruzzi, P; Buonadonna, A; Casali, PG; Dani, C; De Paoli, A; De Sanctis, R; Dei Tos, AP; Fiore, M; Giorello, L; Grignani, G; Gronchi, A; Merlo, DF; Navarria, P; Quagliuolo, V; Sanfilippo, R; Sangalli, C; Stacchiotti, S, 2014) |
"Effective targeted treatment is unavailable for most sarcomas and doxorubicin and ifosfamide-which have been used to treat soft-tissue sarcoma for more than 30 years-still have an important role." | 5.19 | Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. ( Alcindor, T; Blay, JY; dei Tos, AP; Fisher, C; Gelderblom, H; Hartmann, JT; Hermans, C; Hogendoorn, PC; Hohenberger, P; Judson, I; Kerst, JM; Krarup-Hansen, A; Litière, S; Marreaud, S; Schöffski, P; Sufliarsky, J; van der Graaf, WT; Verweij, J; Whelan, J, 2014) |
" Perioperative chemotherapy with adriamycin plus ifosfamide is the current standard treatment for T2bN0M0 high-grade non-round cell soft tissue sarcoma." | 5.19 | A randomized phase II/III trial of perioperative chemotherapy with adriamycin plus ifosfamide versus gemcitabine plus docetaxel for high-grade soft tissue sarcoma: Japan Clinical Oncology Group Study JCOG1306. ( Araki, N; Fukuda, H; Hiraga, H; Iwamoto, Y; Kataoka, K; Kawai, A; Kimura, A; Matsumine, A; Matsunobu, T; Mizusawa, J; Oda, Y; Tanaka, K, 2014) |
"The objective of this Phase I dose escalation study was to explore the safety and tolerability of eltrombopag, an oral, nonpeptide, thrombopoietin receptor agonist, in patients with advanced soft tissue sarcoma (STS) and thrombocytopenia due to treatment with doxorubicin and ifosfamide (AI) combination chemotherapy." | 5.17 | Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide. ( Chawla, SP; Hendifar, A; Kamel, YM; Messam, CA; Patwardhan, R; Staddon, A, 2013) |
"This multicenter, phase II trial evaluated the efficacy and safety of everolimus, an mTOR inhibitor, in patients with metastatic or recurrent bone and soft-tissue sarcoma after the failure of anthracycline- and ifosfamide-containing regimens." | 5.17 | Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide. ( Ahn, JH; Kim, TM; Kim, YJ; Lee, HJ; Lee, J; Lee, KH; Park, KH; Rha, SY; Yoo, C, 2013) |
"Doxorubicin and ifosfamide are highly active drugs for the treatment of high-grade sarcomas, but little is known on the optimal management of young patients who develop such malignancies during pregnancy." | 5.16 | Doxorubicin and ifosfamide for high-grade sarcoma during pregnancy. ( Berrada, N; Bonvalot, S; Boulet, B; Cioffi, A; Domont, J; Le Cesne, A; Lokiec, F; Mir, O; Terrier, P; Trichot, C, 2012) |
"From July 1995 to June 2003, 457 previously untreated patients with incompletely resected embryonal rhabdomyosarcoma (RMS), undifferentiated sarcoma, and soft tissue primitive neuroectodermal tumor at all sites except paratesticular, vagina, and uterus, or with alveolar RMS were randomly assigned to receive either ifosfamide, vincristine, and dactinomycin (IVA) or a six-drug combination (IVA plus carboplatin, epirubicin, and etoposide) both delivered over 27 weeks." | 5.16 | Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatr ( Bergeron, C; Bouvet, N; Ellershaw, C; Jenney, ME; Kelsey, A; Martelli, H; Merks, JH; Oberlin, O; Rey, A; Sanchez de Toledo, J; Scopinaro, M; Spooner, D; Stevens, MC, 2012) |
"Adjuvant chemotherapy with doxorubicin and ifosfamide in resected soft-tissue sarcoma showed no benefit in relapse-free survival or overall survival." | 5.16 | Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. ( Azzarelli, A; Bonvalot, S; Bramwell, VH; Hoekstra, HJ; Hogendoorn, PC; Hohenberger, P; Le Cesne, A; Leahy, M; Marreaud, S; Ouali, M; Reichardt, P; Van Coevorden, F; Verweij, J; Woll, PJ, 2012) |
"Ifosfamide and doxorubicin combination is an active regimen for patients with advanced soft tissue sarcomas (STS) but is burdened by high toxicity." | 5.15 | Optimizing clinical care in patients with advanced soft tissue sarcoma: a phase II study of a new schedule of high-dose continuous infusion ifosfamide and doxorubicin combination. ( Boni, C; Boselli, S; Catania, C; de Braud, F; De Pas, T; Delmonte, A; Frustaci, S; Noberasco, C; Radice, D; Rosati, G; Scalamogna, R; Spitaleri, G; Toffalorio, F; Tucci, A; Vecchio, F, 2011) |
"This phase II clinical trial aims to evaluate the efficacies and toxicities of pre- and postoperative chemotherapy with adriamycin plus ifosfamide on the patients with soft-tissue high-grade sarcomas." | 5.14 | Preoperative and postoperative chemotherapy with ifosfamide and adriamycin for adult high-grade soft-tissue sarcomas in the extremities: Japan Clinical Oncology Group Study JCOG0304. ( Fukuda, H; Iwamoto, Y; Kawamoto, H; Saito, I; Tanaka, K; Yoshimura, K, 2009) |
"To assess the progression-free survival (PFS) and antitumor response to standard-dose doxorubicin compared with sequential dose-dense doxorubicin and ifosfamide in first-line treatment of advanced soft tissue sarcoma." | 5.14 | Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas. ( Andrés, R; Balañá, C; Buesa, JM; Casado, A; Cruz, J; Cubedo, R; de la Cruz, JJ; de Las Peñas, R; Del Muro, XG; Fra, J; Gallego, O; Gómez, MA; López-Pousa, A; Martín, J; Martínez-Trufero, J; Maurel, J; Poveda, A; Rubió, J; Rubio-Viqueira, B; Sevilla, I, 2009) |
"The aim of this study was to evaluate the maximum tolerated dose (MTD) and safety of the combination of non- pegylated liposomal doxorubicin (Myocet) and ifosfamide in patients with metastatic soft tissue sarcomas." | 5.14 | Phase I study of non-pegylated liposomal doxorubicin in combination with ifosfamide in adult patients with metastatic soft tissue sarcomas. ( Barbato, A; Bertuzzi, A; Di Comite, G; Lutman, RF; Mussi, C; Santoro, A; Stroppa, E, 2010) |
"Ifosfamide is a cornerstone of chemotherapy in bone and soft-tissue sarcoma." | 5.14 | Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients. ( Alexandre, J; Anract, P; Billemont, B; Camps, S; Coriat, R; Goldwasser, F; Larousserie, F; Leconte, M; Mir, O; Ropert, S, 2010) |
"Dynamic PET studies with (18)F-FDG were performed in patients with metastatic soft tissue sarcomas who received conventional chemotherapy with doxorubicin hydrochloride (Adriamycin) and ifosfamide (AI-G)." | 5.14 | Prediction of chemotherapy outcome in patients with metastatic soft tissue sarcomas based on dynamic FDG PET (dPET) and a multiparameter analysis. ( Dimitrakopoulou-Strauss, A; Egerer, G; Haberkorn, U; Kasper, B; Schmitt, T; Strauss, LG; Vasamiliette, J, 2010) |
"The evaluation included 31 patients with nonmetastatic soft-tissue sarcomas, who were treated with neoadjuvant chemotherapy consisting of etoposide, ifosfamide, and doxorubicin." | 5.14 | Impact of dynamic 18F-FDG PET on the early prediction of therapy outcome in patients with high-risk soft-tissue sarcomas after neoadjuvant chemotherapy: a feasibility study. ( Dimitrakopoulou-Strauss, A; Egerer, G; Haberkorn, U; Kasper, B; Lehner, B; Mechtersheimer, G; Schmitt, T; Strauss, LG; Stroebel, P; Vasamiliette, J, 2010) |
"The authors studied a dose-intense regimen of epirubicin and ifosfamide with hypofractionated preoperative radiotherapy for high-risk soft tissue sarcomas." | 5.13 | Histologic response of dose-intense chemotherapy with preoperative hypofractionated radiotherapy for patients with high-risk soft tissue sarcomas. ( Hayden, JB; Hosenpud, JR; Hung, AY; Mansoor, A; Montag, AG; Mundt, AJ; Peabody, TD; Ryan, CW; Samuels, B; Undevia, S, 2008) |
"The objective of this study is to assess the effect of anthracyclines/ifosfamide-based adjuvant chemotherapy for soft tissue sarcoma (STS) and provide a relative ranking of regimens for STS." | 5.12 | Effect of anthracyclines/ifosfamide-based adjuvant chemotherapy for soft tissue sarcoma: a conventional and network Meta-analysis. ( Hua, Q; Xu, G; Zhang, T; Zhao, L, 2021) |
"Perioperative three cycles of full-dose of anthracycline and ifosfamide should be proposed on an individual basis, in reference sarcoma centres, to high-risk localized STS of limbs or trunk-wall in certain histologies." | 5.12 | What is the standard indication of adjuvant or neoadjuvant chemotherapy in localized soft-tissue sarcoma? ( Hindi, N; Martin-Broto, J, 2021) |
"High-dose ifosfamide plus doxorubicin is an active regimen for all subtypes of gynecological sarcomas." | 5.12 | Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas. ( Cerny, T; Dietrich, D; Fey, M; Honegger, HP; Jundt, G; Leyvraz, S; Lissoni, A; Sessa, C; Zweifel, M, 2006) |
"To determine clinical activity and toxic effects of ifosfamide when used to treat cats with vaccine-associated sarcoma (VAS)." | 5.12 | Results of a phase II clinical trial on the use of ifosfamide for treatment of cats with vaccine-associated sarcomas. ( Chaffin, K; Khanna, C; Kristal, O; Page, RL; Rassnick, KM; Rodriguez, CO; Rosenberg, MP, 2006) |
"In the prospective high-risk sarcoma (HIRISA) Phase II trial HIRISA1, pediatric patients with high-risk sarcomas received 3 cycles of intensive vincristine, ifosfamide, etoposide, cyclophosphamide, and doxorubicin (VACIE) before radiotherapy and/or surgery began at Week 9 with concurrent vincristine, cyclophosphamide, and doxorubicin (Week 9) and vincristine and ifosfamide (Week 12)." | 5.12 | Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience. ( Billups, CA; Cain, AM; Furman, WL; Hale, GA; Merchant, TE; Navid, F; Pappo, AS; Rao, BN; Santana, VM; Spunt, SL, 2006) |
"Based on the promising results of a Phase I study with a combination of gemcitabine and DTIC performed in advanced soft tissue sarcoma (ASTS) patients, and due to the limited efficacy of second or third line therapies in those patients, we designed a Phase II study to determine the activity of this new regimen." | 5.12 | Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. ( Buesa, JM; Del Muro, JG; Escudero, P; Esteban, E; Fra, J; Gión, M; Goitia, A; López-Pousa, A; Losa, R; Maurel, J; Nadal, R; Sierra, M; Uña, E, 2007) |
"This phase I study evaluated the toxicity of first-line combined pegylated liposomal doxorubicin (Caelyx) and ifosfamide in patients with advanced and/or metastatic soft tissue sarcomas." | 5.12 | Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas. ( Blay, J; Christensen, TB; Daugaard, S; Hermans, C; Judson, I; Marreaud, S; Nielsen, OS; Pink, D; Reichardt, P; van Glabbeke, M, 2006) |
"Having determined in a phase I study the maximum tolerated dose of high-dose ifosfamide combined with high-dose doxorubicin, we now report the long-term results of a phase II trial in advanced soft-tissue sarcomas." | 5.12 | Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies. ( Cerny, T; Christinat, A; Dietrich, D; Fey, MF; Guillou, L; Herrmann, R; Honegger, HP; Leyvraz, S; Pestalozzi, B; Sessa, C; Wernli, M, 2006) |
"This randomized prospective multicenter phase III trial was designed to compare progression-free survival of patients with advanced soft tissue sarcoma receiving either regimen of standard doxorubicin 75 mg/m2 every 21 days, ifosfamide 9 g/m2 over 3 days continuous infusion, or ifosfamide 3 g/m2 per day in 3 hours over 3 days." | 5.12 | Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. ( Blay, JY; Hogendoorn, PC; Kirkpatrick, A; Le Cesne, A; Leahy, MG; Lorigan, P; Papai, Z; Radford, JA; Rodenhuis, S; Van Glabbeke, MM; Verweij, J, 2007) |
" The patients were treated between 1/1/1998 and 6/30/1999 according to the sarcoma protocols COSS-96, CWS-96, and EICESS-92, the median cumulative doses of the focussed drugs were for cisplatin: 360 mg/m(2), for doxorubicin: 270 mg/m(2), and for ifosfamide: 24 g/m(2)." | 5.11 | Late effects surveillance system for sarcoma patients. ( Beck, JD; Bielack, S; Langer, T; Paulussen, M; Stöhr, W; Treuner, J, 2004) |
"Combinations of high-dose ifosfamide (IF; 10-12 g/m2) plus doxorubicin (DX; 50-90 mg/m2) have been administered to patients with advanced soft tissue sarcoma (ASTS) in an attempt to improve therapeutic efficacy." | 5.11 | Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS). ( Balañá, C; Buesa, JM; Casado, A; de las Peñas, R; Fra, J; García del Muro, X; López-Pousa, A; Martín, J; Martínez-Trufero, J; Maurel, J, 2004) |
"5 g m(-2), carboplatin 100 mg m(-2) and etoposide 150 mg m(-2), days 1-4, q 28 days, G-CSF 5 microg kg(-1) starting from day 6) alone and in combination with regional hyperthermia (RHT) in soft tissue sarcoma (STS) refractory to previous standard doxorubicin-ifosfamide-based chemotherapy." | 5.11 | Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults. ( Abdel-Rahman, S; Fahn, W; Fiegl, M; Issels, RD; Schlemmer, M; Wendtner, CM, 2004) |
"Children with recurrent/refractory sarcoma were treated with ifosfamide (1,800 mg/m2/day on day 0-4), carboplatin (400 mg/m2/day on day 0-1), etoposide (100 mg/m2/day on day 0-4) and either rhG-CSF (10 microg/kg/day vs." | 5.11 | Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience. ( Anderson, B; Angiolillo, A; Cairo, MS; Cheung, YK; Davenport, V; Krailo, M; Reaman, G; Van Winkle, P, 2005) |
"The relative value of increasing ifosfamide dose in combination chemotherapy for patients with soft tissue sarcoma (STS) is unclear." | 5.11 | Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. ( Baker, LH; Biermann, JS; Chugh, R; Leu, KM; McGinn, CJ; Sondak, VK; Taylor, JM; Worden, FP; Zalupski, MM, 2005) |
"Ifosfamide and doxorubicin are the most effective agents in the treatment of sarcomas, although their contributions to survival are usually limited." | 5.11 | High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas. ( Akbulut, H; Buyukcelik, A; Demirkazik, A; Icli, F; Pamir, A; Utkan, G; Yalcin, B, 2004) |
"To describe the response rate and survival of children and adolescents with unresected or metastatic nonrhabdomyosarcomatous soft tissue sarcomas (NRSTS) treated with vincristine, ifosfamide, and doxorubicin." | 5.11 | Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study. ( Devidas, M; Gebhardt, M; Grier, HE; Jenkins, J; Marcus, R; Pappo, AS; Pratt, C; Rao, B; Thomas, P, 2005) |
"Doxorubicin and ifosfamide are the two most active agents used to treat soft tissue sarcomas." | 5.11 | Alternating sequential chemotherapy with high-dose ifosfamide and doxorubicin/cyclophosphamide for adult non-small round cell soft tissue sarcomas. ( Abe, S; Araki, N; Beppu, Y; Hasegawa, T; Ihara, K; Ishii, T; Isu, K; Kawai, A; Ozaki, T; Sugiura, H; Tsugane, S; Umeda, T; Wada, T; Yabe, H, 2005) |
"The anthracycline/ifosfamide combination is the most effective chemotherapy in soft tissue sarcoma." | 5.11 | Ifosfamide/liposomal daunorubicin is a well tolerated and active first-line chemotherapy regimen in advanced soft tissue sarcoma: results of a phase II study. ( Deckert, PM; Hütter, G; Keilholz, U; Schmittel, A; Siehl, JM; Szelényi, H; Thiel, E, 2005) |
"This randomized study compared the efficacy of epirubicin-based adjuvant chemotherapy on the disease-free interval (DFI) and overall survival of patients with high-risk soft-tissue sarcomas." | 5.10 | Adjuvant epirubicin with or without Ifosfamide for adult soft-tissue sarcoma. ( Civitelli, S; Coratti, A; Correale, P; D'Aniello, C; Francini, G; Grimaldi, L; Marsili, S; Marzocca, G; Messinese, S; Petrioli, R; Pirtoli, L; Tanzini, G, 2002) |
"The aim of this phase II study was to evaluate the efficacy and toxicity of two regimens of ifosfamide in metastatic soft tissue sarcoma patients given as first- and second-line chemotherapy." | 5.10 | Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. ( Dombernowsky, P; Hermans, C; Judson, I; Krzemieniecki, K; Mouridsen, HT; Nielsen, OS; Spooner, D; Svancarova, L; Van Glabbeke, M; van Oosterom, AT; Verweij, J, 2002) |
"The addition of ifosfamide and etoposide to a standard regimen does not affect the outcome for patients with metastatic disease, but it significantly improves the outcome for patients with nonmetastatic Ewing's sarcoma, primitive neuroectodermal tumor of bone, or primitive sarcoma of bone." | 5.10 | Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. ( Dickman, PS; Donaldson, SS; Fryer, CJ; Gebhardt, MC; Grier, HE; Krailo, MD; Link, MP; Meyers, PA; Miser, JS; Moore, S; Perlman, EJ; Pritchard, DJ; Rausen, AR; Tarbell, NJ; Vietti, TJ, 2003) |
"Cohorts of six patients with sarcoma (66 assessable patients) were treated sequentially with doxorubicin and ifosfamide (AI), with rhTPO by a fixed dose and varying schedules being administered before and/or after chemotherapy in cycle 2 and subsequent cycles." | 5.10 | Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia. ( Benjamin, RS; Broemeling, LD; Broxmeyer, HE; Bueso-Ramos, C; Burgess, A; Folloder, J; Papadopolous, N; Patel, S; Vadhan-Raj, S, 2003) |
"We conducted our study to determine the pharmacokinetics (PK) and clinical efficacy of oral mesna in patients receiving ifosfamide for soft tissue sarcoma." | 5.10 | Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide. ( Baker, LH; Bernardy, H; Demetri, G; Junge, K; Keohan, ML; Mace, JR; Mueller, U; Niebch, G; Romeis, P; Thoma, A; Wagner, T, 2003) |
"Between March 1994 and October 1997, 20 women and 19 men with primary extremity or limb girdle high-grade soft tissue sarcomas were registered to a study of preoperative ifosfamide, mitomycin, doxorubicin, cisplatin (IMAP) plus granulocyte macrophage-colony-stimulating factor (GM-CSF) followed by preoperative irradiation and subsequent limb-sparing surgery." | 5.10 | Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor. ( Buckner, JC; Edmonson, JH; Foo, ML; Gunderson, LL; Haddock, MG; Mahoney, MR; Maples, WJ; O'Connor, MI; Petersen, IA; Pritchard, DJ; Rock, MG; Shives, TC; Sim, FH; Stafford, SL, 2002) |
"To determine whether a prolonged 12-day continuous infusion allows the administration of high-dose ifosfamide (IFO) with an acceptable toxicity profile when combined with full-dose doxorubicin (Adriamycin; ADM) as first-line chemotherapy in patients with advanced soft tissue sarcomas." | 5.10 | Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas. ( Boni, C; Catania, C; Comandone, A; Curigliano, G; de Braud, F; De Pas, T; Marrocco, E; Masci, G; Pagani, O; Tucci, A, 2002) |
"This phase II study was designed to verify the activity and safety of an intensive epirubicin/ifosfamide schedule in untreated soft tissue sarcoma (STS) patients by using both the agents at the identified maximal tolerated doses." | 5.09 | Dose-intensive first-line chemotherapy with epirubicin and continuous infusion ifosfamide in adult patients with advanced soft tissue sarcomas: a phase II study. ( Bertero, G; Cosso, M; Neumaier, C; Palumbo, R; Pastorino, M; Raffo, P; Spadini, N; Toma, S; Valente, S; Villani, G, 1999) |
"This study was conducted to determine the maximum tolerated dose of an intensified MAID (mesna, adriamycin, ifosfamide, dacarbazine) regimen with the support of lenograstim in patients with advanced soft tissue sarcomas." | 5.09 | Phase I-II trial of intensification of the MAID regimen with support of lenograstim (rHuG-CSF) in patients with advanced soft-tissue sarcoma (STS). ( Bui, BN; Chevallier, B; Chevreau, C; Coindre, JM; Cour-Chabernaud, V; Gil, B; Krakowski, I; Maugard, C; Mihura, J, 1999) |
"The aim of this study was to assess the pharmacology, toxicity and activity of high-dose ifosfamide mesna +/- GM-CSF administered by a five-day continuous infusion at a total ifosfamide dose of 12-18 g/m2 in adult patients with advanced sarcomas." | 5.09 | Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK). ( Boddy, AV; Brunner, J; Cerny, T; Honegger, P; Küpfer, A; Leyvraz, S; Schaad, R; Schmitz, SF; Sessa, C; von Briel, T, 1999) |
"Twenty-four children and adolescents with metastatic sarcomas received VACIME chemotherapy, consisting of eight courses of vincristine 2 mg/m(2) on day 0; doxorubicin 20 mg/m(2)/day on days 0-3; cyclophosphamide 360 mg/m(2)/day on days 0-4; ifosfamide 1,800 mg/m(2)/day on days 0-4; mesna 2,400 mg/m(2)/day; and etoposide 100 mg/m(2)/day on days 0-4." | 5.09 | Very intensive, short-term chemotherapy for children and adolescents with metastatic sarcomas. ( Conrad, EU; Felgenhauer, J; Hawkins, D; Lindsley, K; Miser, JS; Pendergrass, T, 2000) |
"In this phase II study the effect of high-dose ifosfamide (HDI) given as a 3-day continuous infusion at a dose of 12 g/m2 repeated every 4 weeks with adequate mesna protection and hydration was evaluated in patients with advanced soft tissue sarcomas." | 5.09 | Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. ( Blay, JY; Hermans, C; Judson, I; Keizer, HJ; Krzemienlecki, K; le Cesne, A; Nielsen, OS; Oosterhuis, JW; Radford, JA; Svancárová, L; van Glabbeke, M; van Hoesel, Q; van Oosterom, A; Verweij, J, 2000) |
"Twenty-four patients with soft tissue or bone sarcoma who were treated with high dose ifosfamide-based chemotherapy were enrolled in this study." | 5.09 | Prospective randomized comparison of morning versus night daily single subcutaneous administration of granulocyte-macrophage-colony stimulating factor in patients with soft tissue or bone sarcoma. ( Akbulut, H; Demirkazik, A; Dinçol, D; Içli, F; Onur, H; Pamir, A; Samur, M; Sencan, O; Senler, FC; Yalçin, B, 2000) |
"This study investigated the population pharmacokinetics of ifosfamide in 15 patients treated for soft tissue sarcoma with 9 or 12 g m-2 ifosfamide by means of a 72 h continuous i." | 5.09 | Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM. ( Beijnen, JH; Huitema, AD; Keizer, HJ; Kerbusch, T; Mathôt, RA; Ouwerkerk, J; Schellens, JH, 2000) |
"The Soft Tissue and Bone Sarcoma Group (STBSG) of the EORTC ran a phase II study to assess the therapeutic activity of high-dose ifosfamide in patients with advanced soft tissue sarcomas by means of response rate (RR)." | 5.09 | Radiologist review versus group peer review of claimed responses in a phase II study on high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the EORTC Soft Tissue and Bone Sarcoma Group. ( Gwyther, SJ; Judson, IR; Nielsen, OS; van Glabbeke, M; Verweij, J, 2000) |
"The efficacy and feasibility of a novel sequential schedule of high-dose ifosfamide (HD-IFO) and full-dose epirubicin (EPI) with granulocyte colony-stimulating factor (G-CSF) was evaluated in adult patients with soft tissue sarcomas (STS)." | 5.09 | A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule. ( Cognetti, F; Gamucci, T; Nardi, M; Serrone, L; Zeuli, M, 2001) |
"The aim of this study was to examine the strategy, feasibility and outcome of neo-adjuvant chemotherapy, with doxorubicin and ifosfamide, in adult patients with 'high-risk' soft-tissue sarcomas." | 5.09 | A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. ( Azzarelli, A; Bramwell, VH; Buesa, J; Ezzat, A; Gortzak, E; Kirkpatrick, A; Oosterhuis, JW; Santoro, A; van Coevorden, F; van Geel, AN; van Glabbeke, M; Verweij, J, 2001) |
"The Epirubicin (EPI) and ifosfamide (IFO) combination has been widely tested in soft tissue sarcomas, even though the optimal schedule of drug administration has still to be defined." | 5.09 | Ifosfamide and epirubicin combination in untreated sarcomas: two treatment schedules. ( Cognetti, F; Nardoni, C; Pacetti, U; Papaldo, P; Serrone, L; Zeuli, M, 2001) |
"Patients with locally advanced or metastatic soft tissue sarcoma refractory to treatment with anthracyclines and ifosfamide were enrolled into the present phase II study." | 5.09 | Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial. ( Amann, G; Attems, Y; Brodowicz, T; Fiebiger, WC; Hejna, M; Köstler, WJ; Krainer, M; Tomek, S; Wiltschke, CH; Zielinski, CC, 2001) |
"The population pharmacokinetics and pharmacodynamics of the cytostatic agent ifosfamide and its main metabolites 2- and 3-dechloroethylifosfamide and 4-hydroxyifosfamide were assessed in patients with soft tissue sarcoma." | 5.09 | Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide and metabolites after a 72-h continuous infusion in patients with soft tissue sarcoma. ( Beijnen, JH; Keizer, HJ; Kerbusch, T; Mathĵt, RA; Ouwerkerk, J; Rodenhuis, S; Schellens, JH, 2001) |
"The study was designed to assess the toxicity and activity of high-dose ifosfamide (HDI) administered by continuous infusion at a dose of 4 g/m2/d over 3 days every 4 weeks in adult patients with advanced soft tissue sarcomas (ASTS) pretreated with doxorubicin and/or a standard-dose ifosfamide (SDI)-containing regimen." | 5.08 | High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. ( Antoine, E; Brain, E; Fontaine, F; Genin, J; Janin, N; Kayitalire, L; Le Cesne, A; Le Chevalier, T; Spielmann, M; Toussaint, C, 1995) |
"The Intergroup Rhabdomyosarcoma Study (IRS) initiated an escalating-dose cyclophosphamide (Cyc) pilot without hematopoietic growth factor (HGF) support in combination with vincristine (Vcr) and actinomycin-D (Amd), known as VAC, to establish a Cyc dose with myelotoxicity comparable to an ifosfamide (Ifos), Vcr, and Amd combination regimen (VAI)." | 5.08 | Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and response. ( Gehan, E; Maurer, H; Newton, WA; Ruymann, FB; Vietti, T; Wharam, M; Wiener, E, 1995) |
"This two-arm, double-blind, randomized trial was conducted to determine the effects of lenograstim, a glycosylated recombinant human granulocyte colony-stimulating factor (rHu-G-CSF), on the hematologic tolerance of patients with sarcoma treated with mesna, doxorubicin, ifosfamide, and doxorubicin (MAID) chemotherapy." | 5.08 | Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity. ( Bonichon, F; Bui, BN; Chevallier, B; Chevreau, C; Cupissol, D; Fargeot, P; Krakowski, I; Maugard-Louboutin, C; Peny, AM; Thyss, A, 1995) |
"Ifosfamide, an oxazaphosphorine analogue, is now commonly used in first-line anthracycline-containing regimens for advanced soft tissue sarcomas, based on its demonstrated single-agent activity in previously treated patients." | 5.08 | High-dose ifosfamide in the treatment of advanced soft tissue sarcomas. ( Tursz, T, 1996) |
"Since dose intensity of doxorubicin is correlated with the clinical response of patients with soft tissue sarcomas and since doxorubicin dose intensity may be compromised in combination chemotherapy, we evaluated the use of recombinant granulocytemacrophage colony-stimulating factor (rGM-CSF) to ameliorate myelosuppression and allow doxorubicin dose escalation in a phase I trial utilizing the MAID combination [Mesna 2." | 5.08 | GM-CSF did not allow doxorubicin dose escalation in the MAID regimen: a phase I trial. A Southwest Oncology Group study. ( Balcerzak, SP; Hicks, LG; Zalupski, M, 1996) |
"Ten patients (three males and seven females) were treated for sarcoma with high-dose ifosfamide (IFO) according to a 4 g/m2 1 h i." | 5.08 | Phenobarbital administration does not affect high-dose ifosfamide pharmacokinetics in humans. ( Lokiec, F; Santoni, J; Tubiana-Hulin, M; Weill, S, 1996) |
" ifosfamide (5 g/m2), carboplatin (300 mg/m2), and etoposide given with WBH, as well as, day 2 and 3 post-WBH (100 mg/m2) for adult patients with refractory sarcoma." | 5.08 | Ifosfamide, carboplatin and etoposide (ICE) combined with 41.8 degrees C whole body hyperthermia in patients with refractory sarcoma. ( Crahé, R; Deeken, M; Eleftheriadis, S; Gutsche, S; Katschinski, DM; Mentzel, M; Robins, HI; Storer, B; Wagner, T; Weiss, C; Wiedemann, GJ, 1996) |
"Ifosfamide is one of the most efficient antimitotic in soft tissue sarcoma." | 5.08 | [High dose ifosfamide at 15 g/m2/cycle: a feasibility study in 10 patients]. ( Baranzelli, MC; Deligny, N; Demaille, MC; Gourmel, B; N'Guyen, M; Pichon, F, 1997) |
"To evaluate the efficacy and feasibility of high-dose ifosfamide (HDI) at a total dose of 14 g/m2 per cycle with mesna in combination with granulocyte colony-stimulating factor (G-CSF) in adult patients with sarcomas." | 5.08 | High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. ( Benjamin, RS; Burgess, MA; Hays, C; Papadopolous, N; Patel, SR; Plager, C; Vadhan-Raj, S, 1997) |
"A phase I study was designed for the amalgamation of two previously studied antisarcoma regimens (ifosfamide+doxorubicin and mitomycin+doxorubicin+cisplatin) supported by molgramostim." | 5.08 | Can molgramostim enhance the antitumor effects of cytotoxic drugs in patients with advanced sarcomas? ( Edmonson, JH; Grill, JP; Kvols, LK; Long, HJ; Mann, BS, 1997) |
"This Phase I/II study investigates increasingly high doses of ifosfamide combined with full dose doxorubicin chemotherapy supported with peripheral blood stem cells (PBSC) and granulocyte-colony stimulating factor (G-CSF) in patients with metastatic soft tissue sarcoma (STS)." | 5.08 | A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. ( Arseniev, L; Bokemeyer, C; Franzke, A; Hartmann, JT; Kanz, L; Link, H; Metzner, B; Schmoll, HJ; Schöber, C, 1997) |
"The purpose of this study was to evaluate tumour response and toxicity to ifosfamide and continuous infusion etoposide in metastatic or locally advanced soft tissue sarcoma, with dose escalations under G-CSF (granulocyte colony-stimulating factor) support." | 5.08 | Ifosfamide and continuous infusion etoposide in advanced adult soft tissue sarcoma. A Scandinavian Sarcoma Group Phase II Study. ( Alvegård, TA; Erlanson, M; Hannisdal, E; Klepp, R; Monge, OR; Raabe, N; Saeter, G; Söderberg, M; Solheim, OP; Strander, H; Turesson, I; Wist, E, 1997) |
"Ifosfamide has important activity in pretreated soft tissue sarcomas (STS), and recent data support a clinically significant dose-response relationship for this agent." | 5.08 | Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas. ( Antimi, M; Gatti, C; Palmeri, S; Palumbo, R; Raffo, P; Toma, S; Villani, G, 1997) |
"The authors evaluate the efficacy and feasibility of dose-intensive doxorubicin and ifosfamide combination chemotherapy in patients with sarcomas." | 5.08 | Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. ( Benjamin, RS; Burgess, MA; Jenkins, J; Papadopolous, N; Patel, SR; Plager, C; Vadhan-Raj, S, 1998) |
"The agent Ifosfamide (IFOS) is active against soft tissue sarcomas (STS), and patients who progress to IFOS at doses < or = 10 g/m2 show remissions when exposed to high-dose ifosfamide (HDI) (i." | 5.08 | Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS) ( Antón, A; Arranz, F; Bellmunt, J; Buesa, JM; Casado, A; Escudero, P; García del Muro, J; López-Pousa, A; Martín, J; Menéndez, D; Poveda, A; Valentí, V, 1998) |
"Ifosfamide and doxorubicin are the most active agents in the treatment of sarcomas and are characterized by a marked dose-response relationship." | 5.08 | Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK). ( Bacchi, M; Bressoud, A; Cerny, T; Hermann, R; Leyvraz, S; Lissoni, A; Sessa, C, 1998) |
"Adriamycin (ADM) and ifosfamide (IFO) are the two most active agents in the treatment of soft tissue sarcomas (STS) with a clear dose-response relationship." | 5.08 | High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible? ( Aapro, MS; De Braud, F; De Pas, T; Fazio, N; Goldhirsch, A; Munzone, E; Nolè, F; Orlando, L; Zampino, MG, 1998) |
"Ifosfamide is an active chemotherapeutic agent in the treatment of soft tissue sarcoma." | 5.07 | Ifosfamide and etoposide in the treatment of advanced soft tissue sarcomas. ( Baker, LH; Blair, SC; Zalupski, MM, 1994) |
"The purpose of this review is to characterize the nephrotoxicity noted in newly diagnosed patients under 21 years of age after treatment with ifosfamide-containing chemotherapy regimens and local irradiation for localized gross residual rhabdomyosarcoma or undifferentiated sarcoma." | 5.07 | Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor. ( Ensign, LG; Foreman, J; Khan, F; Maurer, H; Newton, W; Ortega, J; Ragab, A; Raney, B; Wharam, M; Wiener, E, 1994) |
"5 g/m2 mesna was administered for 7 days, both by continuous infusion, in combination with 50 mg/m2/d oral etoposide for 8 days in 21 patients with sarcomas or other solid tumors." | 5.07 | Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas. ( Hamdan, H; Skubitz, KM; Thompson, RC, 1993) |
"To evaluate the feasibility, toxicity and efficacy of the combination of (IFO) ifosfamide and epirubicin (EPI) given at conventional doses for monochemotherapy, we started a phase II study in advanced/metastatic soft tissue sarcoma patients." | 5.07 | Epirubicin and ifosfamide in advanced soft tissue sarcomas. ( Buonadonna, A; Carbone, A; Crivellari, D; De Paoli, A; Foladore, S; Frustaci, S; Monfardini, S; Morassut, S; Sorio, R, 1993) |
"This three-armed phase III study in adults with advanced soft tissue sarcomas was planned as a comparison of objective regression rates, toxicity, and survival of patients receiving doxorubicin alone, ifosfamide plus doxorubicin, and mitomycin plus doxorubicin plus cisplatin." | 5.07 | Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. ( Blum, RH; Brooks, JS; Edmonson, JH; Frytak, S; Parkinson, DR; Ryan, LM; Shiraki, M, 1993) |
"Doxorubicin alone or with dacarbazine (DTIC; AD) is considered the best available therapy for metastatic adult sarcomas." | 5.07 | An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. ( Antman, K; Balcerzak, SP; Barlogie, B; Cooper, RM; Crowley, J; Elias, A; Natale, RB; Rivkin, SE; Trump, DL; Weiss, GR, 1993) |
"The objective of this phase II trial was to assess the therapeutic activity and toxicity of doxorubicin plus ifosfamide in previously untreated patients with advanced soft-tissue sarcoma." | 5.07 | Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma. ( Blackledge, G; Dombernowsky, P; Mouridsen, HT; Santoro, A; Schütte, J; Somers, R; Steward, W; Thomas, D; van Oosterom, AT; Verweij, J, 1993) |
"A total of 51 patients with large, primary, high-grade soft-tissue sarcomas of the extremities were treated at our institute with two preoperative and three postoperative cycles of doxorubicin plus ifosfamide/mesna." | 5.07 | Preoperative doxorubicin plus ifosfamide in primary soft-tissue sarcomas of the extremities. ( Azzarelli, A; Casali, P; Fissi, S; Montalto, F; Quagliuolo, V; Santoro, A, 1993) |
"The Southwest Oncology Group (SWOG) performed a phase II trial of a combination of ifosfamide/mesna/cisplatin in patients with metastatic soft-tissue sarcoma who had previously received one chemotherapeutic regimen." | 5.07 | Phase II trial of ifosfamide and cisplatin in the treatment of metastatic sarcomas: a Southwest Oncology Group study. ( Balcerzak, SP; Budd, GT; Fabian, C; Metch, B; Stephens, RL; Weick, JK; Weiss, SA, 1993) |
"On the basis of ifosfamide's demonstrated single-agent activity in adult soft-tissue sarcoma, the Eastern Cooperative Oncology Group (ECOG) tested whether ifosfamide would add to the efficacy of doxorubicin in a three-regimen, controlled phase III trial." | 5.07 | Efficacy of ifosfamide in combination with doxorubicin for the treatment of metastatic soft-tissue sarcoma. The Eastern Cooperative Oncology Group. ( Blum, RH; Edmonson, J; Pelletier, L; Ryan, L, 1993) |
"A total of 37 adult patients with locally advanced or metastatic soft-tissue sarcoma (STS) entered a pilot study of combination chemotherapy based on the CYVADIC (cyclophosphamide, vincristine, doxorubicin, and dacarbazine) regimen, in which cyclophosphamide was replaced by ifosfamide and mesna (1 g/m2 ifosfamide given daily on days 1-5 as 2-h infusions, 1." | 5.07 | Ifosfamide, vincristine, doxorubicin and dacarbazine in adult patients with advanced soft-tissue sarcoma. ( Blomqvist, CP; Elomaa, I; Virolainen, M; Wiklund, TA, 1992) |
"Doxorubicin and ifosfamide are the two most active agents used in the treatment of advanced inoperable soft-tissue sarcoma, but their use in combination produces dose-limiting myelosuppression." | 5.07 | Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma Group. ( Blackledge, G; Clavel, M; Greifenberg, B; Soedirman, J; Somers, R; Steward, WP; Thomas, D; Van Glabbeke, M; Van Oosterom, AT; Verweij, J, 1991) |
"In a phase II trial of ifosfamide 2 g/m2 days 1 to 4 with mesna uroprotection in 124 patients who had previously failed treatment for sarcomas, 3% achieved a complete response (CR), and 18% had a CR or partial response (PR)." | 5.06 | Dana-Farber Cancer Institute studies in advanced sarcoma. ( Antman, KH; Elias, A, 1990) |
"European and American investigators have reported response rates of 38% to 83% for ifosfamide alone in pretreated sarcomas." | 5.06 | Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. ( Antman, KH; Elias, A; Grier, HE; Ryan, L; Sherman, D, 1989) |
"In this phase II trial, 105 eligible patients with no prior chemotherapy and advanced sarcoma received doxorubicin, ifosfamide, and dacarbazine (DTIC) with mesna uroprotection (MAID)." | 5.06 | Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. ( Aisner, J; Antman, KH; Collins, J; Elias, A; Ryan, L; Sulkes, A, 1989) |
"Between April 1986 and March 1987, 42 patients with advanced sarcoma were entered in this multi-institutional trial evaluating ifosfamide plus doxorubicin." | 5.06 | Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase II trial. ( Braun, TJ; Hainsworth, JD; Loehrer, PJ; Martelo, OJ; Nicaise, C; Omura, G; Sledge, GW; Usakewicz, J, 1989) |
"The regimen of doxorubicin (DOX), ifosfamide (IFF), and dacarbazine (DTIC) (AID) for previously untreated inoperable or metastatic sarcoma has acceptable toxicity with significant activity." | 5.06 | Doxorubicin, ifosfamide, and dacarbazine (AID) with mesna uroprotection for advanced untreated sarcoma: a phase I study. ( Antman, KH; Elias, AD, 1986) |
"One hundred and seventy-one patients with advanced soft tissue sarcoma entered a randomized crossover phase II study comparing cyclophosphamide (CYCLO) with a new analogue, ifosfamide (IFOS), both administered as 24 h i." | 5.06 | Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas. ( Blackledge, G; Bramwell, VH; Mouridsen, HT; Santoro, A; Somers, R; Sylvester, R; Thomas, D; Van Oosterom, A, 1986) |
"43 patients with metastasizing sarcomas were treated with a combination of either vincristin, adriamycin and cis-platinum (n = 21) or ifosfamide and cis-platinum at three weeks' intervals in each case." | 5.05 | [Chemotherapy in advanced sarcomas (author's transl)]. ( Bierbaum, W; Bremer, K; Firusian, N; Higi, M; Niederle, N; Scheulen, ME; Schmidt, CG; Seeber, S, 1981) |
"A marginal interaction between sex and the type of alkylating agent was observed for event-free survival in the Euro-EWING99-R1 randomized controlled trial (RCT) comparing cyclophosphamide and ifosfamide in Ewing sarcoma." | 4.95 | Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study). ( Anderson, JR; Boddy, AV; De Vathaire, F; Dirksen, U; Fresneau, B; Gaspar, N; Gelderblom, H; Hackshaw, A; Hawkins, DS; Judson, I; Le Deley, MC; Le Teuff, G; Lewis, I; Litière, S; Paulussen, M; Pignon, JP; van den Berg, H; Wheatley, K; Whelan, J, 2017) |
"Ifosfamide and Mesna are currently given to patients for 14 days continuous home-based infusion for the treatment of soft tissue sarcoma." | 4.93 | Evaluation of the stability profile of anticancer drugs: A review of Ifosfamide and Mesna regimen for the treatment of metastatic soft tissue sarcoma. ( Barton, S; Nabhani-Gebara, S; Peron, JM; Salman, D; Swinden, J, 2016) |
"Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma." | 4.91 | Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. ( Kremer, LC; Langer, T; Mulder, RL; Paulides, M; van Dalen, EC, 2015) |
"Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma." | 4.88 | Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. ( Kremer, LC; Langer, T; Mulder, RL; Paulides, M; van Dalen, EC, 2012) |
"Independent favourable prognostic factors for overall survival (OS) were good performance status, female gender, low histological grade, extremity primary tumour site and locally advanced disease; for progression-free survival (PFS), the combination of doxorubicin and ifosfamide, locally advanced disease, and tumour entity with a lower risk to progress for synovial sarcoma patients compared to leiomyosarcoma." | 4.86 | Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Tr ( Blay, JY; Hogendoorn, PC; Krarup-Hansen, A; Le Cesne, A; Ouali, M; Rodenhuis, S; Sleijfer, S; van Glabbeke, M; Verweij, J, 2010) |
"Ifosfamide is a chemotherapeutic prodrug used in the treatment of several tumor entities, including bone and soft-tissue sarcoma." | 4.86 | Palifosfamide, a bifunctional alkylator for the treatment of sarcomas. ( Jung, S; Kasper, B, 2010) |
"Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma." | 4.86 | Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. ( Kremer, LC; Langer, T; Mulder, RL; Paulides, M; van Dalen, EC, 2010) |
" Therefore, gemcitabine should be considered as the best option after doxorubicin failure in leiomyosarcoma patients." | 4.86 | [Chemotherapy options for patients with advanced soft-tissue sarcoma beyond anthracyclines]. ( Bui-Nguyen, B; Italiano, A; Toulmonde, M, 2010) |
"We describe a case of SP that occurred during chemotherapy with ifosfamide and doxorubicin in a patient with an advanced pleomorphic sarcoma." | 4.86 | Spontaneous pneumothorax during chemotherapy: a case report. ( Cathomas, R; Fehr, M; Furrer, M; von Moos, R, 2010) |
"In summary, female sex, low total bilirubin, albumin and haemoglobin levels, and obesity appear to be associated with ifosfamide-induced encephalopathy." | 4.84 | Encephalopathy after high-dose Ifosfamide: a retrospective cohort study and review of the literature. ( Beri, R; Shord, SS; Sweiss, KI, 2008) |
"This meta-analysis examines the role of ifosfamide-based combination chemotherapy in patients with advanced soft tissue sarcoma." | 4.84 | Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma. ( Blackstein, M; Haynes, AE; Stys-Norman, D; Verma, S; Younus, J, 2008) |
"Doxorubicin-based chemotherapy does not appear to offer a survival benefit to patients who have high-risk primary extremity soft tissue sarcomas, whereas ifosfamide-based chemotherapy does." | 4.83 | Advances in chemotherapy for patients with extremity soft tissue sarcoma. ( Eckardt, JJ; Eilber, FC; Eilber, FR; Nelson, SD; Tap, WD, 2006) |
"Ifosfamide and anthracyclines are the only active agents in advanced soft tissue sarcomas." | 4.82 | Ifosfamide in the adjuvant therapy of soft tissue sarcomas. ( Berretta, M; Bidoli, E; Boz, G; Buonadonna, A; De Paoli, A; Frustaci, S; Gherlinzoni, F; La Mura, N, 2003) |
"Few cytotoxic agents are active for the treatment of soft tissue sarcomas of adults: drugs active in monotherapy are doxorubicin, ifosfamide, dacarbazine and ET743." | 4.81 | [High-dose chemotherapy in soft tissue sarcomas of adults]. ( Biron, P; Blay, JY; Ray-Coquard, I, 2001) |
"The current study was performed to evaluate the toxicity profile of therapeutic doses of ifosfamide (IFX) given concurrently with full-dose external beam radiotherapy (EBRT) in patients with soft tissue and bone sarcomas." | 4.81 | Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma. ( Ballo, MT; Benjamin, RS; Burgess, MA; Cormier, JN; Feig, BW; Herzog, CE; Hunt, KK; Patel, SR; Pisters, PW; Raney, RB; Zagars, GK, 2001) |
"Ifosfamide is one of the three most active agents in the treatment of soft tissue sarcomas." | 4.79 | Ifosfamide in the treatment of soft tissue sarcomas. ( Budd, GT; Connelly, EF, 1996) |
"Ifosfamide is an alkylating agent with clinical activity in the treatment of sarcomas, and data support a dose-response relationship in this disease." | 4.79 | High-dose ifosfamide in the treatment of sarcomas of soft tissues and bone. ( Demetri, GD, 1996) |
"This article gives highlights of ongoing pediatric solid tumor and leukemia trials in the United States that use ifosfamide in combination with mesna." | 4.79 | Ongoing clinical studies of ifosfamide for pediatric cancer in the United States. ( Pratt, CB, 1996) |
"We have used ifosfamide to treat patients with sarcomas in four completed single-agent protocols and one pilot study since 1985." | 4.78 | Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience. ( Benjamin, RS; Legha, SS; Nicaise, C; Patel, SR, 1993) |
"Doxorubicin and ifosfamide are currently the two main drugs for the treatment of soft tissue sarcomas in adults." | 4.78 | Perspectives on anthracyclines plus ifosfamide in advanced soft tissue sarcomas. ( Azzarelli, A; Bertulli, R; Casali, P; Devizzi, L; Pastorino, U; Santoro, A; Zucchinelli, P, 1993) |
" The most active single agents against osteosarcoma are doxorubicin (overall response rate, 21%), methotrexate (30% to 40%), cisplatin (25%), and ifosfamide (28%)." | 4.78 | Chemotherapy of advanced sarcomas of bone and soft tissue. ( Antman, KH, 1992) |
"Ifosfamide is an analogue of cyclophosphamide that has been extensively investigated in sarcomas." | 4.78 | The role of ifosfamide in the treatment of adult soft tissue sarcomas, Ewing's sarcoma, and osteosarcoma: a review. ( Dirix, LY; Van Oosterom, AT, 1990) |
"The alkylating agent ifosfamide has demonstrated significant activity against advanced sarcomas." | 4.77 | The role of ifosfamide in the treatment of sarcomas. ( Dirix, LY; Van Oosterom, AT, 1989) |
"The most active single agents in soft-tissue sarcomas are doxorubicin (Adriamycin) and ifosfamide, with response rates of 20-35%." | 4.77 | Chemotherapy of advanced soft-tissue sarcomas. ( Antman, KH; Elias, AD, 1988) |
"The alkylating agent ifosfamide, an analog of cyclophosphamide, has demonstrated significant activity in soft tissue sarcoma and testicular carcinoma." | 4.77 | Ifosfamide. ( Baker, LH; Zalupski, M, 1988) |
"We conducted a multi-institutional retrospective study, identifying sarcoma patients who received anthracyclines and/or ifosfamide during pregnancy." | 4.12 | Pregnancy outcomes related to the treatment of sarcomas with anthracyclines and/or ifosfamide during pregnancy. ( Agulnik, M; Davis, LE; Godbole, S; Hirbe, AC; Livingston, JA; Miller, D; Park, Y; Parkes, A; Posey, K; Robinson, SI; Skubitz, K; Van Tine, BA, 2022) |
"To investigate the value of contrast-enhanced computed tomography (CECT) radiomics features in predicting the efficacy of epirubicin combined with ifosfamide in patients with pulmonary metastases from soft tissue sarcoma." | 4.12 | Prediction of the therapeutic efficacy of epirubicin combined with ifosfamide in patients with lung metastases from soft tissue sarcoma based on contrast-enhanced CT radiomics features. ( Jiang, X; Li, M; Ma, ST; Miao, L; Wang, YM; Zhang, HH, 2022) |
"To compare long-term outcomes of high-grade, primary soft-tissue-sarcoma (STS), using Ifosfamide-Doxorubicin vs local therapy alone, in histology-specific sarcomas." | 4.02 | The role of Ifosfamide-doxorubicin chemotherapy in histology-specific, high grade, locally advanced soft tissue sarcoma, a 14-year experience. ( Burchette, RJ; Goy, BW; Helmstedter, CS; Padmanabhan, A; Syed, S, 2021) |
"For Ewing sarcoma, interval-compressed vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide administered every 2 weeks rather than every 3 weeks has been shown to improve event-free survival in pediatric patients." | 3.96 | Feasibility of Treating Adults with Ewing or Ewing-Like Sarcoma with Interval-Compressed Vincristine, Doxorubicin, and Cyclophosphamide Alternating with Ifosfamide and Etoposide. ( Bassale, S; Davis, LE; Lim, JY; Lu, E; Ryan, CW, 2020) |
"We compared the outcomes in soft tissue sarcoma (STS) treated with olaratumab and doxorubicin (OD) versus doxorubicin, ifosfamide, and mesna (AIM) to assess whether OD could supersede AIM in STS therapy." | 3.96 | Doxorubicin and Olaratumab Versus Doxorubicin, Ifosfamide, and Mesna for Treatment of Advanced Soft Tissue Sarcomas. ( Copeland, VC; Cranmer, LD; Hammer, KJ; Loggers, ET; Pollack, SM; Wagner, MJ, 2020) |
"The objective of this study was to analyze outcomes for patients with soft tissue sarcoma of the extremities using neoadjuvant ifosfamide-based chemotherapy and hypofractionated reduced dose radiotherapy, followed by limb-sparing surgery." | 3.88 | Long-term Outcomes With Ifosfamide-based Hypofractionated Preoperative Chemoradiotherapy for Extremity Soft Tissue Sarcomas. ( Bernthal, NM; Bukata, SV; Chmielowski, B; Dry, SM; Eckardt, JJ; Eilber, FC; Eilber, FR; Federman, N; Kalbasi, A; Kamrava, M; Luu, M; Nelson, SD; Pennington, JD; Reed, JP; Selch, MT; Singh, AS; Steinberg, ML; Wang, PC, 2018) |
"A retrospective search of the Royal Marsden Sarcoma Unit Database was performed to identify patients initially treated with ifosfamide (as single agent or in combination) and who were subsequently rechallenged with single-agent ifosfamide." | 3.88 | Successful Ifosfamide Rechallenge in Soft-Tissue Sarcoma. ( Benson, C; Constantinidou, A; Jones, RL; Judson, I; Messiou, C; Miah, A; Noujaim, J; Thway, K, 2018) |
"This study was designed to assess patterns of recurrence and long-term outcomes of patients undergoing surgery for localized retroperitoneal sarcoma (RPS) after neoadjuvant high dose long-infusion ifosfamide (HLI) and radiotherapy (RT)." | 3.85 | Long-term Follow-up and Post-relapse Outcome of Patients with Localized Retroperitoneal Sarcoma Treated in the Italian Sarcoma Group-Soft Tissue Sarcoma (ISG-STS) Protocol 0303. ( Basso, S; Bertola, G; Bertuzzi, A; Buonadonna, A; Casali, PG; Colombo, C; De Paoli, A; De Sanctis, R; Fiore, M; Giordano, L; Gronchi, A; Marrari, A; Navarria, F; Navarria, P; Quagliuolo, V; Sanfilippo, R; Sangalli, C; Santoro, A, 2017) |
"Anthracycline and ifosfamide-based chemotherapy represents a widely used regimen both in early and advanced settings in soft tissue sarcoma (STS)." | 3.85 | Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR). ( Amadori, D; Bongiovanni, A; De Vita, A; Di Iorio, V; Foca, F; Ibrahim, T; Liverani, C; Mercatali, L; Miserocchi, G; Monti, M; Recine, F; Riva, N, 2017) |
"We retrospectively reviewed outcomes of treatment with VIP (combination of etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma (STS)." | 3.85 | VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma. ( Baek, SW; Choi, YS; Jo, DY; Kim, S; Lee, HJ; Moon, JY; Ryu, H; Song, IC; Yun, HJ, 2017) |
" Finally, the approach is demonstrated in a phase II trial studying two dose levels of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor in soft tissue sarcoma patients over four cycles." | 3.83 | Multivariate Markov models for the conditional probability of toxicity in phase II trials. ( Fernandes, LL; Murray, S; Taylor, JM, 2016) |
"5%) nonmetastatic soft tissue sarcoma received neoadjuvant chemoradiotherapy with ifosfamide (1." | 3.83 | Effective local control of advanced soft tissue sarcoma with neoadjuvant chemoradiotherapy and surgery: A single institutional experience. ( Agaimy, A; Croner, R; Fietkau, R; Hohenberger, W; Lettmaier, S; Ott, O; Semrau, S; Stubbe, F; Vassos, N, 2016) |
"A retrospective study of sarcoma and lymphoma patients receiving ifosfamide chemotherapy was performed at the participating institutions." | 3.81 | An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center. ( Butrynski, J; Cirrone, F; Feng, Y; Fisher, DC; Harris, C; McDonnell, AM; Neuberg, D; Szabatura, AH; Voit, D, 2015) |
"A 67-year-old male patient developed progressive renal failure following successful treatment of a soft tissue sarcoma that comprised surgical resection after neoadjuvant radiochemotherapy with the application of doxorubicin (cumulative dose 180 mg/m²) and ifosfamide (cumulative dose 33 g/m²)." | 3.80 | [End-stage renal disease after sarcoma therapy - case 3/2014]. ( Amann, K; Artunc, F; Bakos, G; Baumann, D; Bunz, H; Ciarimboli, G; Kluba, T; Kopp, HG; Müller, M; Schlatter, E; Steinke, I; Weyrich, P, 2014) |
"For high-risk soft tissue sarcoma (HR-STS) of adults new treatment strategies are needed to improve outcome with regard to local control and overall survival." | 3.80 | Current trials and new aspects in soft tissue sarcoma of adults. ( Issels, RD; Schlemmer, M, 2002) |
"Our data suggest that multimodal treatment with ifosfamide and/or locoregional hyperthermia in combination with neoadjuvant radiotherapy might improve outcome in high-risk soft tissue sarcomas." | 3.79 | Effect of concurrent chemotherapy and hyperthermia on outcome of preoperative radiotherapy of high-risk soft tissue sarcomas. ( Bamberg, M; Eckert, F; Gani, C; Kluba, T; Kopp, HG; Mayer, F; Müller, AC; Zips, D, 2013) |
"Patients (≥18 years old) affected by soft tissue sarcoma and treated with epirubicin and ifosfamide, underwent prophylactic treatment with G-CSF (lenograstim at 263 μg) from day 5 to day 9." | 3.79 | Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma. ( Badalamenti, G; Bronte, G; Fulfaro, F; Incorvaia, L; Leto, G; Maltese, G; Provenzano, S, 2013) |
"Ifosfamide is an alkylating agent, frequently used in the treatment of sarcoma." | 3.77 | Ifosfamide nephropathy in patients with sarcoma. ( Keikhaei, M; Mashhadi, MA; Sanadgol, H, 2011) |
"We retrospectively examined the incidence, severity, and risk factors of ifosfamide encephalopathy in 61 Japanese patients with bone and soft tissue sarcomas at our institution." | 3.76 | Ifosfamide encephalopathy associated with chemotherapy for musculoskeletal sarcomas: incidence, severity, and risk factors. ( Kikuchi, S; Konno, S; Tajino, T; Takeda, A; Yamada, H, 2010) |
"We evaluated the feasibility and toxicity of bevacizumab in combination with sequential high-dose (HD) ifosfamide, carboplatin and etoposide refractory to standard chemotherapy in patients with sarcoma and germ cell cancer (GCC)." | 3.76 | Bevacizumab in combination with sequential high-dose chemotherapy in solid cancer, a feasibility study. ( Arnold, D; Behlendorf, T; Jordan, K; Kegel, T; Mueller, LP; Schmoll, HJ; Sippel, C; Voigt, W; Wolf, HH, 2010) |
"To report two cases of recurrent uterine sarcoma that developed ifosfamide-induced encephalopathy (IIE) with successful management." | 3.76 | Ifosfamide-induced encephalopathy in patients with uterine sarcoma. ( Chang, FW; Liu, YL; Tsai, SH; Yu, MH, 2010) |
"Ifosfamide is currently used to treat pediatric sarcomas and increasing its dosage may be associated with a better response rate." | 3.76 | Prolonged 14-day continuous infusion of high-dose ifosfamide with an external portable pump: feasibility and efficacy in refractory pediatric sarcoma. ( Casanova, M; Cefalo, G; Favini, F; Ferrari, A; Luksch, R; Massimino, M; Meazza, C; Podda, M, 2010) |
" Doxorubicin should be administered preferably as 3-weekly bolus injections at doses higher than 60 mg/m2 because of its dose-response relationship." | 3.76 | The treatment of soft tissue sarcomas with focus on chemotherapy: a review. ( Pinedo, HM; Verweij, J, 1986) |
"A retrospective study of inpatients with sarcoma who received a two or four-day regimen of MAI (mesna, doxorubicin, and ifosfamide) between January 1, 2004 and December 31, 2006 was conducted." | 3.74 | Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant. ( Hatfield Seung, A; Howell, JE; Nesbit, SA; Szabatura, AH, 2008) |
"Our data suggest a potential role for anthracycline- and ifosfamide-containing chemotherapy in the adjuvant setting for early-stage uterine sarcomas." | 3.74 | Anthracycline-based adjuvant chemotherapy in early-stage uterine sarcomas: long-term results of a single institution experience. ( Bamias, A; Bozas, G; Dimopoulos, MA; Gika, D; Kastritis, E; Markaki, S; Papadimitriou, CA; Rodolakis, A; Voulgaris, Z; Zorzou, MP, 2007) |
"Patients treated on sarcoma protocols containing ifosfamide as the only potential gonadotoxic agent, were evaluated, assessing pubertal development, menstrual history in the females and semen analysis in males." | 3.74 | Does ifosfamide affect gonadal function? ( Crofton, PM; Levitt, G; Williams, D, 2008) |
"To report the experience of a single institution in the south of Israel with doxorubicin and ifosfamide-mesna in patients with advanced/recurrent uterine sarcomas." | 3.73 | Doxorubicin and ifosfamide-mesna in advanced and recurrent uterine sarcomas. ( Piura, B; Rabinovich, A, 2005) |
"Medical records of adults and children diagnosed with sarcoma whom received ifosfamide with a cumulative dose >20 g/m(2) were evaluated." | 3.72 | Influence of age upon Ifosfamide-induced nephrotoxicity. ( Blough, D; Friedman, DL; Hawkins, DS; Magbulos, M; McCune, JS; Schuetze, S, 2004) |
"To assess the impact of different factors on response rate (RR), time to tumor progression (TTP), and overall survival time (OS) in patients with locally advanced or metastatic soft tissue sarcoma (ASTS), included in three protocols with high-dose ifosfamide (HDIF)." | 3.72 | Salvage surgical resection after high-dose ifosfamide (HDIF) based regimens in advanced soft tissue sarcoma (ASTS): a potential positive selection bias--a study of the Spanish group for research on sarcomas (GEIS). ( Balañá, C; Buesa, J; Casado, A; de Las Peñas, R; del Muro, XG; López-Pousa, A; Martín, J; Martínez-Trufero, J; Maurel, J; Quintana, MJ, 2004) |
"Twenty-three children and adolescents with metastatic sarcomas received vincristine, doxorubicin, cyclophosphamide, ifosfamide, sodium mercaptoethanesulfonate (mensa), and etoposide (VACIME) chemotherapy, consisting of 8 courses of vincristine 2 mg/m(2) on Day 0, doxorubicin 37." | 3.71 | Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas. ( Douglas, J; Felgenhauer, J; Gooley, T; Hawkins, DS; Kreissman, S; Park, J; Pendergrass, TW; Rowley, SD; Sanders, JE; Thomson, B, 2002) |
"Adriamycin, dacarbazine and ifosfamide are three effective chemotherapy drugs in treating progressive soft tissue sarcoma." | 3.71 | [Continuous-infusion high dose ifosfamide as salvage treatment for pre-treated soft tissue sarcoma]. ( Chen, LK; Liang, Y; Liu, JL; Teng, XY; Xu, GC; Zhou, XM, 2002) |
"The aim of this study was to investigate the severity and time-course of alterations in gastroduodenal and intestinal permeability in relation to nausea/emesis following administration of the highly emetogenic polydrug regimen IFADIC (ifosfamide, Adriamycin, dacarbazine) using a differential lactulose/mannitol absorption (SLM) test." | 3.71 | Alterations in intestinal permeability following the intensified polydrug-chemotherapy IFADIC (ifosfamide, Adriamycin, dacarbazine). ( Brodowicz, T; Fazeny-Dörner, B; Marosi, C; Muhm, M; Veitl, M; Vogelsang, H; Wenzel, C; Zielinski, C, 2002) |
"Ifosfamide is a leading drug in soft tissue sarcoma therapy." | 3.70 | Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas. ( Bergnolo, P; Boglione, A; Bumma, C; Colussi, AM; Comandone, A; Dal Canton, O; Frustaci, S; Leone, L; Monteleone, M; Oliva, C, 1998) |
"In three new approved indications (non Hodgkin's lymphoma, Hodgkin's lymphoma and acute lymphoblastic leukaemia) and in three previously existing indications (ovarian cancer, soft tissue sarcomas and osteogenic sarcomas), non comparative trials show that ifosfamide can induce tumour regression in patients who relapse after a first course of chemotherapy (sometimes containing cyclophosphamide)." | 3.70 | Ifosfamide: new idications-new dose strength. Limited evidence of effectiveness. ( , 1998) |
"Accelerated split-course radiation with 60 to 64 Gy and concurrent chemotherapy using adriamycin/ifosfamide is a safe and effective treatment for soft tissue sarcoma." | 3.70 | [Neoadjuvant radiochemotherapy in soft tissue sarcomas. Optimization of local functional tumor control]. ( Fietkau, R; Grabenbauer, GG; Hohenberger, W; Papadopoulos, T; Sauer, R; Schuchardt, U; Wittekind, C, 1999) |
"Our objective was to assess the efficacy of a standard dose ifosfamide and doxorubicin containing regimen in the treatment of advanced soft tissue sarcomas." | 3.70 | Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy. ( Altundağ, K; Baltali, E; Barişta, I; Celik, I; Firat, D; Güler, N; Güllü, I; Kars, A; Ozişik, Y; Tekuzman, G; Türker, A; Uner, A; Yalçin, S; Zengin, N, 2000) |
" This study compares the kidney toxicity to the kidney of ifosfamide, carboplatin and etoposide (ICE) chemotherapy alone, and ICE chemotherapy combined with either extracorporeal (e-WBH) or radiant-heat-induced hyperthermia (r-WBH) in 43 patients with refractory sarcoma." | 3.70 | Nephrotoxicity of ifosfamide, carboplatin and etoposide (ICE) alone or combined with extracorporeal or radiant-heat-induced whole-body hyperthermia. ( Filejski, W; Gerke, P; Robins, HI; Steinhoff, J; Wiedemann, GJ, 2000) |
"Between 1992 and 1999, 13 consecutive patients with completely resected moderate- to high-grade uterine sarcoma received three cycles of adjuvant ifosfamide (1." | 3.70 | Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma. ( Belinson, JL; Kennedy, AW; Kushner, DM; Markman, M; Rybicki, LA; Webster, KD, 2000) |
"A total of 33 patients (median age, 44 years) with high-grade, adult soft-tissue sarcoma were treated with etoposide given at 600 mg/m2 in a 72-h continuous infusion and ifosfamide given at 1500 mg/m2 per day for 3 days every 3 weeks." | 3.69 | Treatment of advanced, high-grade soft-tissue sarcoma with ifosfamide and continuous-infusion etoposide. ( Saeter, G; Solheim, OP; Talle, K, 1995) |
"Four patients with metastatic ovarian mixed Müllerian sarcoma (2 homologous, 2 heterologous) were treated with mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) chemotherapy." | 3.69 | Mesna, doxorubicin, ifosfamide, and dacarbazine chemotherapy for ovarian mixed müllerian sarcoma: report of four cases. ( Greenberg, S; Patsner, B, 1995) |
"The renal function of newly diagnosed children and young adults with high risk sarcomas was followed during therapy with a high dose ifosfamide-containing regimen." | 3.69 | A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults. ( Balis, FM; Blaney, S; Ho, PT; Izraeli, S; Jarosinski, P; Weaver-McClure, L; Wexler, LH; Zimmerman, K, 1995) |
"Twenty patients with advanced sarcomas entered a pilot study with ifosfamide (IF) and mercaptoethane sulfonate sodium (Mesna) as a second-line treatment for six planned cycles." | 3.69 | High-dose ifosfamide by infusion with Mesna in advanced refractory sarcomas. ( Alkiş, N; Baltali, E; Barişta, I; Celik, I; Güler, N; Güllü, I; Kars, A; Tekuzman, G; Yalçin, S; Zengin, N, 1996) |
"High-dose ifosfamide (HD-IFX) has shown significant antitumor activity in advanced sarcoma and breast carcinoma." | 3.69 | Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis. ( Albanell, J; Baselga, J; Bellmunt, J; Casado, S; Eres, N; Ribas, A, 1997) |
"From January 1990 to December 1995 we treated 35 patients (pts) with bone and soft tissue sarcoma with ifosfamide (IFM)." | 3.69 | [The effects of high-dose ifosfamide in the treatment of bone and soft tissue sarcomas]. ( Ishii, T; Kitoh, M; Satoh, T; Tatezaki, S; Umeda, T; Yonemoto, T, 1997) |
"This study was designed to test the feasibility of administering doxorubicin at an optimal dose-intensity (> 70 mg/m2 per 21 days) in combination with ifosfamide under recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) cover in patients with metastatic soft tissue sarcomas." | 3.68 | Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Grou ( Clavel, M; Crowther, D; Kerbrat, P; Rouesse, J; Somers, R; Spooner, D; Steward, WP; Tueni, E; Tursz, T; Verweij, J, 1993) |
"A total of 64 courses of ifosfamide (IFM) treatments for sarcoma patients were evaluated for toxic effects." | 3.68 | [Toxic effects of ifosfamide in the treatment of bone and soft tissue sarcomas]. ( Ishii, T; Kitoh, M; Satoh, T; Tatezaki, S; Umeda, T, 1993) |
"Between 1982 and 1986, 38 patients with soft-tissue sarcomas were treated with the combination doxorubicin/dacarbazine (group A); between 1986 and 1990, another 46 patients received doxorubicin/ifosfamide (group B); and between 1990 and 1991, 11 patients received an alternating regimen of doxorubicin and ifosfamide (group C)." | 3.68 | Treatment results obtained in metastatic soft-tissue sarcoma with a combination of doxorubicin and dacarbazine or doxorubicin and ifosfamide. ( Agarwal, K; Dietel, M; Hossfeld, DK; Schwarz, R; Weh, HJ; Zornig, C, 1993) |
"Two trials using ifosfamide-based combination chemotherapy for advanced soft-tissue sarcoma have been completed." | 3.68 | Ifosfamide combination regimens for soft-tissue sarcoma. ( Bell, DR; Dalley, D; Levi, J; Simes, RJ; Stuart-Harris, R; Wiltshaw, E, 1993) |
"The response of ifosfamide-based chemotherapeutic regimens was retrospectively analyzed in adult patients with advanced soft-tissue sarcoma who were treated at the West German Tumor Center, Essen, between 1978 and 1990." | 3.68 | Ifosfamide in the treatment of soft-tissue sarcomas: experience at the West German Tumor Center, Essen. ( Kellner, R; Schütte, J; Seeber, S, 1993) |
"Currently, anthracyclines and ifosfamide are the most effective drugs for the treatment of disseminated soft-tissue sarcoma." | 3.68 | A pilot study of rapidly alternating epirubicin/dacarbazine and ifosfamide as first-line therapy for metastatic soft-tissue sarcoma in adults. ( Anagnou, J; Bokemeyer, C; Harstrick, A; Knipp, H; Köhne-Wömpner, CH; Neumann, S; Poliwoda, H; Schmoll, HJ; Schöffski, P; Wipperman, B, 1993) |
"A total of 46 consecutive patients were entered into this study to assess the efficacy and toxicity of an epirubicin/ifosfamide combination in treating locally advanced and/or metastatic adult sarcomas (38 soft-tissue sarcomas and 7 bone sarcomas in 45 evaluable patients)." | 3.68 | Ifosfamide plus epirubicin at escalating doses in the treatment of locally advanced and/or metastatic sarcomas. ( Albanese, E; Barisone, A; Canavese, G; Cantoni, E; Palumbo, R; Reggiardo, G; Rosso, R; Santi, L; Toma, S, 1993) |
"We gave the "optimal" dose of doxorubicin (75 mg/m2) with ifosfamide (5 g/m2), the two most active agents against metastatic soft-tissue sarcomas, in an attempt to determine the feasibility of administration of these doses in combination." | 3.68 | The use of recombinant human granulocyte-macrophage colony-stimulating factor with combination chemotherapy in the treatment of advanced adult soft-tissue sarcomas: early results from the EORTC Soft-Tissue and Bone Sarcoma Group. ( Clavel, M; Crowther, D; Kerbrat, P; Rouesse, J; Somers, R; Spooner, D; Steward, WP; Tueni, E; Tursz, T; Verweij, J, 1993) |
"Twenty-eight patients with non-pretreated metastatic soft tissue sarcomas were entered on a treatment protocol of rapidly alternating epirubicin/dacarbazine and ifosfamide: Epirubicin 100 mg/m2 d1, dacarbazine 500 mg/m2 d1 + d2, ifosfamide 6000 mg/m2 24-h infusion d15; repeated d29." | 3.68 | Epirubicin/dacarbazine rapidly alternated with ifosfamide in the treatment of metastatic soft tissue sarcomas. ( Bokemeyer, C; Harstrick, A; Köhne-Wömpner, CH; Poliwoda, H; Schmoll, HJ; Schöffski, P, 1992) |
"The pharmacokinetics of ifosfamide were studied in 20 patients with soft tissue and bone sarcomas." | 3.68 | Clinical pharmacokinetics of ifosfamide in combination with N-acetylcysteine. ( Ayele, W; Benvenuto, JA; Legha, SS; Newman, RA; Nicaise, C; Raber, MN, 1992) |
"From July 1986 to 1990, 65 patients with deep-seated, advanced sarcomas (43 soft-tissue sarcomas, 12 Ewing's sarcomas, 7 chondrosarcomas and 3 osteosarcomas) were entered in a protocol involving regional hyperthermia (RHT) combined with systemic ifosfamide and etoposide." | 3.68 | Improvement of local control by regional hyperthermia combined with systemic chemotherapy (ifosfamide plus etoposide) in advanced sarcomas: updated report on 65 patients. ( Denzlinger, C; Gerl, A; Issels, RD; Mittermüller, J; Ortmaier, A; Sauer, H; Simon, W; Wilmanns, W, 1991) |
"The mesna, doxorubicin, ifosfamide, dacarbazine regimen produced a 47% response rate (including 10% complete responses) in 105 eligible adults with advanced sarcoma." | 3.68 | Mesna, doxorubicin, ifosfamide, dacarbazine (MAID) regimen for adults with advanced sarcoma. ( Aisner, J; Antman, KH; Elias, A; Ryan, L, 1990) |
"From July 1986 to July 1989, 40 patients (92% pretreated) with deep-seated, advanced soft tissue sarcomas (STS, 25 patients), Ewing's sarcomas (ES, eight patients), osteosarcomas (OS, three patients) and chondrosarcomas (ChS, four patients) were treated at the University of Munich in a protocol involving regional hyperthermia (RHT) combined with ifosfamide plus etoposide." | 3.68 | Ifosfamide plus etoposide combined with regional hyperthermia in patients with locally advanced sarcomas: a phase II study. ( Berger, H; Boehm, E; Denecke, H; Issels, RD; Jauch, KW; Nagele, A; Peter, K; Prenninger, SW; Sauer, H; Wilmanns, W, 1990) |
"The objective of this phase II trial was to assess the therapeutic activity and toxicity of doxorubicin plus ifosfamide in previously untreated patients with advanced soft tissue sarcoma." | 3.68 | Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group. ( Blackledge, G; Dombernowsky, P; Mouridsen, HT; Santoro, A; Schütte, J; Somers, R; Stewart, W; Thomas, D; van Oosterom, AT; Verweij, J, 1990) |
"The combination of ifosfamide (IFO) and epirubicin (EPI) has been found to be an effective regimen in the treatment of metastatic tumours and shows remarkable activity in heavily pretreated breast cancer patients." | 3.68 | Epirubicin and ifosfamide in patients with refractory breast cancer and other metastatic solid tumours. ( Hoffmann, W; Könner, J; Migeod, F; Seeber, S; Weidmann, B, 1990) |
"Forty-three adult patients with locally advanced or metastatic soft tissue sarcoma entered a pilot study of combination chemotherapy comprising 50 mg of doxorubicin/m2 by intravenous bolus, 850 mg of dacarbazine/m2 by 1-hour infusion, and 5 g of ifosfamide/m2 by 24-hour infusion with mesna uroprotection." | 3.67 | Combination chemotherapy with doxorubicin, dacarbazine, and ifosfamide in advanced adult soft tissue sarcoma. Canadian Sarcoma Group--National Cancer Institute of Canada Clinical Trials Group. ( Bramwell, V; Eisenhauer, E; Knowling, M; Quirt, I; Verma, S; Warr, D; Young, V, 1989) |
"Early results with ifosfamide plus mesna in soft tissue sarcoma showed an initial response rate of 38% in 42 patients." | 3.67 | Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma. ( Fisher, C; Harmer, C; McKinna, A; Westbury, G; Wiltshaw, E, 1986) |
"One hundred twenty-four children and young adults with recurrent tumors, predominantly sarcomas, were treated with the combination of ifosfamide, etoposide, and the uroprotector, mesna (2-mercaptoethane sulphonate), in a phase II trial." | 3.67 | Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. ( Forquer, R; Jarosinski, P; Kinsella, TJ; Magrath, I; Miser, JS; Triche, TJ; Tsokos, M; Wesley, R, 1987) |
"Fifty-four patients with advanced soft tissue sarcoma were treated with a combination of ifosfamide (5 g/m2) and adriamycin (40-60 mg/m2) at 3 weekly intervals." | 3.67 | A phase I-II study of ifosfamide in combination with adriamycin in the treatment of adult soft tissue sarcoma. ( Fisher, C; King, M; MacMillan, S; Mansi, JL; Stuart-Harris, R; Wiltshaw, E, 1988) |
"We have evaluated the activity of ifosfamide in 75 patients with recurrent sarcomas and pediatric solid tumors." | 3.67 | A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people. ( Arasi, V; Magrath, I; Miser, J; Raynor, A; Rosenberg, S; Sandlund, J, 1986) |
" Hemorrhagic cystitis was not observed in patients treated with 400-500 mg of mesna iv every 4 hours during ifosfamide treatment." | 3.67 | Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. ( Antman, KH; Montella, D; Rosenbaum, C; Schwen, M, 1985) |
"In a phase II study, 42 patients with advanced soft-tissue sarcoma were treated with ifosfamide by 24-h infusion and mesna by 4-h IV bolus, repeated every 3 weeks." | 3.66 | High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma. ( Gowing, NF; Harper, PG; Kaye, SB; Mooney, CA; Parsons, CA; Stuart-Harris, RC; Wiltshaw, E, 1983) |
"The efficacy of ifosfamide combination chemotherapy was studied in 164 patients, 94 with advanced testicular carcinoma and 70 with metastatic sarcoma." | 3.66 | Ifosfamide in combination chemotherapy for sarcomas and testicular carcinomas. ( Cremer, M; Niederle, N; Scheulen, ME; Schmidt, CG; Schütte, J; Seeber, S, 1983) |
"The value of neoadjuvant chemotherapy in soft tissue sarcoma (STS) is not completely understood." | 3.11 | Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial. ( Bagué, S; Bianchi, G; Blay, JY; Braglia, L; Brunello, A; Bruzzi, P; Casali, PG; Coindre, JM; Dei Tos, AP; Diaz-Beveridge, R; Donati, DM; Ferraresi, V; Fontana, V; Grignani, G; Gronchi, A; Infante, G; Lopez-Pousa, A; Lugowska, I; Marchesi, E; Marrari, A; Martin-Broto, J; Merlo, DF; Miceli, R; Morosi, C; Palassini, E; Palmerini, E; Pasquali, S; Picci, P; Quagliuolo, V; Stacchiotti, S; Tendero, O, 2022) |
"The therapy of high-risk soft tissue sarcomas (STS) remains an interdisciplinary challenge." | 3.01 | Hyperthermia in the treatment of high-risk soft tissue sarcomas: a systematic review. ( Ademaj, A; Corradini, S; Eckert, F; Flörcken, A; Ghadjar, P; Issels, R; Kaul, D; Lindner, LH; Oberacker, E; Ott, OJ; Pink, D; Potkrajcic, V; Reichardt, P; Riesterer, O; Roohani, S; Spalek, MJ; Veltsista, PD; Zips, D, 2023) |
"The value of chemotherapy in soft tissue sarcoma (STS) remains controversial." | 2.94 | Value of peri-operative chemotherapy in patients with CINSARC high-risk localized grade 1 or 2 soft tissue sarcoma: study protocol of the target selection phase III CHIC-STS trial. ( Cabarrou, B; Chevreau, C; Chibon, F; Filleron, T; Le Guellec, S; Lesluyes, T; Lodin, S; Massoubre, A; Mounier, M; Poublanc, M; Valentin, T, 2020) |
"Patients with soft tissue sarcoma are at risk for local recurrence and distant metastases despite optimal local treatment." | 2.87 | Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial. ( Abdel-Rahman, S; Angele, M; Belka, C; Daugaard, S; Dürr, HR; Ghadjar, P; Gronchi, A; Hiddemann, W; Hohenberger, P; Issels, RD; Jauch, KW; Knösel, T; Lindner, LH; Mansmann, U; Mella, O; Reichardt, P; Salat, C; Schmidt, M; Verweij, J; Vujaskovic, Z; Wessalowski, R; Wust, P, 2018) |
"Patients with Stage III non-round cell soft tissue sarcomas in the extremities were eligible." | 2.80 | Perioperative chemotherapy with ifosfamide and doxorubicin for high-grade soft tissue sarcomas in the extremities (JCOG0304). ( Araki, N; Chuman, H; Fukuda, H; Hatano, H; Hiruma, T; Iwamoto, Y; Mizusawa, J; Morioka, H; Ozaki, T; Takahashi, M; Tanaka, K; Tsuchiya, H, 2015) |
"Metastatic soft tissue sarcoma (STS) prognosis remains poor and few cytotoxic agents offer proven efficacy." | 2.77 | High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial. ( Bay, JO; Blay, JY; Bonichon, F; Bui-Nguyen, B; Chevreau, C; Coindre, JM; Cupissol, D; Italiano, A; Jimenez, M; Lotz, JP; Mathoulin-Pélissier, S; Penel, N; Ray-Coquard, I; Thyss, A, 2012) |
"The role of chemotherapy in high-risk soft tissue sarcoma is controversial." | 2.76 | A phase II study evaluating neo-/adjuvant EIA chemotherapy, surgical resection and radiotherapy in high-risk soft tissue sarcoma. ( Bischof, M; Dietrich, S; Dimitrakopoulou-Strauss, A; Egerer, G; Ho, AD; Kasper, B; Lehner, B; Mechtersheimer, G; Roeder, F; Schmitt, T; Strauss, LG; Wuchter, P, 2011) |
"Prognosis of patients with metastatic soft tissue sarcoma remains poor." | 2.75 | Consolidation with high-dose chemotherapy and stem cell support for responding patients with metastatic soft tissue sarcomas: prospective, single-institutional phase II study. ( Dietrich, S; Egerer, G; Ho, AD; Kasper, B; Scharrenbroich, I; Schmitt, T; Wuchter, P, 2010) |
" Fifty-nine patients underwent primary surgery by wide or marginal excision and were subsequently randomized to receive radiotherapy alone or in combination with six courses of chemotherapy consisting of ifosfamide, DTIC, and doxorubicin administered in 14-day intervals supported by G-CSF on days 5-13." | 2.75 | Intensified adjuvant IFADIC chemotherapy in combination with radiotherapy versus radiotherapy alone for soft tissue sarcoma: long-term follow-up of a prospective randomized feasibility trial. ( Abdolvahab, F; Brodowicz, T; Dominkus, M; Ebm, C; Fakhrai, N; Jantsch, M; Kauer-Dorner, D; Kostler, WJ; Pokrajac, B; Zielinski, CC, 2010) |
" A novel five-drug combination of etoposide, vincristine, dactinomycin, ifosfamide, and doxorubicin (EVAIA) was evaluated for high-risk patients, but cumulative chemotherapy dosage and treatment duration were reduced for the remaining individuals as compared with that of the previous trial CWS-86." | 2.74 | Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults. ( Bielack, SS; Brecht, I; Dantonello, TM; Dickerhoff, R; Gadner, H; Greiner, J; Greulich, M; Harms, D; Herbst, M; Int-Veen, C; Juergens, H; Kirsch, S; Klingebiel, T; Koscielniak, E; Leuschner, I; Marky, I; Scheel-Walter, HG; Schmelzle, R; Schmidt, BF; Treuner, J, 2009) |
"To compare the radiological criteria RECIST, WHO, and tumor volume for evaluation of tumor response in patients with soft tissue sarcomas (STS) showing either good or poor pathohistological response to neoadjuvant chemotherapy combined with regional hyperthermia, and to examine the dependence of the findings on the applied thermal dose." | 2.74 | Comparison of radiological and pathohistological response to neoadjuvant chemotherapy combined with regional hyperthermia (RHT) and study of response dependence on the applied thermal parameters in patients with soft tissue sarcomas (STS). ( Abdel-Rahman, S; Issels, RD; Lindner, LH; Reiser, MF; Santl, M; Stahl, R; Wang, T, 2009) |
"Ifosfamide is a chemotherapeutic agent that requires cytochrome P450 3A (CYP3A) for bioactivation and metabolism." | 2.73 | Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma. ( Baker, LH; Chugh, R; Griffith, KA; Leu, KM; Taylor, JM; Thomas, DG; Wagner, T; Worden, FP; Zalupski, MM, 2007) |
"Six patients experienced early disease progression, and four patients died while on treatment." | 2.73 | Experience of the use of trabectedin (ET-743, Yondelis) in 21 patients with pre-treated advanced sarcoma from a single centre. ( Daniels, S; McTiernan, A; Roylance, R; Seddon, B; Sykes, K; Whelan, J, 2007) |
"Eligibility included a high-grade soft tissue sarcoma > or = 8 cm in diameter of the extremities and body wall." | 2.72 | Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. ( Blum, RH; DeLaney, TF; Eisenberg, B; Ettinger, DS; Harmon, DC; Harris, J; Kraybill, WG; Letson, GD; Lucas, DR; Spiro, IJ, 2006) |
" Samples for pharmacokinetic analysis were obtained after the MTD was reached." | 2.72 | Phase I trial and pharmacokinetic analysis of ifosfamide in cats with sarcomas. ( Beaulieu, BB; Kristal, O; Lewis, LD; Moore, AS; Northrup, NC; Page, RL; Rassnick, KM, 2006) |
"Uterine sarcomas are rare tumors." | 2.72 | Concurrent radiochemotherapy of locally recurrent or advanced sarcomas of the uterus. ( Fietkau, R; Gerber, B; Klautke, G; Kortmann, B; Reimer, T, 2006) |
"Noninvasive MR thermography of soft tissue sarcoma was feasible and suitable for validating the quality of heating during RHT." | 2.72 | Noninvasive magnetic resonance thermography of soft tissue sarcomas during regional hyperthermia: correlation with response and direct thermometry. ( Budach, V; Felix, R; Ganter, H; Gellermann, J; Hildebrandt, B; Issels, R; Reichardt, P; Tunn, PU; Wlodarczyk, W; Wust, P, 2006) |
"Prognosis of patients with metastatic soft tissue sarcomas (MSTS) is poor even after response to doxorubicin-based chemotherapy." | 2.72 | Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas. ( Abdel-Rahman, S; Baumert, J; Falk, M; Hentrich, M; Hiddemann, W; Issels, RD; Licht, T; Salat, C; Schlemmer, M; Straka, C; Wendtner, CM, 2006) |
"To determine the efficacy of neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for local tumor control and overall survival (OS) in adult patients with retroperitoneal or visceral (RP/V) high-risk soft tissue sarcomas (HR-STS)." | 2.70 | Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas. ( Abdel-Rahman, S; Baumert, J; Baur, A; Hiddemann, W; Issels, RD; Krych, M; Lindner, LH; Wendtner, CM, 2002) |
"Adjuvant chemotherapy for soft tissue sarcoma is controversial because previous trials reported conflicting results." | 2.70 | Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. ( Apice, G; Azzarelli, A; Barbieri, E; Bonetti, M; Buonadonna, A; Comandone, A; De Paoli, A; Frustaci, S; Gherlinzoni, F; Olmi, P; Picci, P; Pignatti, G; Serraino, D; Zmerly, H, 2001) |
"In this phase II study, activity and safety of neoadjuvant regional hyperthermia (RHT) combined with chemotherapy was investigated in 59 patients with primary advanced or recurrent high-risk soft-tissue sarcoma (STS)." | 2.70 | Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults: long-term results of a phase II study. ( Abdel-Rahman, S; Aydemir, U; Falk, MH; Hiddemann, W; Issels, RD; Kurze, V; Sauer, H; Wendtner, C, 2001) |
" 54 patients were prospectively treated with four cycles of etoposide, ifosfamide and doxorubicin (EIA) combined with regional hyperthermia (RHT) followed by surgery, another four cycles of EIA without RHT and external beam radiation." | 2.70 | Treatment of primary, recurrent or inadequately resected high-risk soft-tissue sarcomas (STS) of adults: results of a phase II pilot study (RHT-95) of neoadjuvant chemotherapy combined with regional hyperthermia. ( Abdel-Rahman, S; Baumert, J; Falk, MH; Hiddemann, W; Issels, RD; Krych, M; Santl, M; Wendtner, C, 2001) |
" These results indicate that there is no identifiable pharmacokinetic basis for insistence on either bolus or infusional methods of IFOS administration." | 2.69 | The pharmacokinetics and metabolism of ifosfamide during bolus and infusional administration: a randomized cross-over study. ( Brennan, C; Hartley, JM; Nicholson, PW; Singer, JM; Souhami, RL, 1998) |
"The goal of the second German Soft Tissue Sarcoma Study CWS-86 (1985 to 1990) was to improve the prognosis in children and adolescents with soft tissue sarcoma by means of a clinical trial comprising intensive chemotherapy and risk-adapted local therapy." | 2.69 | Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. ( Gadner, H; Harms, D; Henze, G; Herbst, M; Jürgens, H; Klingebiel, T; Knietig, R; Koscielniak, E; Morgan, M; Schmidt, BF; Treuner, J, 1999) |
"Etoposide monotherapy was successful in 8%; the effectiveness of cisplatin was 5-23%." | 2.69 | The efficacy of a combination of etoposide, ifosfamide, and cisplatin in the treatment of patients with soft tissue sarcoma. ( Bodoky, G; Eckhardt, S; Láng, I; Pápai, Z; Poller, I; Rahóty, P; Szántó, J; Szendroi, M, 2000) |
"Gemcitabine was administered as a 360 min infusion on days 1, 8 and 15 of a 28 day cycle." | 2.69 | Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. ( Dietzmann, A; Genvresse, I; Grunewald, R; Koschuth, A; Possinger, K; Späth-Schwalbe, E, 2000) |
"Patients with non-resectable soft tissue sarcomas of the extremities do not live longer if they are treated by amputation or disarticulation." | 2.69 | Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. ( Bejkos, D; Bischof-Delaloye, A; Chassot, PG; Chiolero, R; Genton, A; Guillou, L; Landry, M; Lejeune, FJ; Leyvraz, PF; Leyvraz, S; Liénard, D; Mirimanoff, RO; Mosimann, F; Pujol, N; Raffoul, W, 2000) |
"More effective high-dose combination regimens are needed which have broad cytotoxic activity, steep dose-response relations and non-overlapping non-hematologic toxicities (to allow administration of full doses of each agent)." | 2.68 | Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support. ( Ayash, LJ; Elias, AD; Frei, E; Gonin, R; Mazanet, R; McCauley, M; Schnipper, L; Schwartz, G; Tepler, I; Wheeler, C, 1995) |
"In advanced soft tissue sarcomas of adults, single-agent doxorubicin is still the standard chemotherapy against which more intensive or new drug treatments should be compared." | 2.68 | Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. ( Buesa, J; Casali, P; Mouridsen, H; Rankin, E; Santoro, A; Somers, R; Spooner, D; Steward, W; Tursz, T; Verweij, J, 1995) |
" No clinical evidence of renal failure was attributed to the high dosage of the drug in the course of assays of biochemical components of the blood, blood- and urine-beta-2-microglobulins, N-acetyl-D-hexoaminidase (NAG) level in urine, creatinine clearance and complex renoscintigraphy data." | 2.68 | [High-dose ifosfamide in the treatment of patients with soft tissue sarcoma]. ( Averinova, SG; Garin, AM; Kashkadaeva, AV; Liubimova, NV; Romanova, LF; Shiriaev, SV; Sidorova, NI; Tiuliandin, SA, 1996) |
"Ifosfamide (5 g/m2) was compared with its parent analogue cyclophosphamide (1." | 2.67 | Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group. ( Blackledge, G; Bramwell, VH; Dombernowsky, P; Mouridsen, HT; Onsrud, M; Santoro, A; Somers, R; Sylvester, R; Thomas, D; Verweij, J, 1993) |
"Ifosfamide dosage was not increased." | 2.67 | Epirubicin and ifosfamide in advanced soft tissue sarcoma: a phase II study. ( Chevallier, B; Facchini, T; Fargeot, P; Leyvraz, S; Olivier, JP; Vo Van, ML, 1993) |
"Patients with localized high-risk soft tissue sarcoma are at high risk for both local recurrence and distant metastases despite optimal surgical treatment." | 2.61 | [Multimodal treatment of sarcomas: standards and new aspects in pharmacological and radio-oncological treatment]. ( Lindner, LH, 2019) |
"Localized soft tissue sarcoma may be cured with complete tumor excision, but overall, outcomes are sub-optimal." | 2.58 | Selection of Patients With Localized Extremity Soft Tissue Sarcoma for Treatment With Perioperative Chemotherapy. ( Charlson, J, 2018) |
"Proximal epithelioid sarcoma (PES) originating from the pleura is a clinical entity rarely reported in the literature." | 2.53 | [Pleural epithelioid sarcoma: about a case and review of the literature]. ( Akasbi, Y; Amara, B; Arifi, S; Chatar, A; Fatemi, H; Lemrabet, FZ; Mellas, N; Ouahbi, H; Oualla, K; Tizniti, S, 2016) |
"Sarcomas are a group of rare solid tumours arising from mesenchymal or connective tissue." | 2.50 | Soft tissue sarcoma: an update on systemic treatment options for patients with advanced disease. ( Cornillie, J; Hompes, D; Li, H; Schöffski, P; Wozniak, A, 2014) |
"Soft tissue sarcomas are rare tumours in adults and therefore require a multidisciplinary approach for optimal management." | 2.47 | Systemic management strategies for metastatic soft tissue sarcoma. ( Movva, S; Verschraegen, C, 2011) |
"Soft tissue sarcomas are a heterogeneous group of connective tissue tumors, with more than 50 different subtypes." | 2.44 | Chemotherapeutic management of soft tissue sarcoma. ( Thornton, K, 2008) |
"Soft tissue sarcomas are rare cancers of mesenchymal origin." | 2.44 | Emerging drugs for the treatment of soft tissue sarcomas. ( Alberti, L; Blay, JY; Cassier, PA; Dufresne, A; Fayette, J; Ranchere, D; Ray-Coquard, I, 2007) |
"In advanced epithelial ovarian cancer, it has been tested in association with cisplatin, achieving results equal, if not better than cyclophosphamide, with acceptable toxicity." | 2.42 | Ifosfamide in the treatment of malignant epithelial ovarian tumors. ( Fei, F; Fruscio, R; Lissoni, AA; Rossi, R; Villa, A; Zani, G, 2003) |
"For high-risk soft tissue sarcomas (HR-STS) of adults, new treatment strategies are needed to improve outcome with regard to local control and overall survival." | 2.42 | Ifosfamide with regional hyperthermia in soft-tissue sarcomas. ( Issels, RD; Schlemmer, M; Wendtner, CM, 2003) |
"Soft tissue sarcomas are a heterogeneous group of malignancies arising from mesenchymal tissues." | 2.42 | Emerging treatments for soft tissue sarcoma of adults. ( Fahn, W; Issels, RD, 2004) |
"Primary soft tissue sarcoma (STS) of the breast is a rare and heterogeneous disease." | 2.41 | Primary soft tissue sarcoma of the breast. ( Benjamin, RS; Trent II, JC; Valero, V, 2001) |
" Such simultaneous administration enabled us to substantially increase the dosage intensity of both, thereby increasing the effectiveness of each drug." | 2.40 | Infusional chemotherapy combined with recombinant human granulocyte colony stimulating factor: advantages and limitations. ( Lackman, RD; Weiss, AJ, 1997) |
"The first chemotherapy study of soft tissue sarcoma (STS) by the Scandinavian Sarcoma Group was started in 1981 (SSG I)." | 2.40 | Chemotherapy in soft tissue sarcoma. The Scandinavian Sarcoma Group experience. ( Alvegård, TA; Fernberg, JO; Hall, KS; Monge, O; Saeter, G; Strander, H; Wiklund, T, 1999) |
"The groups active in the treatment of osteosarcomas and Ewing's sarcomas should be encouraged to investigate the new active drugs in the relapsing patients." | 2.39 | New drugs for the treatment of sarcomas. ( van Oosterom, AT; Verweij, J, 1995) |
"Osteosarcoma is a clinically heterogeneous disease which continues to resist biologic diagnosis, classification, or staging." | 2.39 | Problems and controversies in the management of childhood sarcomas. ( Womer, RB, 1996) |
"The role of chemotherapy for soft tissue sarcoma with the exception of rhabdomyosarcoma remains controversial." | 2.38 | [Chemotherapy for soft tissue sarcoma--current concepts and review]. ( Hatakeyama, K; Ishii, T; Umeda, T; Wakita, H, 1993) |
"Sarcomas are a relatively rare and heterogeneous group of malignant tumors of principally mesenchymal origin." | 2.38 | The clinical management of soft tissue sarcomas. ( Elias, AD, 1992) |
"In epithelial ovarian cancer, responses were observed in eight (20%) of 41 evaluable patients, with three (7%) complete responses." | 2.38 | Gynecologic Oncology Group studies with ifosfamide. ( Blessing, JA; Homesley, H; Manetta, A; McGuire, W; Sutton, GP, 1992) |
"Thoracic sarcomas are rare malignancies, with limited data for unresectable/advanced scenarios." | 1.91 | Epirubicin, cisplatin plus ifosfamide versus standard chemotherapeutic regimens for advanced/unresectable primary thoracic sarcomas. ( Alatorre-Alexander, JA; Carrasco-CaraChards, S; Cruz-Zermeño, M; de Jesús Rodríguez-Zea, I; Godina-Flores, A; Green-Renner, D; Guzmán-Casta, J; Guzmán-Huesca, J; Imaz-Olguin, V; Juarez-Vignon Whaley, JJ; Martínez-Barrera, LM; Riera-Sala, R; Rodriguez-Cid, JR; Sánchez-Domínguez, G; Sánchez-Ríos, CP; Santillán-Doherty, PJ; Seidman-Sorsby, A; Sosa-Sánchez, R, 2023) |
"A population pharmacokinetic approach was applied to analyze data obtained in 42 patients at cycle 1 (without aprepitant) and cycle 2 (with aprepitant for 34 of them)." | 1.91 | Population pharmacokinetic analysis reveals no impact of aprepitant on the pharmacokinetics of ifosfamide, 2-dechloroifosfamide, and 3-dechloroifosfamide. ( Allal, B; Chaltiel, L; Chatelut, E; Chevreau, C; Filleron, T; Firmin, N; Lambert, M; Mseddi, M; Toulmonde, M; Valentin, T; Yakoubi, M, 2023) |
"Treatment of highly malignant soft tissue sarcomas (STSs) requires multicomponent therapy including surgery, radiotherapy, and chemotherapy." | 1.91 | Perspectives of Cell Sensitivity/Resistance Assay in Soft Tissue Sarcomas Chemotherapy. ( Anastasia, TA; Belitsky, GA; Bokhyan, BY; Fetisov, TI; Khazanova, SA; Kirsanov, KI; Lovenger, AA; Marshall, VI; Rogozhin, DV; Shtompel, PA; Trapeznikova, ES; Yakubovskaya, MG; Zinovieva, VY, 2023) |
"However, because sarcoma is very rare, there is little evidence regarding the management of elderly patients with sarcoma." | 1.72 | Management of elderly patients with bone and soft tissue sarcomas: JCOG Bone and Soft Tissue Tumor Study Group. ( Ozaki, T; Tanaka, K, 2022) |
"Pancreatic Ewing's sarcoma is not reported commonly, with inconsistent clinical manifestations." | 1.72 | Rare presentation in a rare case of pancreatic extraosseous Ewing's sarcoma: A case report. ( Chan, WT; Hou, JY; Jiang, CB; Lee, HC; Liu, HC; Liu, YC; Sheu, JC; Wu, PS; Yeh, TC; Yeung, CY, 2022) |
"Soft tissue sarcomas are a group of tumors derived from the mesenchymal origin." | 1.56 | Epithelioid Hyalinizing Sarcoma With MGA-NUTM1 Fusion. ( Al-Rohil, RN; Bentley, RC; Cardona, DM; Feng, X; Jour, G; Shen, G; Underwood, CIM, 2020) |
"Uterine sarcomas are very rare tumours with different histotypes, molecular features and clinical outcomes; therefore, it is difficult to carry out prospective clinical trials, and this often results in heterogeneous management of patients in the clinical practice." | 1.56 | Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia). ( Aristei, C; Biondetti, PR; Cananzi, FCM; Casali, P; Ciccarone, F; Colombo, N; Comandone, A; Corvo', R; De Iaco, P; Dei Tos, AP; Donato, V; Ferrandina, G; Fiore, M; Gadducci, A; Gronchi, A; Guerriero, S; Infante, A; Lorusso, D; Odicino, F; Pirronti, T; Quagliuolo, V; Sanfilippo, R; Scambia, G; Testa, AC; Zannoni, GF, 2020) |
"Although 40% of cases of soft tissue sarcoma (STS) are diagnosed in patients aged ≥65 years, this group is largely excluded from or under-represented in clinical trials and receives disproportionately less treatment than younger patients." | 1.51 | Sarcomas and old age: few options for such a large patient population. ( Jones, RL, 2019) |
"Treatment goals for advanced soft tissue sarcoma (STS) vary according to disease stage and treatment line." | 1.51 | Which goals should we pursue in each line of treatment for advanced soft tissue sarcoma? ( Hindi, N; Martin-Broto, J; Moura, DS, 2019) |
"Olaratumab (OLA), a monoclonal antibody against platelet-derived growth factor receptor alpha (PDGFRα), has recently been used against soft-tissue sarcoma (STS) combined with doxorubicin (DOX), with limited efficacy." | 1.51 | Olaratumab combined with doxorubicin and ifosfamide overcomes individual doxorubicin and olaratumab resistance of an undifferentiated soft-tissue sarcoma in a PDOX mouse model. ( Bouvet, M; Hayashi, K; Higuchi, T; Hoffman, RM; Igarashi, K; Kimura, H; Miwa, S; Miyake, K; Oshiro, H; Razmjooei, S; Singh, SR; Sugisawa, N; Tsuchiya, H; Yamamoto, N; Zhang, Z, 2019) |
"Eighteen patients (35." | 1.48 | Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin. ( Armento, G; Badalamenti, G; Catania, G; Incorvaia, L; Maltese, G; Napolitano, A; Santini, D; Silletta, M; Spalato Ceruso, M; Tonini, G; Valeri, S; Vincenzi, B, 2018) |
"On multivariate analysis, positive surgical margins negatively impacted LRC, DFS, and OS (hazard ratio [HR]=10." | 1.43 | The Impact of Perioperative Chemotherapy Timing in Conjunction With Postoperative External-Beam Radiation Therapy on Extremity Soft-Tissue Sarcomas Outcome. ( Benedetto, P; Conway, S; Dosch, A; Fernandez, G; Kwon, D; Mahmoud, O; Pitcher, JD; Temple, HT; Trent, J; Wolfson, AH, 2016) |
"OBJECT Primary CNS sarcomas are very rare pediatric tumors with no defined standard of care." | 1.43 | Successful treatment of primary intracranial sarcoma with the ICE chemotherapy regimen and focal radiation in children. ( Bartels, U; Bouffet, E; Hader, W; Hawkins, C; Lafay-Cousin, L; Laperriere, N; Laughlin, S; Lindzon, G; Nordal, R; Taylor, MD, 2016) |
"Malignant meningioma has a bad prognosis." | 1.43 | A successful case of an anaplastic meningioma treated with chemotherapy for soft tissue sarcomas. ( Buccoliero, AM; Farina, S; Favre, C; Fonte, C; Genitori, L; Guidi, M; Lucchesi, M; Sardi, I; Scoccianti, S, 2016) |
"Soft tissue sarcomas are a heterogeneous group of malignant tumors." | 1.40 | Chemotherapy influences the pseudocapsule composition in soft tissue sarcomas. ( Cheng, EY; Clohisy, DR; Manivel, JC; O'Donnell, PW, 2014) |
"As adjuvant chemotherapy (AC) for soft tissue sarcomas is controversial, we performed a retrospective analysis of patients seen at Washington University in St." | 1.40 | Risk-stratified patients with resectable soft tissue sarcoma benefit from epirubicin-based adjuvant chemotherapy. ( Adkins, DR; Luo, J; Montgomery, L; Morgensztern, D; Schenone, AD; Van Tine, BA, 2014) |
"No significant dose-response effect of adjuvant RT was demonstrated." | 1.39 | Patterns of local recurrence and dose fractionation of adjuvant radiation therapy in 462 patients with soft tissue sarcoma of extremity and trunk wall. ( Bauer, HC; Bruland, OS; Eide, GE; Engellau, J; Engström, K; Jebsen, NL; Monge, OR; Muren, LP; Trovik, CS, 2013) |
"The spindle cell rhabdomyosarcoma is a rare variant of the embryonal rhabdomyosarcoma, mostly occurring in childhood." | 1.39 | Spindle cell rhabdomyosarcoma of the prostate. ( Ellinger, J; Fechner, G; Goltz, D; Latz, S; Leuschner, I; Marx, C; Müller, SC, 2013) |
"Epithelioid sarcoma is a rare soft tissue sarcoma subtype." | 1.38 | Role of palliative chemotherapy in advanced epithelioid sarcoma. ( Al-Muderis, O; Constantinidou, A; Fisher, C; Jones, RL; Judson, IR; Olmos, D; Scurr, M; Thway, K, 2012) |
"High-risk soft tissue sarcoma was defined as high-grade malignancy and at least two of the following criteria: size≥8 cm, vascular invasion, or necrosis." | 1.37 | Five-year results from a Scandinavian sarcoma group study (SSG XIII) of adjuvant chemotherapy combined with accelerated radiotherapy in high-risk soft tissue sarcoma of extremities and trunk wall. ( Bruland, ØS; Engellau, J; Eriksson, M; Folin, A; Hall, KS; Jebsen, NL; Trovik, CS; Turesson, I, 2011) |
"Grade 3 toxic events were observed in 18 patients (30%) and Grade 4 events in 6 patients (10%)." | 1.37 | Determinants of toxicity, patterns of failure, and outcome among adult patients with soft tissue sarcomas of the extremity and superficial trunk treated with greater than conventional doses of perioperative high-dose-rate brachytherapy and external beam r ( Cambeiro, M; Fernández Sanmamed, M; Gaztañaga, M; Martín-Algarra, S; Martinez-Monge, R; Pagola, M; San Julián, M; San Miguel, I; Vázquez-García, B, 2011) |
"Ifosfamide is an alkylating agent with well-demonstrated efficacy against STS, and dose-dependent activity." | 1.37 | High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients. ( Baek, KK; Chang, MH; Han, B; Lee, J; Lee, SH; Lim, T; Park, JO, 2011) |
"Breast stromal sarcoma is very rare, accounting for less than 1% of mammary neoplasms, and the treatment strategy is not well established, especially regarding chemotherapy." | 1.37 | Stromal sarcoma of the breast with lung metastases showing a clinical complete response to doxorubicin plus ifosfamide treatment: report of a case. ( Inoue, K; Iwase, H; Kuriwaki, K; Sueta, A; Yamamoto, Y, 2011) |
"The resulting treatment-induced necrosis rates are predictive of subsequent metastatic risk, and this information may provide an opportunity to guide postoperative systemic therapies." | 1.36 | Primary tumor necrosis predicts distant control in locally advanced soft-tissue sarcomas after preoperative concurrent chemoradiotherapy. ( Connell, PP; Haydon, RC; Luu, HH; MacDermed, DM; Miller, LL; Montag, AG; Peabody, TD; Simon, MA; Undevia, SD, 2010) |
"Extraskeletal Ewing's sarcoma (EES) is a rare form of soft tissue sarcoma." | 1.36 | Extraskeletal Ewing's sarcoma family of tumours in adults: analysis of 57 patients from a single institution. ( Ajarim, D; Al Dayel, F; Allam, A; Bazarbashi, S; El Weshi, A; Memon, M; Pant, R, 2010) |
"Soft tissue sarcoma is a malignant connective tissue tumor that may arise anywhere in the body and from diverse mesenchymal elements." | 1.35 | Should patients with high-risk soft tissue sarcoma receive adjuvant chemotherapy? ( Patel, S; Schuetze, SM, 2009) |
"The response of adult soft tissue sarcoma (STS) to chemotherapy is uncertain." | 1.34 | [Responses of 109 adult soft tissue sarcoma patients to chemotherapy]. ( Guan, ZZ; Huang, HQ; Jiang, WQ; Li, FH; Lin, TY; Luo, HY; Qiu, MZ; Sun, XF; Wang, F; Wang, SS; Xu, F; Xu, GC; Xu, RH, 2007) |
"Although FDC sarcoma is considered a low-grade tumor, the tumor in the present case not only developed at an unusual location with bone metastasis but also involved bone marrow." | 1.33 | Mediastinal follicular dendritic cell sarcoma involving bone marrow: a case report and review of the literature. ( Admirand, JH; Bueso-Ramos, CE; Ford, RJ; Jiang, L; Moran, C, 2006) |
"Numerous studies on extremity soft tissue sarcomas have consistently shown that presentation with locally recurrent disease is associated with the development of subsequent local recurrences and that large tumor size and high histologic grade are significant factors associated with decreased survival." | 1.32 | High-grade extremity soft tissue sarcomas: factors predictive of local recurrence and its effect on morbidity and mortality. ( Dorey, F; Eckardt, J; Eilber, FC; Eilber, FR; Nelson, SD; Rosen, G; Selch, M, 2003) |
"Congenital mesoblastic nephroma was originally considered to be a benign neoplasm." | 1.32 | Use of sarcoma-based chemotherapy in a case of congenital mesoblastic nephroma with liver metastases. ( Hitchcock, RJ; Mitchell, CD; Patel, Y, 2003) |
"Thirty-seven patients had distant metastases at presentation." | 1.32 | Alveolar soft part sarcoma in Japan: multi-institutional study of 57 patients from the Japanese Musculoskeletal Oncology Group. ( Hatano, H; Hotta, T; Kawashima, H; Morita, T; Ogose, A; Ueda, T; Yazawa, Y, 2003) |
"Patients had Ewing's sarcoma/primitive neuroectodermal tumour (PNET), rhabdomyosarcoma, non-rhabdo soft tissue sarcomas or other advanced soft tissue tumours." | 1.31 | Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children. ( Daller, RT; Fenton, JG; Miser, JS; Womer, RB, 2000) |
"Prospective, multicenter study in 44 soft tissue sarcoma (STS) patients with first relapse." | 1.30 | Treatment of children with relapsed soft tissue sarcoma: report of the German CESS/CWS REZ 91 trial. ( Hess, CF; Jürgens, H; Klingebiel, T; Koscielniak, E; Pertl, U; Pötter, R; Rossi, R; Schött, C; Spaar, HJ; Treuner, J; van Heek-Romanowski, R; Willnow, U, 1998) |
" So we compared VAC protocol and ifosfamiide for toxic effects." | 1.30 | Toxicity of chemotherapeutical protocols in the treatment of uterine sarcomas (Vincristine, actinomycin D, Cyclophosphamide VAC versus ifosfamide). ( Erman, O; Simşek, T; Trak, B; Uner, M; Zorlu, GC, 1998) |
"The role and value of chemotherapy for soft tissue sarcomas remain unclear." | 1.30 | [Chemotherapy for pulmonary metastases of soft tissue sarcoma]. ( Kito, M; Umeda, T, 1998) |
"The interval between diagnosis of Ewing's sarcoma and the diagnosis of the SM was 17-78 months for the four AMLs, 96 months for the MDS and 82-136 months for the three sarcomas." | 1.30 | Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies. ( Ahrens, S; Dunst, J; Harms, D; Jürgens, H; Paulussen, M; Rübe, C; Winkelmann, W; Zoubek, A, 1998) |
" A critical question in comparing an experimental treatment to a standard is how much increase in an adverse event rate is an acceptable trade-off for achieving a targeted improvement in efficacy, or vice versa." | 1.30 | Treatment comparisons based on two-dimensional safety and efficacy alternatives in oncology trials. ( Cheng, SC; Thall, PF, 1999) |
"Ifosfamide was administered at the daily dose of 1200 mg/m2/24 h." | 1.29 | [Peri-operative chemotherapy during resection of pulmonary metastases of sarcoma]. ( Azorin, JF; Delepine, G; Delepine, N; Destable, MD; Pocard, M; Tremblay, B, 1994) |
"Ifosfamide was escalated from 5 to 10 g/m2 with a fixed carboplatin dose of 480 mg/m2." | 1.29 | Ifosfamide and carboplatin combined with 41.8 degrees C whole-body hyperthermia in patients with refractory sarcoma and malignant teratoma. ( Bucsky, P; d'Oleire, F; Eleftheriadis, S; Feddersen, S; Geisler, J; Klouche, M; Knop, E; Mentzel, M; Schmucker, P; Wiedemann, GJ, 1994) |
"Ifosfamide was infused into 14 patients with advanced sarcoma for 5 days at a dose of 2." | 1.29 | Depletion of total cysteine, glutathione, and homocysteine in plasma by ifosfamide/mesna therapy. ( Cerny, T; Hartmann, B; Junker, E; Küpfer, A; Lauterburg, BH; Nguyen, T, 1994) |
"The OHS osteosarcoma tumors caused sclerotic lesions with high and uniform isotope uptake, and the MHMX unclassified sarcoma showed a mixed pattern with both sclerotic and lytic areas, whereas the LOX melanoma caused lytic bone lesions with low uptake of the radionuclide." | 1.29 | Validity and usefulness of human tumor models established by intratibial cell inoculation in nude rats. ( Bruland, O; Fodstad, O; Kjønniksen, I; Winderen, M, 1994) |
" Estimated pharmacokinetic parameters (clearance, volume of distribution, and half-life) were dependent on body size and age but not any other patient variable." | 1.29 | Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children. ( Boddy, AV; Idle, JR; Pearson, AD; Price, L; Wyllie, R; Yule, SM, 1993) |
"From November 1990 to September 1991, 23 adults with high-risk, nonmetastatic sarcomas (20 soft-tissue sarcomas and 3 chondrosarcomas) were entered in a pilot protocol (RHT-91) involving regional hyperthermia combined with systemic chemotherapy followed by surgery." | 1.29 | Preoperative systemic etoposide/ifosfamide/doxorubicin chemotherapy combined with regional hyperthermia in high-risk sarcoma: a pilot study. ( Abdel-Rahman, S; Berger, H; Bosse, D; Issels, RD; Jauch, KW; Panzer, M; Peter, K; Sauer, H; Starck, M; Stiegler, H, 1993) |
"Paclitaxel was given at a dose of 120 mg/m2 to five patients, 135 mg/m2 to five patients, 150 mg/m2 to three patients, and 175 mg/m2 to 11 patients." | 1.29 | Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study. ( Asbury, RF; Boros, L; Chang, AY; Garrow, GC; Hui, L, 1996) |
"Ifosfamide is a newly available analog of cyclophosphamide in the oxazaphosphorine drug class." | 1.28 | Ifosfamide vs cyclophosphamide in cancer therapy. ( Weiss, RB, 1991) |
"The model systems were human breast carcinoma (MX1/3) and human sarcoma (S117) grown in nude mice." | 1.28 | Local hyperthermia enhances cyclophosphamide, ifosfamide and cis-diamminedichloroplatinum cytotoxicity on human-derived breast carcinoma and sarcoma xenografts in nude mice. ( Biersack, A; Roszinski, S; Wagner, T; Weiss, C; Wiedemann, G, 1992) |
"Ifosfamide/mesna has activity in a wide range of gynecologic malignancies." | 1.28 | Early phase II Gynecologic Oncology Group experience with ifosfamide/mesna in gynecologic malignancies. ( Berman, ML; Blessing, JA; Homesley, HD; Photopulos, G; Sutton, GP, 1990) |
" We have studied in patients with advanced cancer the feasibility and bioavailability of a subcutaneously administered isotonic and neutral (pH 7) IFO solution given continuously over 10 h for up to 5 days." | 1.28 | Bioavailability of subcutaneous ifosfamide and feasibility of continuous outpatient application in cancer patients. ( Brunner, KW; Cerny, T; Küpfer, A; Zeugin, T, 1990) |
"Between 1982 and 1986, 38 patients with soft tissue sarcomas were treated with a combination of ADM/DTIC (group A), another 45 (group B) received ADM/IFO between 1986 and 1990." | 1.28 | Chemotherapy of metastatic soft tissue sarcoma with a combination of adriamycin and DTIC or adriamycin and ifosfamide. ( Dietel, M; Hossfeld, DK; Schwarz, R; Weh, HJ; Wingberg, D; Zornig, C; Zügel, M, 1990) |
Research
Studies (496)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 39 (7.86) | 18.7374 |
1990's | 153 (30.85) | 18.2507 |
2000's | 140 (28.23) | 29.6817 |
2010's | 126 (25.40) | 24.3611 |
2020's | 38 (7.66) | 2.80 |
Authors
Authors | Studies |
---|---|
Kim, JH | 1 |
Kim, SH | 1 |
Jeon, MK | 1 |
Kim, JE | 1 |
Kim, KH | 1 |
Yun, KH | 1 |
Jeung, HC | 1 |
Rha, SY | 2 |
Ahn, JH | 2 |
Kim, HS | 1 |
Benjamin, RS | 9 |
Pasquali, S | 2 |
Palmerini, E | 3 |
Quagliuolo, V | 9 |
Martin-Broto, J | 5 |
Lopez-Pousa, A | 11 |
Grignani, G | 5 |
Brunello, A | 3 |
Blay, JY | 18 |
Tendero, O | 2 |
Diaz-Beveridge, R | 1 |
Ferraresi, V | 1 |
Lugowska, I | 1 |
Infante, G | 1 |
Braglia, L | 1 |
Merlo, DF | 2 |
Fontana, V | 1 |
Marchesi, E | 1 |
Donati, DM | 1 |
Palassini, E | 3 |
Bianchi, G | 1 |
Marrari, A | 4 |
Morosi, C | 1 |
Stacchiotti, S | 8 |
Bagué, S | 1 |
Coindre, JM | 5 |
Dei Tos, AP | 7 |
Picci, P | 5 |
Bruzzi, P | 2 |
Miceli, R | 2 |
Casali, PG | 8 |
Gronchi, A | 14 |
Goy, BW | 1 |
Syed, S | 1 |
Padmanabhan, A | 1 |
Burchette, RJ | 1 |
Helmstedter, CS | 1 |
Kinoshita, H | 1 |
Hagiwara, Y | 1 |
Ishii, T | 6 |
Kamoda, H | 1 |
Tsukanishi, T | 1 |
Ohtori, S | 1 |
Yonemoto, T | 3 |
Oda, Y | 2 |
Tanaka, K | 6 |
Hirose, T | 1 |
Hasegawa, T | 2 |
Hiruta, N | 1 |
Hisaoka, M | 1 |
Yoshimoto, M | 1 |
Otsuka, H | 1 |
Bekki, H | 1 |
Endo, M | 1 |
Kunisada, T | 2 |
Hiruma, T | 3 |
Tsuchiya, H | 3 |
Katagiri, H | 2 |
Matsumoto, Y | 2 |
Kawai, A | 4 |
Nakayama, R | 2 |
Kawashima, H | 3 |
Takenaka, S | 2 |
Emori, M | 2 |
Watanuki, M | 2 |
Yoshida, Y | 1 |
Okamoto, T | 1 |
Mizusawa, J | 3 |
Fukuda, H | 5 |
Ozaki, T | 6 |
Iwamoto, Y | 5 |
Nojima, T | 1 |
Moreau-Bachelard, C | 1 |
Campion, L | 1 |
Toulmonde, M | 5 |
Le Cesne, A | 9 |
Brahmi, M | 2 |
Italiano, A | 5 |
Mir, O | 3 |
Piperno-Neumann, S | 4 |
Laurence, V | 1 |
Firmin, N | 2 |
Penel, N | 6 |
Duffaud, F | 3 |
Chevreau, C | 8 |
Bertucci, F | 2 |
Narciso, B | 1 |
Dubray-Longeras, P | 1 |
Delcambre, C | 2 |
Saada-Bouzid, E | 2 |
Boudou-Rouquette, P | 1 |
Soulie, P | 1 |
Perrin, C | 1 |
Bompas, E | 3 |
Acem, I | 1 |
van Houdt, WJ | 2 |
Grünhagen, DJ | 1 |
van der Graaf, WTA | 2 |
Rueten-Budde, AJ | 1 |
Gelderblom, H | 7 |
Verhoef, C | 1 |
van de Sande, MAJ | 1 |
Miller, D | 1 |
Livingston, JA | 1 |
Park, Y | 1 |
Posey, K | 1 |
Godbole, S | 1 |
Skubitz, K | 1 |
Robinson, SI | 1 |
Agulnik, M | 1 |
Davis, LE | 2 |
Van Tine, BA | 2 |
Hirbe, AC | 1 |
Parkes, A | 1 |
Sanfilippo, RG | 1 |
Marreaud, SI | 1 |
Judson, IR | 3 |
Litiere, S | 8 |
Kasper, B | 12 |
Schöffski, P | 6 |
Schoot, RA | 1 |
Chisholm, JC | 1 |
Casanova, M | 4 |
Minard-Colin, V | 1 |
Geoerger, B | 1 |
Cameron, AL | 1 |
Coppadoro, B | 1 |
Zanetti, I | 3 |
Orbach, D | 5 |
Kelsey, A | 3 |
Rogers, T | 1 |
Guizani, C | 1 |
Elze, M | 1 |
Ben-Arush, M | 1 |
McHugh, K | 1 |
van Rijn, RR | 1 |
Ferman, S | 1 |
Gallego, S | 1 |
Ferrari, A | 6 |
Jenney, M | 1 |
Bisogno, G | 4 |
Merks, JHM | 1 |
Machida, R | 1 |
Tsukushi, S | 1 |
Asanuma, K | 1 |
Hiraga, H | 2 |
Hiraoka, K | 1 |
Abe, S | 2 |
Nishida, Y | 1 |
Nagano, A | 1 |
Suehara, Y | 1 |
Kawano, M | 1 |
Morii, T | 1 |
Hatano, H | 3 |
Toguchida, J | 1 |
Okuma, T | 2 |
Takeyama, M | 1 |
Akisue, T | 1 |
Furuta, T | 1 |
Outani, H | 1 |
Yamamoto, T | 1 |
Kataoka, T | 1 |
Miao, L | 1 |
Ma, ST | 1 |
Jiang, X | 1 |
Zhang, HH | 1 |
Wang, YM | 1 |
Li, M | 1 |
Liu, X | 1 |
Jiang, S | 1 |
Wang, H | 1 |
Wu, X | 1 |
Yan, W | 1 |
Chen, Y | 1 |
Xu, Y | 2 |
Wang, C | 1 |
Yao, W | 1 |
Wang, J | 1 |
Yu, L | 1 |
Miao, J | 1 |
Chen, H | 1 |
Xia, J | 1 |
Huang, M | 1 |
Zhang, X | 1 |
Luo, Z | 1 |
Liu, YC | 3 |
Yeh, TC | 3 |
Wu, PS | 3 |
Sheu, JC | 3 |
Lee, HC | 3 |
Yeung, CY | 3 |
Jiang, CB | 3 |
Liu, HC | 3 |
Hou, JY | 3 |
Chan, WT | 3 |
Rodriguez-Cid, JR | 3 |
Juarez-Vignon Whaley, JJ | 3 |
Sánchez-Domínguez, G | 3 |
Guzmán-Casta, J | 3 |
Carrasco-CaraChards, S | 3 |
Guzmán-Huesca, J | 3 |
Riera-Sala, R | 3 |
Sánchez-Ríos, CP | 3 |
Cruz-Zermeño, M | 3 |
Seidman-Sorsby, A | 3 |
de Jesús Rodríguez-Zea, I | 3 |
Alatorre-Alexander, JA | 3 |
Martínez-Barrera, LM | 3 |
Santillán-Doherty, PJ | 3 |
Godina-Flores, A | 3 |
Imaz-Olguin, V | 3 |
Sosa-Sánchez, R | 3 |
Green-Renner, D | 3 |
Merjaneh, N | 1 |
Kim, H | 1 |
Escoto, H | 1 |
Metts, J | 1 |
Ray, A | 1 |
Bukowinski, A | 1 |
LeBlanc, Z | 1 |
Fair, D | 1 |
Watanbe, M | 1 |
Alva, E | 1 |
Todd, K | 1 |
Daley, J | 1 |
Hartt, D | 1 |
Cramer, SL | 1 |
Szabo, S | 1 |
Pressey, JG | 1 |
Valentin, T | 2 |
Lambert, M | 1 |
Chaltiel, L | 1 |
Allal, B | 1 |
Mseddi, M | 1 |
Yakoubi, M | 1 |
Filleron, T | 2 |
Chatelut, E | 1 |
Gutierrez-Sainz, L | 1 |
Martinez-Fdez, S | 1 |
Pedregosa-Barbas, J | 1 |
Peña, J | 1 |
Alameda, M | 1 |
Viñal, D | 1 |
Villamayor, J | 1 |
Martinez-Recio, S | 1 |
Perez-Wert, P | 1 |
Pertejo-Fernandez, A | 1 |
Gallego, A | 1 |
Martinez-Marin, V | 1 |
Zamora, P | 1 |
Espinosa, E | 1 |
Mendiola, M | 1 |
Feliu, J | 1 |
Redondo, A | 1 |
Veltsista, PD | 1 |
Oberacker, E | 1 |
Ademaj, A | 1 |
Corradini, S | 1 |
Eckert, F | 3 |
Flörcken, A | 1 |
Kaul, D | 1 |
Lindner, LH | 7 |
Issels, R | 2 |
Ott, OJ | 1 |
Pink, D | 2 |
Potkrajcic, V | 1 |
Reichardt, P | 9 |
Roohani, S | 1 |
Spalek, MJ | 1 |
Riesterer, O | 1 |
Zips, D | 2 |
Ghadjar, P | 2 |
Fetisov, TI | 1 |
Khazanova, SA | 1 |
Shtompel, PA | 1 |
Trapeznikova, ES | 1 |
Zinovieva, VY | 1 |
Marshall, VI | 1 |
Lovenger, AA | 1 |
Rogozhin, DV | 1 |
Anastasia, TA | 1 |
Bokhyan, BY | 1 |
Belitsky, GA | 1 |
Yakubovskaya, MG | 1 |
Kirsanov, KI | 1 |
Jones, RL | 4 |
Hindi, N | 2 |
Moura, DS | 1 |
Lu, E | 2 |
Ryan, CW | 3 |
Bassale, S | 1 |
Lim, JY | 1 |
D'Ambrosio, L | 2 |
Touati, N | 2 |
Flippot, R | 1 |
Czarnecka, AM | 1 |
Sanfilippo, R | 4 |
Katz, D | 1 |
Vincenzi, B | 2 |
Stark, DP | 1 |
Mazzeo, F | 1 |
Tuchscherer, A | 1 |
Sherriff, J | 1 |
Estival, A | 2 |
Sents, W | 1 |
Ray-Coquard, I | 7 |
Tolomeo, F | 1 |
Rutkowski, P | 1 |
Hammer, KJ | 1 |
Copeland, VC | 1 |
Loggers, ET | 1 |
Pollack, SM | 1 |
Wagner, MJ | 1 |
Cranmer, LD | 1 |
Findlay, BL | 1 |
Gargollo, PC | 1 |
Granberg, CF | 1 |
Le Guellec, S | 1 |
Cabarrou, B | 1 |
Lesluyes, T | 1 |
Lodin, S | 1 |
Massoubre, A | 1 |
Mounier, M | 1 |
Poublanc, M | 1 |
Chibon, F | 1 |
Ryckewaert, T | 1 |
Pannier, D | 1 |
Underwood, CIM | 1 |
Cardona, DM | 1 |
Bentley, RC | 1 |
Shen, G | 1 |
Feng, X | 1 |
Jour, G | 1 |
Al-Rohil, RN | 1 |
Ferrandina, G | 1 |
Aristei, C | 1 |
Biondetti, PR | 1 |
Cananzi, FCM | 1 |
Casali, P | 5 |
Ciccarone, F | 1 |
Colombo, N | 1 |
Comandone, A | 9 |
Corvo', R | 1 |
De Iaco, P | 1 |
Donato, V | 1 |
Fiore, M | 4 |
Gadducci, A | 1 |
Guerriero, S | 1 |
Infante, A | 1 |
Odicino, F | 1 |
Pirronti, T | 1 |
Testa, AC | 1 |
Zannoni, GF | 1 |
Scambia, G | 1 |
Lorusso, D | 1 |
Byun, DJ | 1 |
Katz, LM | 1 |
Xiao, J | 1 |
Rapp, TB | 1 |
Paoluzzi, L | 1 |
Rosen, G | 5 |
Schiff, PB | 1 |
Modi, JN | 1 |
Cimino, SK | 1 |
Schmoll, HJ | 5 |
Heißner, K | 1 |
Kopp, HG | 3 |
Kessler, T | 1 |
Mayer-Steinacker, R | 1 |
Rüssel, J | 1 |
Egerer, G | 8 |
Crysandt, M | 1 |
Niederwieser, D | 1 |
Kunitz, A | 1 |
Eigendorff, E | 1 |
Petersen, I | 2 |
Steighardt, J | 1 |
Cygon, F | 1 |
Meinert, F | 1 |
Stein, A | 1 |
Hua, Q | 1 |
Xu, G | 1 |
Zhao, L | 2 |
Zhang, T | 1 |
Marquina, G | 1 |
Dudzisz-Śledź, M | 1 |
Steeghs, N | 1 |
Karavasilis, V | 1 |
de Haan, J | 1 |
Wozniak, A | 2 |
Cousin, S | 1 |
Domènech, M | 1 |
Bovée, JVMG | 1 |
Charon-Barra, C | 1 |
Marreaud, S | 5 |
De Meulemeester, L | 1 |
Olungu, C | 1 |
Young, RJ | 1 |
Lia, M | 1 |
Hogendoorn, PCW | 1 |
Fisher, C | 5 |
Mechtersheimer, G | 4 |
Daugaard, S | 4 |
Sciot, R | 1 |
Collin, F | 1 |
Messiou, C | 2 |
Grünwald, V | 1 |
van der Graaf, W | 1 |
Wardelmann, E | 1 |
Judson, I | 9 |
Teepen, JC | 1 |
van Leeuwen, FE | 1 |
Tissing, WJ | 1 |
van Dulmen-den Broeder, E | 1 |
van den Heuvel-Eibrink, MM | 1 |
van der Pal, HJ | 1 |
Loonen, JJ | 1 |
Bresters, D | 1 |
Versluys, B | 1 |
Neggers, SJCMM | 1 |
Jaspers, MWM | 1 |
Hauptmann, M | 1 |
van der Heiden-van der Loo, M | 1 |
Visser, O | 1 |
Kremer, LCM | 1 |
Ronckers, CM | 1 |
De Sanctis, R | 5 |
Giordano, L | 2 |
Colombo, C | 1 |
De Paoli, A | 9 |
Navarria, P | 2 |
Sangalli, C | 3 |
Buonadonna, A | 6 |
Bertola, G | 2 |
Navarria, F | 1 |
Bertuzzi, A | 3 |
Basso, S | 1 |
Santoro, A | 18 |
Issels, RD | 15 |
Verweij, J | 26 |
Wessalowski, R | 2 |
Wust, P | 3 |
Hohenberger, P | 6 |
Angele, M | 1 |
Salat, C | 3 |
Vujaskovic, Z | 2 |
Mella, O | 1 |
Mansmann, U | 2 |
Dürr, HR | 2 |
Knösel, T | 1 |
Abdel-Rahman, S | 9 |
Schmidt, M | 1 |
Hiddemann, W | 6 |
Jauch, KW | 4 |
Belka, C | 2 |
Badalamenti, G | 2 |
Armento, G | 1 |
Silletta, M | 1 |
Spalato Ceruso, M | 1 |
Catania, G | 1 |
Napolitano, A | 1 |
Maltese, G | 2 |
Valeri, S | 1 |
Incorvaia, L | 2 |
Santini, D | 1 |
Tonini, G | 1 |
García Del Muro, X | 2 |
Maurel, J | 5 |
Martínez Trufero, J | 1 |
Lavernia, J | 1 |
López Pousa, A | 1 |
de Las Peñas, R | 4 |
Cubedo, R | 3 |
Berros, JP | 1 |
Casado Herráez, A | 1 |
de Juan, A | 1 |
Martín Broto, J | 2 |
Pennington, JD | 1 |
Eilber, FC | 6 |
Eilber, FR | 5 |
Singh, AS | 1 |
Reed, JP | 1 |
Chmielowski, B | 1 |
Eckardt, JJ | 4 |
Bukata, SV | 1 |
Bernthal, NM | 1 |
Federman, N | 1 |
Nelson, SD | 5 |
Dry, SM | 2 |
Wang, PC | 1 |
Luu, M | 1 |
Selch, MT | 1 |
Steinberg, ML | 1 |
Kalbasi, A | 1 |
Kamrava, M | 1 |
Chowdhary, M | 1 |
Sen, N | 1 |
Jeans, EB | 1 |
Miller, L | 1 |
Batus, M | 1 |
Gitelis, S | 1 |
Wang, D | 1 |
Abrams, RA | 1 |
Lee, J | 3 |
Jung, HA | 1 |
Kim, Y | 1 |
Choi, S | 1 |
Han, J | 1 |
Choi, YL | 1 |
Lee, SH | 2 |
Ahn, JS | 1 |
Park, K | 1 |
Sun, JM | 1 |
Schiavetti, A | 1 |
Pedetti, V | 1 |
Varrasso, G | 1 |
Marrucci, O | 1 |
Celani, C | 1 |
Andreoli, G | 1 |
Bonci, E | 1 |
Charlson, J | 1 |
Pizzamiglio, S | 2 |
Verderio, P | 4 |
Woll, PJ | 2 |
Higuchi, T | 1 |
Miyake, K | 1 |
Sugisawa, N | 1 |
Oshiro, H | 1 |
Zhang, Z | 1 |
Razmjooei, S | 1 |
Yamamoto, N | 1 |
Hayashi, K | 1 |
Kimura, H | 1 |
Miwa, S | 1 |
Igarashi, K | 1 |
Bouvet, M | 1 |
Singh, SR | 1 |
Hoffman, RM | 1 |
Spunt, SL | 2 |
Francotte, N | 1 |
De Salvo, GL | 1 |
Chi, YY | 1 |
Hayes-Jordan, A | 1 |
Kao, SC | 1 |
Brennan, B | 1 |
Weiss, AR | 1 |
van Noesel, MM | 1 |
Million, L | 1 |
Alaggio, R | 2 |
Parham, DM | 1 |
Randall, RL | 1 |
McCarville, MB | 1 |
Hawkins, DS | 4 |
Nevala, R | 1 |
Tukiainen, E | 1 |
Tarkkanen, M | 1 |
Böhling, T | 1 |
Blomqvist, C | 1 |
Sampo, M | 1 |
Chawla, SP | 4 |
Staddon, A | 1 |
Hendifar, A | 2 |
Messam, CA | 1 |
Patwardhan, R | 1 |
Kamel, YM | 1 |
Gani, C | 1 |
Kluba, T | 2 |
Mayer, F | 1 |
Bamberg, M | 1 |
Müller, AC | 1 |
O'Donnell, PW | 1 |
Manivel, JC | 1 |
Cheng, EY | 1 |
Clohisy, DR | 1 |
Johnson, K | 1 |
Notrica, DM | 1 |
Carpentieri, D | 1 |
Jaroszewski, D | 1 |
Henry, MM | 1 |
Jebsen, NL | 2 |
Engellau, J | 2 |
Engström, K | 1 |
Bauer, HC | 1 |
Monge, OR | 2 |
Muren, LP | 1 |
Eide, GE | 1 |
Trovik, CS | 2 |
Bruland, OS | 1 |
Martín-Liberal, J | 1 |
Broto, JM | 1 |
Gallego, O | 2 |
Brendel, E | 1 |
Tirado, OM | 1 |
del Muro, XG | 3 |
Chocarro, G | 1 |
Amesty, MV | 1 |
Hernández, F | 1 |
Chenu, BG | 1 |
Ortíz, R | 1 |
Hernández, S | 1 |
Sánchez, A | 1 |
Gámez, M | 1 |
Santamaría, ML | 1 |
Tovar, JA | 1 |
Yoo, C | 1 |
Park, KH | 1 |
Kim, TM | 1 |
Kim, YJ | 1 |
Lee, HJ | 2 |
Lee, KH | 1 |
Dani, C | 1 |
Giorello, L | 1 |
Cao, J | 1 |
Huang, XE | 1 |
Liu, J | 1 |
Wu, XY | 1 |
Lu, YY | 1 |
Okuno, S | 1 |
Shives, T | 1 |
Mahoney, M | 1 |
Haddock, M | 1 |
Sim, F | 1 |
O'Connor, MI | 2 |
Markovic, SN | 1 |
Maples, W | 1 |
Leahy, MG | 2 |
Nguyen, BB | 1 |
Patel, SR | 8 |
Staddon, AP | 2 |
Lardelli, P | 1 |
Nieto, A | 1 |
Alfaro, V | 1 |
Dutour, A | 1 |
Josserand, V | 1 |
Jury, D | 1 |
Guillermet, S | 1 |
Decouvelaere, AV | 1 |
Chotel, F | 1 |
Pointecouteau, T | 1 |
Rizo, P | 1 |
Coll, JL | 1 |
Schenone, AD | 1 |
Luo, J | 1 |
Montgomery, L | 1 |
Morgensztern, D | 1 |
Adkins, DR | 1 |
Hartmann, JT | 3 |
Kerst, JM | 1 |
Sufliarsky, J | 1 |
Whelan, J | 3 |
Krarup-Hansen, A | 2 |
Alcindor, T | 1 |
Hermans, C | 5 |
Hogendoorn, PC | 4 |
van der Graaf, WT | 1 |
Dincbas, FO | 1 |
Oksuz, DC | 1 |
Yetmen, O | 1 |
Hiz, M | 1 |
Dervisoglu, S | 1 |
Turna, H | 1 |
Kantarci, F | 1 |
Mandel, NM | 1 |
Koca, S | 1 |
Szabatura, AH | 2 |
Cirrone, F | 1 |
Harris, C | 1 |
McDonnell, AM | 1 |
Feng, Y | 1 |
Voit, D | 1 |
Neuberg, D | 1 |
Butrynski, J | 1 |
Fisher, DC | 1 |
Baumann, D | 1 |
Amann, K | 1 |
Schlatter, E | 1 |
Ciarimboli, G | 1 |
Müller, M | 1 |
Bakos, G | 1 |
Steinke, I | 1 |
Bunz, H | 1 |
Weyrich, P | 1 |
Artunc, F | 1 |
Mahmoud, O | 1 |
Dosch, A | 1 |
Kwon, D | 1 |
Pitcher, JD | 1 |
Conway, S | 1 |
Benedetto, P | 1 |
Fernandez, G | 1 |
Trent, J | 1 |
Temple, HT | 1 |
Wolfson, AH | 1 |
Roeder, F | 2 |
Lehner, B | 3 |
Schmitt, T | 6 |
Sedlaczek, O | 1 |
Grüllich, C | 1 |
Wuchter, P | 4 |
Hensley, FW | 1 |
Huber, PE | 1 |
Debus, J | 1 |
Bischof, M | 2 |
Cornillie, J | 1 |
Li, H | 1 |
Hompes, D | 1 |
Kataoka, K | 1 |
Kimura, A | 1 |
Matsunobu, T | 2 |
Matsumine, A | 1 |
Araki, N | 3 |
Siurala, M | 1 |
Bramante, S | 1 |
Vassilev, L | 1 |
Hirvinen, M | 1 |
Parviainen, S | 1 |
Tähtinen, S | 1 |
Guse, K | 1 |
Cerullo, V | 1 |
Kanerva, A | 1 |
Kipar, A | 1 |
Vähä-Koskela, M | 1 |
Hemminki, A | 1 |
Salman, D | 1 |
Swinden, J | 1 |
Barton, S | 1 |
Peron, JM | 1 |
Nabhani-Gebara, S | 1 |
De Niro, JE | 1 |
Cham, EM | 1 |
Silkiss, RZ | 1 |
Basso, U | 3 |
Marchetti, S | 1 |
Colombo, P | 1 |
Lutman, RF | 2 |
Chuman, H | 2 |
Takahashi, M | 1 |
Morioka, H | 1 |
Pápai, Z | 3 |
Tolcher, AW | 1 |
Cupissol, D | 4 |
Babovic, N | 1 |
Isambert, N | 2 |
Franke, FA | 1 |
Cohen, P | 1 |
Le-Guennec, S | 1 |
Demetri, GD | 4 |
Schuler, M | 1 |
Davis, EJ | 1 |
Chugh, R | 3 |
Lucas, DR | 3 |
Biermann, JS | 3 |
Zalupski, MM | 4 |
Feng, M | 1 |
Wong, SL | 1 |
Jacobson, J | 1 |
Zyczynski, L | 1 |
Reinke, D | 1 |
Metko, G | 1 |
Baker, LH | 7 |
Schuetze, SM | 3 |
Semenova, AI | 1 |
Protsenko, SA | 1 |
Komarov, YI | 1 |
Teletaeva, GM | 1 |
Latipova, DH | 1 |
Novik, AV | 1 |
Fernandes, LL | 1 |
Murray, S | 1 |
Taylor, JM | 3 |
Ferrari, S | 3 |
Bottelli, S | 1 |
Libertini, M | 1 |
Mulder, RL | 3 |
Paulides, M | 7 |
Langer, T | 8 |
Kremer, LC | 3 |
van Dalen, EC | 3 |
Noujaim, J | 1 |
Constantinidou, A | 2 |
Thway, K | 2 |
Miah, A | 1 |
Benson, C | 1 |
Rizzato, MD | 1 |
Rastrelli, M | 1 |
Roma, A | 1 |
Maruzzo, M | 1 |
Fiduccia, P | 1 |
Buzzaccarini, MS | 1 |
Scarzello, G | 1 |
Rossi, CR | 1 |
Zagonel, V | 1 |
Lafay-Cousin, L | 1 |
Lindzon, G | 1 |
Taylor, MD | 1 |
Hader, W | 1 |
Hawkins, C | 1 |
Nordal, R | 1 |
Laperriere, N | 1 |
Laughlin, S | 1 |
Bouffet, E | 2 |
Bartels, U | 1 |
Stubbe, F | 1 |
Agaimy, A | 1 |
Ott, O | 1 |
Lettmaier, S | 1 |
Vassos, N | 1 |
Croner, R | 1 |
Hohenberger, W | 2 |
Fietkau, R | 3 |
Semrau, S | 1 |
Tsukamoto, S | 1 |
Kurematsu, Y | 1 |
Honoki, K | 1 |
Kido, A | 1 |
Somekawa, S | 1 |
Kaya, D | 1 |
Sadamitsu, T | 1 |
Fukui, H | 1 |
Tanaka, Y | 1 |
Wang, B | 1 |
Yu, X | 1 |
Xu, S | 1 |
Xu, M | 1 |
Saha, D | 1 |
Basu, A | 1 |
Maiti, A | 1 |
Rodriguez, E | 1 |
Matsuo, K | 1 |
Takazawa, Y | 1 |
Ross, MS | 1 |
Elishaev, E | 1 |
Podzielinski, I | 1 |
Yunokawa, M | 1 |
Sheridan, TB | 1 |
Bush, SH | 1 |
Klobocista, MM | 1 |
Blake, EA | 1 |
Takano, T | 1 |
Matsuzaki, S | 1 |
Baba, T | 1 |
Satoh, S | 1 |
Shida, M | 1 |
Nishikawa, T | 1 |
Ikeda, Y | 1 |
Adachi, S | 1 |
Yokoyama, T | 1 |
Takekuma, M | 1 |
Fujiwara, K | 2 |
Hazama, Y | 1 |
Kadogami, D | 1 |
Moffitt, MN | 1 |
Takeuchi, S | 1 |
Nishimura, M | 1 |
Iwasaki, K | 1 |
Ushioda, N | 1 |
Johnson, MS | 1 |
Yoshida, M | 1 |
Hakam, A | 1 |
Li, SW | 1 |
Richmond, AM | 1 |
Machida, H | 1 |
Mhawech-Fauceglia, P | 1 |
Ueda, Y | 1 |
Yoshino, K | 1 |
Yamaguchi, K | 1 |
Oishi, T | 1 |
Kajiwara, H | 1 |
Hasegawa, K | 1 |
Yasuda, M | 1 |
Kawana, K | 1 |
Suda, K | 1 |
Miyake, TM | 1 |
Moriya, T | 1 |
Yuba, Y | 1 |
Morgan, T | 1 |
Fukagawa, T | 1 |
Wakatsuki, A | 1 |
Sugiyama, T | 1 |
Pejovic, T | 1 |
Nagano, T | 1 |
Shimoya, K | 1 |
Andoh, M | 1 |
Shiki, Y | 1 |
Enomoto, T | 1 |
Sasaki, T | 1 |
Mikami, M | 1 |
Shimada, M | 1 |
Konishi, I | 1 |
Kimura, T | 1 |
Post, MD | 1 |
Shahzad, MM | 1 |
Im, DD | 1 |
Yoshida, H | 1 |
Omatsu, K | 1 |
Ueland, FR | 1 |
Kelley, JL | 1 |
Karabakhtsian, RG | 1 |
Roman, LD | 1 |
Seddon, B | 2 |
Lucchesi, M | 1 |
Buccoliero, AM | 1 |
Scoccianti, S | 1 |
Guidi, M | 1 |
Farina, S | 1 |
Fonte, C | 1 |
Favre, C | 1 |
Genitori, L | 1 |
Sardi, I | 1 |
Bongiovanni, A | 1 |
Monti, M | 1 |
Foca, F | 1 |
Recine, F | 1 |
Riva, N | 1 |
Di Iorio, V | 1 |
Liverani, C | 1 |
De Vita, A | 1 |
Miserocchi, G | 1 |
Mercatali, L | 1 |
Amadori, D | 1 |
Ibrahim, T | 1 |
Kusaba, H | 1 |
Kumagai, H | 1 |
Inadomi, K | 1 |
Harimaya, K | 1 |
Takayoshi, K | 1 |
Arita, S | 1 |
Ariyama, H | 1 |
Akashi, K | 1 |
Baba, E | 1 |
Watanabe, T | 1 |
Kurata, T | 1 |
Sano, K | 1 |
Suzuki, S | 1 |
Kaneko, T | 1 |
Motobayashi, M | 1 |
Shigemura, T | 1 |
Sumi, T | 1 |
Koike, K | 1 |
Nakazawa, Y | 1 |
Fresneau, B | 1 |
Hackshaw, A | 1 |
Paulussen, M | 3 |
Anderson, JR | 2 |
Dirksen, U | 1 |
Lewis, I | 1 |
van den Berg, H | 1 |
Gaspar, N | 1 |
Boddy, AV | 6 |
Wheatley, K | 1 |
Pignon, JP | 1 |
De Vathaire, F | 3 |
Le Deley, MC | 1 |
Le Teuff, G | 1 |
Moon, JY | 1 |
Baek, SW | 1 |
Ryu, H | 1 |
Choi, YS | 1 |
Song, IC | 1 |
Yun, HJ | 1 |
Jo, DY | 1 |
Kim, S | 1 |
Stoeckle, E | 1 |
Michot, A | 1 |
Rigal, L | 1 |
Babre, F | 1 |
Sargos, P | 1 |
Henriques de Figueiredo, B | 1 |
Brouste, V | 1 |
Le Loarer, F | 1 |
Kind, M | 2 |
Ouahbi, H | 1 |
Akasbi, Y | 1 |
Oualla, K | 1 |
Amara, B | 1 |
Chatar, A | 1 |
Tizniti, S | 1 |
Fatemi, H | 1 |
Lemrabet, FZ | 1 |
Arifi, S | 1 |
Mellas, N | 1 |
Thornton, K | 2 |
Pesce, CE | 1 |
Choti, MA | 1 |
Hosokawa, S | 1 |
Takebayashi, S | 1 |
Mineta, H | 1 |
Suzuki, K | 1 |
Baba, S | 1 |
Howell, JE | 1 |
Hatfield Seung, A | 1 |
Nesbit, SA | 1 |
Sweiss, KI | 1 |
Beri, R | 1 |
Shord, SS | 1 |
Wei, ZG | 1 |
Tang, LF | 1 |
Chen, ZM | 1 |
Tang, HF | 1 |
Li, MJ | 1 |
Fayette, J | 2 |
Thyss, A | 3 |
Guillemet, C | 2 |
Rios, M | 1 |
Rolland, F | 1 |
Fargeot, P | 3 |
Bay, JO | 2 |
Mathoulin-Pelissier, S | 2 |
Bui-Nguyen, B | 3 |
Kawamoto, H | 1 |
Saito, I | 1 |
Yoshimura, K | 1 |
Ridola, V | 2 |
Fawaz, O | 2 |
Aubier, F | 1 |
Bergeron, C | 4 |
Pichon, F | 2 |
Gentet, JC | 2 |
Schmitt, C | 2 |
Dufour, C | 1 |
Oberlin, O | 4 |
Dantonello, TM | 1 |
Int-Veen, C | 2 |
Harms, D | 3 |
Leuschner, I | 2 |
Schmidt, BF | 2 |
Herbst, M | 2 |
Juergens, H | 1 |
Scheel-Walter, HG | 1 |
Bielack, SS | 1 |
Klingebiel, T | 5 |
Dickerhoff, R | 1 |
Kirsch, S | 1 |
Brecht, I | 1 |
Schmelzle, R | 1 |
Greulich, M | 1 |
Gadner, H | 3 |
Greiner, J | 1 |
Marky, I | 2 |
Treuner, J | 6 |
Koscielniak, E | 6 |
Fra, J | 4 |
Martín, J | 7 |
Cruz, J | 1 |
Casado, A | 5 |
Poveda, A | 4 |
Martínez-Trufero, J | 3 |
Balañá, C | 3 |
Gómez, MA | 1 |
Rubio-Viqueira, B | 1 |
Rubió, J | 1 |
Andrés, R | 1 |
Sevilla, I | 1 |
de la Cruz, JJ | 1 |
Buesa, JM | 5 |
Benz, MR | 1 |
Czernin, J | 1 |
Allen-Auerbach, MS | 1 |
Tap, WD | 2 |
Elashoff, D | 1 |
Chow, K | 1 |
Evilevitch, V | 1 |
Phelps, ME | 1 |
Weber, WA | 1 |
MacDermed, DM | 1 |
Miller, LL | 1 |
Peabody, TD | 2 |
Simon, MA | 1 |
Luu, HH | 1 |
Haydon, RC | 1 |
Montag, AG | 2 |
Undevia, SD | 1 |
Connell, PP | 1 |
Stroppa, E | 1 |
Di Comite, G | 1 |
Mussi, C | 1 |
Barbato, A | 1 |
Coriat, R | 1 |
Camps, S | 1 |
Ropert, S | 1 |
Billemont, B | 1 |
Leconte, M | 1 |
Larousserie, F | 1 |
Anract, P | 1 |
Alexandre, J | 1 |
Goldwasser, F | 1 |
Lashkari, A | 1 |
Chow, WA | 1 |
Valdes, F | 1 |
Leong, L | 1 |
Phan, V | 1 |
Twardowski, P | 1 |
Kapoor, N | 1 |
Molina, A | 1 |
Al-Kadhimi, Z | 1 |
Frankel, P | 1 |
Somlo, G | 1 |
Stahl, R | 1 |
Wang, T | 1 |
Santl, M | 2 |
Reiser, MF | 1 |
Peeters, J | 1 |
Meitert, J | 1 |
Beck, JD | 5 |
Yuen, C | 1 |
Ho, AD | 4 |
Patel, S | 2 |
Rey, A | 4 |
Niaudet, P | 2 |
Defachelles, AS | 1 |
Rubie, H | 1 |
Munzer, M | 1 |
Plantaz, D | 1 |
Deville, A | 1 |
Minard, V | 1 |
Corradini, N | 1 |
Leverger, G | 1 |
Sleijfer, S | 2 |
Ouali, M | 2 |
van Glabbeke, M | 9 |
Rodenhuis, S | 4 |
Scharrenbroich, I | 1 |
Dietrich, S | 3 |
Jung, S | 1 |
Shimizu, H | 1 |
Tanibuchi, A | 1 |
Akaishi, M | 1 |
Mikami, S | 1 |
Mukai, M | 1 |
Takahashi, T | 1 |
Yozu, R | 1 |
Postovsky, S | 1 |
Vlodavsky, E | 1 |
Kuten, A | 2 |
Shendler, Y | 1 |
Doweck, I | 1 |
Ben Arush, MW | 2 |
Tajino, T | 1 |
Kikuchi, S | 1 |
Yamada, H | 1 |
Takeda, A | 1 |
Konno, S | 1 |
Jordan, K | 1 |
Wolf, HH | 1 |
Voigt, W | 1 |
Kegel, T | 1 |
Mueller, LP | 1 |
Behlendorf, T | 1 |
Sippel, C | 1 |
Arnold, D | 1 |
Dimitrakopoulou-Strauss, A | 4 |
Strauss, LG | 4 |
Vasamiliette, J | 2 |
Haberkorn, U | 3 |
Stroebel, P | 1 |
Schem, BC | 1 |
Wendtner, CM | 5 |
Ploner, F | 1 |
Baur-Melnyk, A | 1 |
Barnoud, R | 1 |
Collardeau-Frachon, S | 1 |
de la Roche, E | 1 |
Vasiljevic, A | 1 |
Thomson, V | 1 |
Ranchère, D | 2 |
Devouassoux, G | 1 |
Devouassoux-Shisheboran, M | 1 |
El Weshi, A | 1 |
Allam, A | 1 |
Ajarim, D | 1 |
Al Dayel, F | 1 |
Pant, R | 1 |
Bazarbashi, S | 1 |
Memon, M | 1 |
Liu, YL | 1 |
Tsai, SH | 1 |
Chang, FW | 1 |
Yu, MH | 1 |
Matuschek, C | 1 |
Mueller, AC | 1 |
Weinmann, M | 1 |
Budach, W | 2 |
Meazza, C | 2 |
Luksch, R | 1 |
Podda, M | 1 |
Favini, F | 1 |
Cefalo, G | 2 |
Massimino, M | 2 |
Anderson, P | 1 |
Hirota, M | 1 |
Ishikawa, N | 1 |
Oi, M | 1 |
Tedoriya, T | 1 |
Fehr, M | 1 |
von Moos, R | 1 |
Furrer, M | 1 |
Cathomas, R | 1 |
Bruland, ØS | 1 |
Eriksson, M | 1 |
Turesson, I | 2 |
Folin, A | 1 |
Hall, KS | 2 |
Fakhrai, N | 1 |
Ebm, C | 1 |
Kostler, WJ | 3 |
Jantsch, M | 1 |
Abdolvahab, F | 1 |
Dominkus, M | 1 |
Pokrajac, B | 1 |
Kauer-Dorner, D | 1 |
Zielinski, CC | 3 |
Brodowicz, T | 4 |
Olmos, D | 1 |
Al-Muderis, O | 1 |
Scurr, M | 1 |
De Pas, T | 5 |
Rosati, G | 1 |
Spitaleri, G | 1 |
Boni, C | 2 |
Tucci, A | 3 |
Frustaci, S | 8 |
Scalamogna, R | 1 |
Radice, D | 1 |
Boselli, S | 1 |
Toffalorio, F | 1 |
Catania, C | 2 |
Noberasco, C | 1 |
Delmonte, A | 1 |
Vecchio, F | 1 |
de Braud, F | 4 |
Bonichon, F | 2 |
Lotz, JP | 1 |
Jimenez, M | 1 |
San Miguel, I | 1 |
San Julián, M | 1 |
Cambeiro, M | 1 |
Fernández Sanmamed, M | 1 |
Vázquez-García, B | 1 |
Pagola, M | 1 |
Gaztañaga, M | 1 |
Martín-Algarra, S | 1 |
Martinez-Monge, R | 1 |
Reed, D | 1 |
Altiok, S | 1 |
Mashhadi, MA | 1 |
Sanadgol, H | 1 |
Keikhaei, M | 1 |
Chang, MH | 1 |
Baek, KK | 1 |
Han, B | 1 |
Lim, T | 1 |
Park, JO | 1 |
Berrada, N | 1 |
Domont, J | 1 |
Cioffi, A | 1 |
Boulet, B | 1 |
Terrier, P | 1 |
Bonvalot, S | 2 |
Trichot, C | 1 |
Lokiec, F | 2 |
Sueta, A | 1 |
Yamamoto, Y | 1 |
Inoue, K | 1 |
Kuriwaki, K | 1 |
Iwase, H | 1 |
Rosenberg, P | 1 |
Carinelli, S | 1 |
Peiretti, M | 1 |
Zanagnolo, V | 1 |
Maggioni, A | 1 |
Brandts, CH | 1 |
Schulz, C | 1 |
Willich, N | 2 |
Steffen, B | 1 |
Hardes, J | 1 |
Gosheger, G | 1 |
Winkelmann, W | 2 |
Serve, H | 1 |
Heinecke, A | 1 |
Berdel, WE | 1 |
Thomas, M | 1 |
Movva, S | 1 |
Verschraegen, C | 1 |
Wang, K | 1 |
Geng, Y | 1 |
Shao, Y | 1 |
Yin, Y | 1 |
Ogura, K | 1 |
Goto, T | 2 |
Imanishi, J | 1 |
Shinoda, Y | 1 |
Tsuda, Y | 1 |
Kobayashi, H | 2 |
Akiyama, T | 1 |
Hirata, M | 1 |
Yamamoto, A | 1 |
Kawano, H | 1 |
Mullen, JT | 2 |
Kobayashi, W | 1 |
Wang, JJ | 1 |
Harmon, DC | 4 |
Choy, E | 2 |
Hornicek, FJ | 3 |
Rosenberg, AE | 1 |
Chen, YL | 2 |
Spiro, IJ | 3 |
DeLaney, TF | 4 |
Tschoep-Lechner, K | 1 |
Drexler, I | 1 |
Hammer, D | 1 |
Neumann, D | 1 |
Pohla, H | 1 |
Sutter, G | 1 |
Noessner, E | 1 |
Mercuri, M | 1 |
Mariani, L | 1 |
Valagussa, P | 1 |
Longhi, A | 1 |
Sanchez de Toledo, J | 2 |
Martelli, H | 1 |
Jenney, ME | 1 |
Scopinaro, M | 1 |
Merks, JH | 1 |
Bouvet, N | 1 |
Ellershaw, C | 1 |
Spooner, D | 5 |
Stevens, MC | 2 |
Burnside, N | 1 |
MacGowan, SW | 1 |
Azzarelli, A | 6 |
Hoekstra, HJ | 1 |
Leahy, M | 1 |
Van Coevorden, F | 2 |
Bramwell, VH | 5 |
Look Hong, NJ | 1 |
Yoon, SS | 1 |
Nielsen, GP | 1 |
Szymonifka, J | 1 |
Yeap, BY | 1 |
Ferraro, A | 1 |
Majò, J | 1 |
Pautier, P | 1 |
Floquet, A | 1 |
Gladieff, L | 1 |
Selle, F | 1 |
Weber, B | 1 |
Largillier, R | 1 |
Opinel, P | 1 |
Reynaud-Bougnoux, A | 1 |
Kerbrat, P | 3 |
Netter-Pinon, G | 1 |
Pinto, N | 1 |
Duvillard, P | 1 |
Haie-Meder, C | 1 |
Lhommé, C | 1 |
Latz, S | 1 |
Ellinger, J | 1 |
Goltz, D | 1 |
Marx, C | 1 |
Müller, SC | 1 |
Fechner, G | 1 |
Provenzano, S | 1 |
Bronte, G | 1 |
Leto, G | 1 |
Fulfaro, F | 1 |
Krych, M | 2 |
Baumert, J | 3 |
Baur, A | 1 |
Serrone, L | 3 |
Nardoni, C | 2 |
Gelibter, A | 1 |
Felici, A | 1 |
Cognetti, F | 3 |
Blot, E | 1 |
Decaudin, D | 1 |
Veyradier, A | 1 |
Bardier, A | 1 |
Zagame, OL | 1 |
Pouillart, P | 1 |
Felgenhauer, J | 2 |
Park, J | 1 |
Kreissman, S | 1 |
Thomson, B | 1 |
Douglas, J | 1 |
Rowley, SD | 1 |
Gooley, T | 1 |
Sanders, JE | 1 |
Pendergrass, TW | 1 |
Petrioli, R | 1 |
Coratti, A | 1 |
Correale, P | 1 |
D'Aniello, C | 1 |
Grimaldi, L | 1 |
Tanzini, G | 1 |
Civitelli, S | 1 |
Marsili, S | 1 |
Messinese, S | 1 |
Marzocca, G | 1 |
Pirtoli, L | 1 |
Francini, G | 1 |
van Oosterom, AT | 10 |
Mouridsen, HT | 6 |
Nielsen, OS | 5 |
Dombernowsky, P | 7 |
Krzemieniecki, K | 1 |
Svancarova, L | 2 |
Chen, LK | 1 |
Xu, GC | 2 |
Teng, XY | 1 |
Liang, Y | 1 |
Liu, JL | 1 |
Zhou, XM | 1 |
Huang, YH | 1 |
Wen, XP | 1 |
Hu, L | 1 |
Selch, M | 4 |
Dorey, F | 2 |
Eckardt, J | 3 |
Toma, S | 6 |
Romanini, A | 2 |
Massidda, B | 1 |
Labianca, R | 1 |
Massacesi, C | 1 |
Antimi, M | 2 |
Biasco, G | 1 |
Aglietta, M | 1 |
Apice, G | 2 |
Grier, HE | 3 |
Krailo, MD | 1 |
Tarbell, NJ | 1 |
Link, MP | 1 |
Fryer, CJ | 1 |
Pritchard, DJ | 2 |
Gebhardt, MC | 2 |
Dickman, PS | 1 |
Perlman, EJ | 1 |
Meyers, PA | 1 |
Donaldson, SS | 2 |
Moore, S | 1 |
Rausen, AR | 1 |
Vietti, TJ | 1 |
Miser, JS | 5 |
Wall, N | 1 |
Starkhammar, H | 1 |
Westermann, AM | 1 |
Wiedemann, GJ | 5 |
Jager, E | 1 |
Jager, D | 1 |
Katschinski, DM | 3 |
Knuth, A | 1 |
Vörde Sive Vörding, PZ | 1 |
Van Dijk, JD | 1 |
Finet, J | 1 |
Neumann, A | 1 |
Longo, W | 1 |
Bakhshandeh, A | 1 |
Tiggelaar, CL | 1 |
Gillis, W | 1 |
Bailey, H | 1 |
Peters, SO | 1 |
Robins, HI | 4 |
Patel, Y | 1 |
Mitchell, CD | 1 |
Hitchcock, RJ | 1 |
O'Sullivan, B | 1 |
Bell, RS | 1 |
Suit, HD | 1 |
Mankin, HJ | 1 |
Rosenberg, AL | 1 |
Rosenthal, DI | 1 |
Miryousefi, F | 1 |
Ancukiewicz, M | 1 |
Ogose, A | 1 |
Yazawa, Y | 1 |
Ueda, T | 1 |
Hotta, T | 1 |
Morita, T | 1 |
Vadhan-Raj, S | 3 |
Bueso-Ramos, C | 1 |
Folloder, J | 1 |
Papadopolous, N | 3 |
Burgess, A | 1 |
Broemeling, LD | 1 |
Broxmeyer, HE | 1 |
Lissoni, AA | 1 |
Fei, F | 1 |
Rossi, R | 4 |
Fruscio, R | 1 |
Villa, A | 1 |
Zani, G | 1 |
Schlemmer, M | 4 |
Bidoli, E | 1 |
La Mura, N | 1 |
Berretta, M | 1 |
Boz, G | 1 |
Gherlinzoni, F | 2 |
Mace, JR | 1 |
Keohan, ML | 1 |
Bernardy, H | 1 |
Junge, K | 1 |
Niebch, G | 1 |
Romeis, P | 1 |
Thoma, A | 1 |
Wagner, T | 4 |
Mueller, U | 1 |
Demetri, G | 1 |
Stöhr, W | 4 |
Bielack, S | 4 |
Ohata, N | 1 |
Morimoto, Y | 1 |
Tanaka, M | 1 |
Inoue, H | 1 |
McCune, JS | 1 |
Friedman, DL | 1 |
Schuetze, S | 1 |
Blough, D | 1 |
Magbulos, M | 1 |
Fiegl, M | 1 |
Fahn, W | 2 |
Buesa, J | 4 |
Quintana, MJ | 1 |
Kosaku, H | 1 |
Hozumi, T | 1 |
Kondo, T | 1 |
Van Winkle, P | 1 |
Angiolillo, A | 1 |
Krailo, M | 1 |
Cheung, YK | 1 |
Anderson, B | 1 |
Davenport, V | 1 |
Reaman, G | 1 |
Cairo, MS | 2 |
Grobmyer, SR | 1 |
Maki, RG | 1 |
Mazumdar, M | 1 |
Riedel, E | 1 |
Brennan, MF | 1 |
Singer, S | 1 |
Worden, FP | 2 |
Sondak, VK | 1 |
Leu, KM | 2 |
McGinn, CJ | 1 |
Yalcin, B | 2 |
Pamir, A | 2 |
Buyukcelik, A | 1 |
Utkan, G | 1 |
Akbulut, H | 2 |
Demirkazik, A | 2 |
Icli, F | 2 |
Rapidis, AD | 1 |
Gakiopoulou, H | 1 |
Stavrianos, SD | 1 |
Vilos, GA | 1 |
Faratzis, G | 1 |
Douzinas, EE | 1 |
Givalos, N | 1 |
Patsouris, E | 1 |
Scagnellato, A | 1 |
Prete, A | 1 |
D'Angelo, P | 1 |
Di Cataldo, A | 1 |
Carli, M | 2 |
Pappo, AS | 4 |
Devidas, M | 1 |
Jenkins, J | 2 |
Rao, B | 1 |
Marcus, R | 1 |
Thomas, P | 1 |
Gebhardt, M | 1 |
Pratt, C | 1 |
Dusenbery, KE | 1 |
Potish, RA | 1 |
Argenta, PA | 1 |
Judson, PL | 1 |
Umeda, T | 5 |
Wada, T | 1 |
Ihara, K | 1 |
Isu, K | 1 |
Sugiura, H | 1 |
Yabe, H | 1 |
Tsugane, S | 1 |
Beppu, Y | 1 |
Siehl, JM | 1 |
Thiel, E | 1 |
Schmittel, A | 1 |
Hütter, G | 1 |
Deckert, PM | 1 |
Szelényi, H | 1 |
Keilholz, U | 1 |
Uchida, A | 1 |
Tabata, M | 1 |
Kiura, K | 1 |
Tanimoto, Y | 1 |
Kanehiro, A | 1 |
Aoe, M | 1 |
Ohohara, N | 1 |
Ueoka, H | 1 |
Tanimoto, M | 1 |
Piura, B | 1 |
Rabinovich, A | 1 |
Terrier-Lacombe, MJ | 1 |
van Unnik, A | 1 |
Quintana, E | 1 |
Fan, SK | 1 |
Wang, YG | 1 |
Jeon, IS | 1 |
Lee, SM | 1 |
Pisters, PW | 3 |
Kraybill, WG | 1 |
Harris, J | 1 |
Ettinger, DS | 1 |
Blum, RH | 3 |
Letson, GD | 1 |
Eisenberg, B | 1 |
Ferringer, T | 1 |
Banks, PM | 1 |
Metcalf, JS | 1 |
Leyvraz, S | 6 |
Zweifel, M | 1 |
Jundt, G | 1 |
Lissoni, A | 2 |
Cerny, T | 6 |
Sessa, C | 4 |
Fey, M | 1 |
Dietrich, D | 2 |
Honegger, HP | 2 |
Rassnick, KM | 2 |
Moore, AS | 1 |
Northrup, NC | 1 |
Kristal, O | 2 |
Beaulieu, BB | 1 |
Lewis, LD | 1 |
Page, RL | 2 |
Rodriguez, CO | 1 |
Khanna, C | 1 |
Rosenberg, MP | 1 |
Chaffin, K | 1 |
Navid, F | 1 |
Santana, VM | 1 |
Billups, CA | 1 |
Merchant, TE | 1 |
Furman, WL | 2 |
Cain, AM | 1 |
Rao, BN | 2 |
Hale, GA | 1 |
Jürgens, H | 6 |
Kortmann, B | 1 |
Reimer, T | 1 |
Gerber, B | 1 |
Klautke, G | 1 |
Losa, R | 1 |
Sierra, M | 1 |
Goitia, A | 1 |
Uña, E | 1 |
Nadal, R | 1 |
Del Muro, JG | 1 |
Gión, M | 1 |
Escudero, P | 3 |
Esteban, E | 1 |
Suppiah, R | 1 |
Wood, L | 1 |
Elson, P | 1 |
Budd, GT | 3 |
Christensen, TB | 1 |
Blay, J | 1 |
Gellermann, J | 1 |
Hildebrandt, B | 1 |
Ganter, H | 1 |
Wlodarczyk, W | 1 |
Budach, V | 2 |
Felix, R | 1 |
Tunn, PU | 1 |
Herrmann, R | 1 |
Guillou, L | 2 |
Christinat, A | 1 |
Fey, MF | 1 |
Wernli, M | 1 |
Pestalozzi, B | 1 |
Jiang, L | 1 |
Admirand, JH | 1 |
Moran, C | 1 |
Ford, RJ | 1 |
Bueso-Ramos, CE | 1 |
Falk, M | 1 |
Licht, T | 1 |
Straka, C | 1 |
Hentrich, M | 1 |
Cassier, PA | 1 |
Dufresne, A | 1 |
Alberti, L | 1 |
Kim, KT | 1 |
Han, SY | 1 |
Park, EH | 1 |
Jang, JS | 1 |
Roh, MH | 1 |
Lee, SW | 1 |
Jeong, JS | 1 |
Dörr, HG | 1 |
Bölling, T | 1 |
Sauer, R | 2 |
Griffith, KA | 1 |
Thomas, DG | 2 |
Papadimitriou, CA | 1 |
Zorzou, MP | 1 |
Markaki, S | 1 |
Rodolakis, A | 1 |
Voulgaris, Z | 1 |
Bozas, G | 1 |
Kastritis, E | 1 |
Bamias, A | 1 |
Gika, D | 1 |
Dimopoulos, MA | 1 |
Roylance, R | 1 |
McTiernan, A | 1 |
Sykes, K | 1 |
Daniels, S | 1 |
Lorigan, P | 1 |
Radford, JA | 2 |
Van Glabbeke, MM | 1 |
Kirkpatrick, A | 2 |
Bertoni, F | 1 |
Bacci, G | 1 |
Rossi, E | 1 |
Stefani, M | 1 |
Ghiotto, C | 1 |
Marino, D | 1 |
Crivellari, G | 1 |
Monfardini, S | 3 |
Williams, D | 1 |
Crofton, PM | 1 |
Levitt, G | 1 |
Tascilar, M | 1 |
Loos, WJ | 1 |
Seynaeve, C | 1 |
Qiu, MZ | 1 |
Xu, F | 1 |
Wang, SS | 1 |
Luo, HY | 1 |
Wang, F | 1 |
Li, FH | 1 |
Sun, XF | 1 |
Lin, TY | 1 |
Huang, HQ | 1 |
Jiang, WQ | 1 |
Guan, ZZ | 1 |
Xu, RH | 1 |
Iagaru, A | 1 |
Masamed, R | 1 |
Menendez, LR | 1 |
Fedenko, A | 1 |
Conti, PS | 1 |
Chandra, P | 1 |
Schmidt, RM | 1 |
Madan, P | 1 |
Topkara, VK | 1 |
Boos, J | 1 |
Beske, F | 1 |
Hallmen, E | 1 |
Dantonello, T | 1 |
Kazanowska, B | 1 |
Verma, S | 2 |
Younus, J | 1 |
Stys-Norman, D | 1 |
Haynes, AE | 1 |
Blackstein, M | 1 |
Hosenpud, JR | 1 |
Samuels, B | 1 |
Hayden, JB | 1 |
Hung, AY | 1 |
Mansoor, A | 1 |
Mundt, AJ | 2 |
Undevia, S | 1 |
Kshirsagar, MP | 1 |
Hamre, MR | 1 |
Seeber, S | 5 |
Dimitriadis, K | 1 |
Schütte, J | 7 |
Schmidt, CG | 3 |
Stuart-Harris, R | 3 |
Harper, PG | 2 |
Kaye, SB | 2 |
Wiltshaw, E | 5 |
Stuart-Harris, RC | 1 |
Parsons, CA | 1 |
Mooney, CA | 1 |
Gowing, NF | 1 |
Niederle, N | 2 |
Scheulen, ME | 2 |
Cremer, M | 1 |
Burkert, H | 1 |
Utracka-Hutka, B | 1 |
Czownicki, Z | 1 |
Bierbaum, W | 1 |
Bremer, K | 1 |
Firusian, N | 1 |
Higi, M | 1 |
Elias, AD | 6 |
Eilber, F | 1 |
Forscher, C | 2 |
Fu, YS | 1 |
Saeter, G | 3 |
Talle, K | 1 |
Solheim, OP | 2 |
Antoine, E | 1 |
Spielmann, M | 1 |
Le Chevalier, T | 1 |
Brain, E | 1 |
Toussaint, C | 1 |
Janin, N | 1 |
Kayitalire, L | 1 |
Fontaine, F | 1 |
Genin, J | 1 |
Palumbo, R | 5 |
Ruymann, FB | 1 |
Vietti, T | 1 |
Gehan, E | 1 |
Wiener, E | 2 |
Wharam, M | 2 |
Newton, WA | 1 |
Maurer, H | 2 |
Bui, BN | 2 |
Chevallier, B | 3 |
Krakowski, I | 2 |
Peny, AM | 1 |
Maugard-Louboutin, C | 1 |
Ayash, LJ | 2 |
Wheeler, C | 2 |
Schwartz, G | 1 |
Tepler, I | 1 |
Gonin, R | 1 |
McCauley, M | 1 |
Mazanet, R | 1 |
Schnipper, L | 2 |
Frei, E | 1 |
Tursz, T | 5 |
Mouridsen, H | 4 |
Steward, W | 3 |
Somers, R | 10 |
Rankin, E | 1 |
Boros, L | 2 |
Garrow, GC | 2 |
Asbury, RF | 2 |
Chang, AY | 2 |
Yule, SM | 3 |
Wyllie, R | 2 |
Price, L | 2 |
Pearson, AD | 5 |
Idle, JR | 4 |
Patsner, B | 1 |
Greenberg, S | 1 |
Cole, M | 1 |
Fields, KK | 1 |
Elfenbein, GJ | 1 |
Lazarus, HM | 1 |
Cooper, BW | 1 |
Perkins, JB | 1 |
Creger, RJ | 1 |
Ballester, OF | 1 |
Hiemenz, JH | 1 |
Janssen, WE | 1 |
Zorsky, PE | 1 |
Pocard, M | 1 |
Azorin, JF | 1 |
Delepine, N | 1 |
Delepine, G | 1 |
Tremblay, B | 1 |
Destable, MD | 1 |
d'Oleire, F | 1 |
Knop, E | 1 |
Eleftheriadis, S | 2 |
Bucsky, P | 1 |
Feddersen, S | 1 |
Klouche, M | 1 |
Geisler, J | 1 |
Mentzel, M | 3 |
Schmucker, P | 1 |
Blair, SC | 1 |
Raney, B | 1 |
Ensign, LG | 1 |
Foreman, J | 1 |
Khan, F | 1 |
Newton, W | 1 |
Ortega, J | 1 |
Ragab, A | 1 |
Lauterburg, BH | 1 |
Nguyen, T | 1 |
Hartmann, B | 1 |
Junker, E | 1 |
Küpfer, A | 3 |
Arndt, C | 1 |
Morgenstern, B | 1 |
Wilson, D | 1 |
Liedtke, R | 1 |
Miser, J | 2 |
Stuschke, M | 1 |
Kjønniksen, I | 1 |
Winderen, M | 1 |
Bruland, O | 1 |
Fodstad, O | 1 |
Hatakeyama, K | 1 |
Wakita, H | 1 |
Skubitz, KM | 1 |
Hamdan, H | 1 |
Thompson, RC | 1 |
Foladore, S | 1 |
Crivellari, D | 1 |
Carbone, A | 1 |
Sorio, R | 2 |
Morassut, S | 1 |
Craft, AW | 1 |
Edmonson, JH | 4 |
Ryan, LM | 1 |
Brooks, JS | 1 |
Shiraki, M | 1 |
Frytak, S | 1 |
Parkinson, DR | 1 |
Antman, K | 1 |
Crowley, J | 1 |
Balcerzak, SP | 3 |
Rivkin, SE | 1 |
Weiss, GR | 1 |
Elias, A | 6 |
Natale, RB | 1 |
Cooper, RM | 1 |
Barlogie, B | 1 |
Trump, DL | 1 |
González-Manzano, R | 1 |
Vieitez, JM | 1 |
Tangco, E | 1 |
Fernandez de Alava, E | 1 |
Herranz, P | 1 |
Garcia-Foncillas, J | 1 |
Hibi, S | 1 |
Naya, M | 1 |
Takaya, K | 1 |
Morimoto, M | 1 |
Kataoka, Y | 1 |
Todo, S | 1 |
Imashuku, S | 1 |
Steward, WP | 5 |
Clavel, M | 4 |
Crowther, D | 3 |
Rouesse, J | 3 |
Tueni, E | 2 |
Gilard, V | 2 |
Malet-Martino, MC | 2 |
de Forni, M | 2 |
Niemeyer, U | 2 |
Ader, JC | 1 |
Martino, R | 2 |
Kitoh, M | 2 |
Tatezaki, S | 2 |
Satoh, T | 2 |
Legha, SS | 2 |
Nicaise, C | 3 |
Blackledge, G | 8 |
Onsrud, M | 2 |
Thomas, D | 7 |
Sylvester, R | 3 |
Weh, HJ | 2 |
Agarwal, K | 1 |
Zornig, C | 2 |
Schwarz, R | 2 |
Dietel, M | 2 |
Hossfeld, DK | 2 |
Dalley, D | 1 |
Bell, DR | 1 |
Levi, J | 1 |
Simes, RJ | 1 |
Kellner, R | 1 |
Fissi, S | 1 |
Montalto, F | 1 |
Metch, B | 1 |
Weiss, SA | 1 |
Weick, JK | 1 |
Fabian, C | 1 |
Stephens, RL | 1 |
Harstrick, A | 2 |
Bokemeyer, C | 3 |
Köhne-Wömpner, CH | 2 |
Knipp, H | 1 |
Anagnou, J | 1 |
Wipperman, B | 1 |
Neumann, S | 1 |
Poliwoda, H | 2 |
Pastorino, U | 2 |
Bertulli, R | 1 |
Zucchinelli, P | 2 |
Devizzi, L | 2 |
Canavese, G | 1 |
Albanese, E | 1 |
Cantoni, E | 1 |
Barisone, A | 1 |
Reggiardo, G | 1 |
Rosso, R | 1 |
Santi, L | 2 |
Bosse, D | 1 |
Starck, M | 1 |
Panzer, M | 1 |
Stiegler, H | 1 |
Berger, H | 2 |
Sauer, H | 4 |
Peter, K | 2 |
Edmonson, J | 1 |
Ryan, L | 5 |
Pelletier, L | 1 |
Olivier, JP | 1 |
Facchini, T | 1 |
Vo Van, ML | 1 |
Vantongelen, K | 1 |
Michelotti, A | 1 |
Giannessi, P | 1 |
Bengala, C | 1 |
Conte, P | 1 |
Ho, PT | 1 |
Zimmerman, K | 1 |
Wexler, LH | 1 |
Blaney, S | 1 |
Jarosinski, P | 2 |
Weaver-McClure, L | 1 |
Izraeli, S | 1 |
Balis, FM | 1 |
Güllü, I | 3 |
Yalçin, S | 5 |
Tekuzman, G | 3 |
Barişta, I | 3 |
Alkiş, N | 1 |
Celik, I | 3 |
Zengin, N | 2 |
Güler, N | 2 |
Kars, A | 3 |
Baltali, E | 2 |
Connelly, EF | 1 |
Hui, L | 1 |
Pratt, CB | 3 |
Bui, NB | 1 |
Stöckle, E | 1 |
Kantor, G | 1 |
Thomas, L | 1 |
English, M | 1 |
Skinner, R | 1 |
Roguin, A | 1 |
Higasi, A | 1 |
Psikakos, G | 1 |
Papanicolaou, A | 1 |
Boutis, L | 1 |
Goutzioulis, M | 1 |
Makedos, G | 1 |
Papanicolaou, N | 1 |
Hicks, LG | 1 |
Zalupski, M | 2 |
Santoni, J | 1 |
Weill, S | 1 |
Tubiana-Hulin, M | 1 |
Weiss, AJ | 1 |
Lackman, RD | 1 |
Womer, RB | 2 |
Gutsche, S | 1 |
Deeken, M | 1 |
Crahé, R | 1 |
Weiss, C | 2 |
Storer, B | 1 |
Tiuliandin, SA | 1 |
Liubimova, NV | 1 |
Sidorova, NI | 1 |
Averinova, SG | 1 |
Kashkadaeva, AV | 1 |
Romanova, LF | 1 |
Shiriaev, SV | 1 |
Garin, AM | 1 |
Mulkerin, DL | 1 |
Touhidi, R | 1 |
Baranzelli, MC | 1 |
Gourmel, B | 1 |
N'Guyen, M | 1 |
Deligny, N | 1 |
Demaille, MC | 1 |
Galligioni, E | 1 |
Favaro, D | 1 |
Lo Re, G | 1 |
Tumolo, S | 1 |
Plager, C | 3 |
Burgess, MA | 4 |
Hays, C | 1 |
Bellmunt, J | 2 |
Eres, N | 1 |
Ribas, A | 1 |
Casado, S | 1 |
Albanell, J | 1 |
Baselga, J | 1 |
Long, HJ | 2 |
Kvols, LK | 1 |
Mann, BS | 1 |
Grill, JP | 1 |
Franzke, A | 1 |
Schöber, C | 1 |
Arseniev, L | 1 |
Metzner, B | 1 |
Link, H | 1 |
Kanz, L | 1 |
Tesoro-Tess, JD | 1 |
Gianni, MC | 1 |
Fossati-Bellani, F | 1 |
Lombardi, F | 1 |
Therasse, P | 1 |
Alvegård, TA | 2 |
Strander, H | 2 |
Klepp, R | 1 |
Söderberg, M | 1 |
Wist, E | 1 |
Raabe, N | 1 |
Erlanson, M | 1 |
Hannisdal, E | 1 |
Palmeri, S | 1 |
Gatti, C | 1 |
Raffo, P | 2 |
Villani, G | 2 |
Walter, AW | 1 |
Shearer, PD | 1 |
Greenwald, CA | 1 |
Bowman, LC | 1 |
Gajjar, A | 1 |
Jenkins, JJ | 1 |
Theis, JG | 2 |
Chan, HS | 2 |
Greenberg, ML | 2 |
Malkin, D | 2 |
Karaskov, V | 2 |
Moncica, I | 2 |
Koren, G | 2 |
Doyle, J | 2 |
Singer, JM | 1 |
Hartley, JM | 1 |
Brennan, C | 1 |
Nicholson, PW | 1 |
Souhami, RL | 1 |
Pertl, U | 1 |
Hess, CF | 1 |
Pötter, R | 1 |
van Heek-Romanowski, R | 1 |
Schött, C | 1 |
Spaar, HJ | 1 |
Willnow, U | 1 |
Tilgner, J | 1 |
Dörken, B | 1 |
Pronzato, P | 1 |
Losardo, P | 1 |
Pensa, F | 1 |
Tognoni, A | 1 |
Lévy, E | 1 |
Thirion, P | 1 |
Piedbois, P | 1 |
Ozişik, Y | 2 |
Antón, A | 2 |
García del Muro, J | 2 |
Simşek, T | 1 |
Uner, M | 1 |
Trak, B | 1 |
Erman, O | 1 |
Zorlu, GC | 1 |
Kito, M | 1 |
Dunst, J | 1 |
Ahrens, S | 1 |
Rübe, C | 1 |
Zoubek, A | 1 |
Arranz, F | 1 |
Valentí, V | 1 |
Menéndez, D | 1 |
Bacchi, M | 1 |
Bressoud, A | 1 |
Hermann, R | 1 |
Orlando, L | 1 |
Nolè, F | 1 |
Munzone, E | 1 |
Zampino, MG | 1 |
Fazio, N | 1 |
Aapro, MS | 1 |
Goldhirsch, A | 1 |
Leone, L | 1 |
Oliva, C | 1 |
Monteleone, M | 1 |
Colussi, AM | 1 |
Dal Canton, O | 1 |
Bergnolo, P | 1 |
Boglione, A | 1 |
Bumma, C | 1 |
Arndt, CA | 1 |
Nascimento, AG | 1 |
Schroeder, G | 1 |
Schomberg, PJ | 1 |
Neglia, JP | 1 |
Sencer, SF | 1 |
Silberman, TL | 1 |
Moertel, CL | 1 |
Tillisch, JK | 1 |
Neumaier, C | 1 |
Cosso, M | 1 |
Bertero, G | 1 |
Spadini, N | 1 |
Valente, S | 1 |
Pastorino, M | 1 |
Czyzewski, EA | 1 |
Goldman, S | 1 |
Nachman, J | 1 |
Rubin, C | 1 |
Hallahan, DE | 1 |
Maugard, C | 1 |
Mihura, J | 1 |
Gil, B | 1 |
Cour-Chabernaud, V | 1 |
Schuchardt, U | 1 |
Wittekind, C | 1 |
Papadopoulos, T | 1 |
Grabenbauer, GG | 1 |
Fernberg, JO | 1 |
Wiklund, T | 1 |
Monge, O | 1 |
Sawyer, M | 1 |
Bramwell, V | 3 |
Wiltschke, C | 1 |
von Briel, T | 1 |
Schaad, R | 1 |
Schmitz, SF | 1 |
Honegger, P | 1 |
Brunner, J | 1 |
Huuhtanen, RL | 1 |
Wiklund, TA | 2 |
Blomqvist, CP | 2 |
Böhling, TO | 1 |
Virolainen, MJ | 1 |
Tribukait, B | 1 |
Andersson, LC | 1 |
Henze, G | 1 |
Morgan, M | 1 |
Knietig, R | 1 |
Hawkins, D | 1 |
Pendergrass, T | 1 |
Lindsley, K | 1 |
Conrad, EU | 1 |
Türker, A | 1 |
Altundağ, K | 1 |
Uner, A | 1 |
Firat, D | 1 |
van Hoesel, Q | 2 |
Keizer, HJ | 4 |
van Oosterom, A | 4 |
Krzemienlecki, K | 1 |
Oosterhuis, JW | 2 |
Daller, RT | 1 |
Fenton, JG | 1 |
Gerke, P | 1 |
Filejski, W | 1 |
Steinhoff, J | 1 |
Dinçol, D | 1 |
Samur, M | 1 |
Sencan, O | 1 |
Onur, H | 1 |
Senler, FC | 1 |
Kerbusch, T | 2 |
Huitema, AD | 1 |
Ouwerkerk, J | 2 |
Mathôt, RA | 1 |
Schellens, JH | 2 |
Beijnen, JH | 2 |
Frisch, J | 1 |
Bodoky, G | 1 |
Szántó, J | 1 |
Poller, I | 1 |
Rahóty, P | 1 |
Eckhardt, S | 1 |
Láng, I | 1 |
Szendroi, M | 1 |
Späth-Schwalbe, E | 1 |
Genvresse, I | 1 |
Koschuth, A | 1 |
Dietzmann, A | 1 |
Grunewald, R | 1 |
Possinger, K | 1 |
Kushner, DM | 1 |
Webster, KD | 1 |
Belinson, JL | 1 |
Rybicki, LA | 1 |
Kennedy, AW | 1 |
Markman, M | 1 |
Gwyther, SJ | 1 |
Meric, F | 1 |
Milas, M | 1 |
Hunt, KK | 2 |
Hess, KR | 1 |
Hildebrandt, G | 1 |
Papadopolous, NE | 1 |
Pollock, RE | 1 |
Feig, BW | 2 |
Bouhour, D | 1 |
Dumontet, C | 2 |
Philip, T | 2 |
Biron, P | 3 |
Lejeune, FJ | 1 |
Pujol, N | 1 |
Liénard, D | 1 |
Mosimann, F | 1 |
Raffoul, W | 1 |
Genton, A | 1 |
Landry, M | 1 |
Chassot, PG | 1 |
Chiolero, R | 1 |
Bischof-Delaloye, A | 1 |
Mirimanoff, RO | 1 |
Bejkos, D | 1 |
Leyvraz, PF | 1 |
Lopez, AM | 1 |
Ketchum, M | 1 |
Nichols, H | 1 |
Xu, MJ | 1 |
Peng, YM | 1 |
Dorr, R | 1 |
Alberts, DS | 1 |
Bonetti, M | 1 |
Olmi, P | 1 |
Pignatti, G | 1 |
Barbieri, E | 1 |
Zmerly, H | 1 |
Serraino, D | 1 |
Bangalore, N | 1 |
Bhargava, P | 2 |
Hawkins, MJ | 1 |
Thall, PF | 1 |
Cheng, SC | 1 |
Zeuli, M | 2 |
Gamucci, T | 1 |
Nardi, M | 1 |
Gortzak, E | 1 |
van Geel, AN | 1 |
Ezzat, A | 1 |
Wendtner, C | 2 |
Falk, MH | 2 |
Kurze, V | 1 |
Aydemir, U | 1 |
Papaldo, P | 1 |
Pacetti, U | 1 |
Attems, Y | 1 |
Hejna, M | 1 |
Tomek, S | 1 |
Amann, G | 1 |
Fiebiger, WC | 1 |
Wiltschke, CH | 1 |
Krainer, M | 1 |
Mathĵt, RA | 1 |
Cormier, JN | 1 |
Herzog, CE | 1 |
Ballo, MT | 1 |
Raney, RB | 2 |
Zagars, GK | 1 |
Peterson, AC | 1 |
Porter, M | 1 |
Porter, J | 1 |
Barr, FG | 1 |
Qualman, SJ | 1 |
Wiener, ES | 1 |
Maurer, HM | 1 |
Crist, WM | 1 |
Petersen, IA | 1 |
Shives, TC | 1 |
Mahoney, MR | 1 |
Rock, MG | 1 |
Haddock, MG | 1 |
Sim, FH | 1 |
Maples, WJ | 1 |
Gunderson, LL | 1 |
Foo, ML | 1 |
Buckner, JC | 2 |
Stafford, SL | 1 |
Curigliano, G | 1 |
Masci, G | 1 |
Pagani, O | 1 |
Marrocco, E | 1 |
Fazeny-Dörner, B | 1 |
Veitl, M | 1 |
Wenzel, C | 1 |
Zielinski, C | 1 |
Muhm, M | 1 |
Vogelsang, H | 1 |
Marosi, C | 1 |
Trent II, JC | 1 |
Valero, V | 1 |
Ritter, S | 1 |
Schröder, HJ | 1 |
Mitrou, PS | 1 |
Fischer, M | 1 |
Mitrou, G | 1 |
Röttger, P | 1 |
Van Glabekke, M | 1 |
Meckenstock, R | 1 |
Chauvin, F | 1 |
Philip, I | 1 |
Brunat-Mentigny, M | 1 |
Antman, KH | 9 |
Sutton, GP | 2 |
Blessing, JA | 2 |
Manetta, A | 1 |
Homesley, H | 1 |
McGuire, W | 1 |
Crasnier, F | 1 |
Chouini-Lalanne, N | 1 |
Vierhout, ME | 1 |
Chadha-Ajwani, S | 1 |
Wijnen, JA | 1 |
Splinter, TA | 1 |
Zondervan, PE | 1 |
Ras, JH | 1 |
Drogendijk, AC | 1 |
Virolainen, M | 1 |
Elomaa, I | 1 |
Sogno, G | 1 |
Venturino, A | 1 |
Bignami, P | 1 |
Bonadonna, G | 1 |
Benvenuto, JA | 1 |
Ayele, W | 1 |
Raber, MN | 1 |
Newman, RA | 1 |
Weiss, RB | 2 |
Pinkerton, CR | 1 |
Suarez, A | 1 |
McDowell, H | 1 |
Comoy, E | 1 |
Flamant, F | 1 |
Wiedemann, G | 1 |
Roszinski, S | 1 |
Biersack, A | 1 |
Mittermüller, J | 1 |
Gerl, A | 1 |
Simon, W | 1 |
Ortmaier, A | 1 |
Denzlinger, C | 1 |
Wilmanns, W | 2 |
Greifenberg, B | 1 |
Soedirman, J | 1 |
Eder, JP | 1 |
Deary, J | 1 |
Weissman, L | 1 |
Schryber, S | 1 |
Hunt, M | 1 |
Critchlow, J | 1 |
Shaw, PJ | 1 |
Eden, T | 1 |
Aisner, J | 2 |
Baker, WJ | 1 |
Fistel, SJ | 1 |
Jones, RV | 1 |
Photopulos, G | 1 |
Berman, ML | 1 |
Homesley, HD | 1 |
Prenninger, SW | 1 |
Nagele, A | 1 |
Boehm, E | 1 |
Denecke, H | 1 |
Zaidi, SH | 1 |
Iqbal, Z | 1 |
Mallick, JA | 1 |
Zeugin, T | 1 |
Brunner, KW | 1 |
Zügel, M | 1 |
Wingberg, D | 1 |
Stewart, W | 2 |
Dirix, LY | 2 |
Hoffmann, W | 1 |
Weidmann, B | 1 |
Migeod, F | 1 |
Könner, J | 1 |
Scheulen, M | 1 |
Czeglarski, G | 1 |
Sherman, D | 1 |
Douglass, EC | 1 |
Etcubanas, E | 1 |
Goren, MP | 1 |
Green, AA | 1 |
Hayes, FA | 1 |
Horowitz, ME | 1 |
Meyer, WH | 1 |
Thompson, EI | 1 |
Wilimas, JA | 1 |
Willemse, PH | 1 |
de Vries, EG | 1 |
Loprinzi, CL | 1 |
Schaid, DJ | 1 |
Sulkes, A | 1 |
Collins, J | 1 |
Boven, E | 1 |
Calame, JJ | 1 |
Molthoff, CF | 1 |
Pinedo, HM | 3 |
Loehrer, PJ | 1 |
Sledge, GW | 1 |
Usakewicz, J | 1 |
Hainsworth, JD | 1 |
Martelo, OJ | 1 |
Omura, G | 1 |
Braun, TJ | 1 |
Quirt, I | 1 |
Warr, D | 1 |
Young, V | 1 |
Knowling, M | 1 |
Eisenhauer, E | 1 |
Cantwell, BM | 2 |
Harris, AL | 2 |
Westbury, G | 1 |
Harmer, C | 1 |
McKinna, A | 1 |
Kinsella, TJ | 1 |
Triche, TJ | 1 |
Tsokos, M | 1 |
Forquer, R | 1 |
Wesley, R | 1 |
Magrath, I | 2 |
Carmichael, J | 1 |
Ghani, S | 1 |
Mansi, JL | 1 |
MacMillan, S | 1 |
King, M | 1 |
Zamboglou, N | 1 |
Fürst, G | 1 |
Pape, H | 1 |
Bannach, B | 1 |
Molls, M | 1 |
Schmitt, G | 1 |
Cavalli, F | 1 |
Verwey, J | 1 |
von Oosterom, A | 1 |
Hartlapp, JH | 2 |
Münch, HJ | 2 |
Illiger, HJ | 2 |
Wolter, H | 2 |
Jensen, JC | 2 |
de Kraker, J | 1 |
Voûte, PA | 1 |
Sandlund, J | 1 |
Raynor, A | 1 |
Rosenberg, S | 1 |
Arasi, V | 1 |
Brade, WP | 1 |
Herdrich, K | 1 |
Varini, M | 1 |
Montella, D | 1 |
Rosenbaum, C | 1 |
Schwen, M | 1 |
Clinical Trials (39)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Phase II Study of Pemetrexed Plus Cisplatin in Patients With Refractory Soft Tissue Sarcoma[NCT03809637] | Phase 2 | 37 participants (Actual) | Interventional | 2017-01-10 | Active, not recruiting | ||
An Open-label, Multi-center, Randomized Study of the Safety and Effect on Event-free Survival of Bevacizumab in Combination With Standard Chemotherapy in Childhood and Adolescent Patients With Metastatic Rhabdomyosarcoma and Non-rhabdomyosarcoma Soft Tiss[NCT00643565] | Phase 2 | 154 participants (Actual) | Interventional | 2008-07-29 | Completed | ||
A Protocol For Nonmetastatic Rhabdomyosarcoma [RMS-2005][NCT00379457] | Phase 3 | 600 participants (Anticipated) | Interventional | 2006-06-30 | Recruiting | ||
Pegylated-liposome Doxorubicin Combined With Ifosfamide As First-line Treatment for Patients With Advanced or Metastatic Soft Tissue Sarcoma[NCT03268772] | Phase 2 | 40 participants (Actual) | Interventional | 2015-04-01 | Active, not recruiting | ||
Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Soft Tissue Sarcoma[NCT04307277] | Phase 3 | 600 participants (Anticipated) | Interventional | 2020-10-09 | Recruiting | ||
"A Phase II Multicenter Study Comparing the Efficacy of the Oral Angiogenesis Inhibitor Nintedanib With the Intravenous Cytotoxic Compound Ifosfamide for Treatment of Patients With Advanced Metastatic Soft Tissue Sarcoma After Failure of Systemic Non-oxaz[NCT02808247] | Phase 2 | 80 participants (Actual) | Interventional | 2017-07-07 | Terminated (stopped due to Exceed of pre-specified number of failures in the experimental arm) | ||
Randomized Study Comparing Neoadjuvant Chemotherapy Etoposide + Ifosfamide + Adriamycin (EIA) Combined With Regional Hyperthermia (RHT) Versus Neoadjuvant Chemotherapy Alone in the Treatment of High-Risk Soft Tissue Sarcomas in Adults[NCT00003052] | Phase 3 | 340 participants (Anticipated) | Interventional | 1997-07-31 | Completed | ||
Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age[NCT00346164] | Phase 3 | 588 participants (Actual) | Interventional | 2007-02-05 | Completed | ||
An Open-label, Dose Ranging Study to Assess the Safety, Efficacy, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist (Eltrombopag) Administered to Subjects Receiving Adriamycin and Ifosfamide (AI) Regimen[NCT00358540] | Phase 1 | 18 participants (Actual) | Interventional | 2006-06-01 | Completed | ||
An Evaluation of PET/CT Imaging as a Predictor of Disease Free Survival Following Neo-Adjuvant Chemotherapy for Soft Tissue Sarcoma[NCT00346125] | 70 participants (Actual) | Interventional | 2006-04-10 | Completed | |||
A Phase II Multicenter Trial of RAD001 in Patients With Metastatic or Recurrent Sarcomas[NCT01830153] | Phase 2 | 41 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
A Phase II Trial of Apatinib in Relapsed and Unresectable High-grade Osteosarcoma After Failure of Standard Multimodal Therapy[NCT02711007] | Phase 2/Phase 3 | 37 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
A Randomized, Multicenter, Phase III Trial of Trabectedin (Yondelis) Versus Doxorubicin-based Chemotherapy as First-Line Therapy in Patients With Translocation-Related Sarcomas (TRS)[NCT00796120] | Phase 3 | 121 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
Randomised Trial Of Single Agent Doxorubicin Versus Doxorubicin Plus Ifosfamide In The First Line Treatment Of Advanced Or Metastatic Soft Tissue Sarcoma[NCT00061984] | Phase 3 | 455 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
Trabectedin in Soft Tissue Sarcomas. A Retrospective Observational Analysis (TrObs)[NCT02793050] | 510 participants (Actual) | Observational | 2016-06-15 | Completed | |||
RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions.[NCT03375437] | 376 participants (Actual) | Interventional | 2018-02-15 | Active, not recruiting | |||
A Phase II Study Evaluating Neo-/Adjuvant EIA Chemotherapy, Surgical Resection and Radiotherapy in High-risk Soft Tissue Sarcoma[NCT01382030] | Phase 2 | 50 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
A Multinational, Randomized, Double-blind Placebo Controlled Study of AVE8062 (25 mg/m2) Administered Every 3 Weeks in Patients With Advanced-stage Soft Tissue Sarcoma, Treated With Cisplatin (75 mg) After Failure of Anthracycline and Ifosfamide Chemother[NCT00699517] | Phase 3 | 355 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy[NCT01710176] | Phase 3 | 550 participants (Actual) | Interventional | 2011-06-01 | Active, not recruiting | ||
A Randomised Phase-III Trial of the Cooperative Weichteilsarkom Study Group (CWS) for Localised High-risk Rhabdomyosarcoma and Localised Rhabdomyosarcoma-like Soft Tissue Sarcoma in Children, Adolescents, and Young Adults[NCT00876031] | Phase 3 | 195 participants (Actual) | Interventional | 2009-07-01 | Completed | ||
The Use of Ifosfamide, Doxorubicin and Hypofractionated Radiotherapy in Neoadjuvant Treatment of High-grade Extremity Soft Tissue and Non-metastatic Sarcomas[NCT02812654] | Phase 2 | 70 participants (Anticipated) | Interventional | 2015-03-31 | Recruiting | ||
Evaluation of Individual Radiosensitivity of Cancer Patients to be Treated by Radiotherapy or Radiochemotherapy Per-operative[NCT02797405] | 97 participants (Actual) | Interventional | 2016-10-31 | Terminated (stopped due to Withdrawal of analysis study Partner.) | |||
First in Man Study Investigating the Biodistribution, the Safety and Optimal Recommended Dose of a New Radiolabelled Monoclonal Antibody Targeting Frizzled Homolog 10 (FZD10) in Patients With Relapsed or Refractory Non Resectable Synovial Sarcomas[NCT01469975] | Phase 1 | 20 participants (Actual) | Interventional | 2011-12-31 | Terminated (stopped due to Too slow accrual.) | ||
Multicentric, Randomized Phase II Trial for the Treatment of Patients With Relapsed Osteosarcoma[NCT02718482] | Phase 2 | 7 participants (Actual) | Interventional | 2016-04-06 | Terminated (stopped due to Not adequate enrollment (sample size not possible to reach)) | ||
MMT 95 Study For Rhabdomyosarcoma and Other Malignant Soft Tissue Tumors of Childhood[NCT00002898] | Phase 3 | 400 participants (Anticipated) | Interventional | 1995-01-31 | Completed | ||
RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA[NCT00002641] | Phase 3 | 350 participants (Anticipated) | Interventional | 1995-02-28 | Completed | ||
A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas[NCT00881595] | Phase 2 | 0 participants (Actual) | Interventional | 2009-02-28 | Withdrawn (stopped due to No patients accrued since study opened) | ||
Prospective Evaluation of the Prognostic Relevance of PCR Positivity in Blood and Bone Marrow in Non-Metastatic Ewings Sarcoma[NCT00339898] | 414 participants (Actual) | Observational | 2004-03-12 | Completed | |||
A PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY AND RADIATION THERAPY IN THE MANAGEMENT OF HIGH-RISK, HIGH-GRADE, SOFT TISSUE SARCOMAS OF THE EXTREMITIES AND BODY WALL[NCT00002791] | Phase 2 | 0 participants | Interventional | 1997-02-28 | Completed | ||
Continuous 5 Days Infusion of High Dose Ifosfamide and Adriamycin in Patients With Advanced Sarcoma[NCT00002526] | Phase 2 | 20 participants (Actual) | Interventional | 1993-01-31 | Completed | ||
Randomized Phase III Trial of Two Investigational Schedules of Ifosfamide vs. Standard Dose Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma[NCT00003212] | Phase 3 | 780 participants (Anticipated) | Interventional | 1998-01-31 | Completed | ||
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft Tissue Sarcoma After Pre-treatment Failure: an Open-label, Multicenter Phase II Study[NCT01136499] | Phase 2 | 53 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
Phase II Prospective Study With BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas, After Anthracycline-based Therapy[NCT00406601] | Phase 2 | 69 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
Comparing the Effectiveness and Toxicity for Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma Patients Who Had Received Total Dose of Anthracycline Antibiotics More Than 300mg/m2 With Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus[NCT03342300] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2017-11-06 | Withdrawn (stopped due to No participants enrolled) | ||
A Phase 2 Study of Cabozantinib (XL184), a Dual Inhibitor of MET and VEGFR, in Patients With Metastatic Refractory Soft Tissue Sarcoma[NCT01755195] | Phase 2 | 55 participants (Actual) | Interventional | 2013-01-15 | Active, not recruiting | ||
Determination of Tumor Response Rate by RECIST and FDG-PET Criteria to Dacarbazine in Metastatic Soft Tissue and Bone Sarcoma[NCT00802880] | Phase 2 | 80 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
A Phase II Study on Preoperative Administration of Gleevec in Patients With Initially Non-Resectable Gastrointestinal Stromal Tumor[NCT00290485] | Phase 2 | 50 participants | Interventional | 2005-08-31 | Recruiting | ||
Breast Sarcomas: A Retrospective Analysis of Clinical Features and Outcomes[NCT04749446] | 300 participants (Anticipated) | Observational | 2021-04-02 | Recruiting | |||
Late Effects of Treatment in Survivors of Pediatric Sarcomas[NCT00006515] | 39 participants (Actual) | Observational | 2000-11-16 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Area Under the Curve at Steady State (AUCss) of Bevacizumab
AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption. AUCss is expressed in milligrams times days per milliliter (mg*day/mL). (NCT00643565)
Timeframe: Pre- and within 3 hours post-dose on Days 1, 8, and 15 of Cycle 1, Day 1 of Cycle 2-4 of induction phase
Intervention | mg*day/mL (Mean) |
---|---|
Bevacizumab + Chemotherapy | 1010 |
Clearance of Bevacizumab
CL is a quantitative measure of the rate at which a drug substance is removed from the body. CL is expressed in milliliters per day (mL/day). (NCT00643565)
Timeframe: Pre- and within 3 hours post-dose on Days 1, 8, and 15 of Cycle 1, Day 1 of Cycle 2-4 of induction phase (1 cycle = 3 weeks)
Intervention | mL/day (Mean) |
---|---|
Bevacizumab + Chemotherapy | 167 |
Duration of Response
Duration of Response was defined as time between first objective response and the occurrence of an EFS event (described in Outcome Measure 1). Objective response was defined in Outcome Measure 3. Median duration of response was estimated using Kaplan-Meier estimates and 95% CI for median was computed using the method of Brookmeyer and Crowley. (NCT00643565)
Timeframe: Screening up to approximately 6.75 years
Intervention | months (Median) |
---|---|
Chemotherapy | NA |
Bevacizumab + Chemotherapy | 17.48 |
EFS Duration as Per IRC Assessment
EFS was defined as the time between randomization and occurrence of EFS event. EFS events are described in Outcome Measure 1. Median EFS was estimated using Kaplan-Meier estimates and 95% confidence intervals (CI) for median was computed using the method of Brookmeyer and Crowley. (NCT00643565)
Timeframe: Screening up to approximately 6.75 years (assessed at screening, Cycles 4, 7 of induction phase, Cycles 1, 4, 7, 10 of maintenance, then every 3 months for 1.5 years and thereafter every 6 months for 2.5 years)
Intervention | months (Median) |
---|---|
Chemotherapy | 14.85 |
Bevacizumab + Chemotherapy | 20.63 |
Half-Life of Bevacizumab
Half-life is the time measured for the plasma concentration to decrease by one half. (NCT00643565)
Timeframe: Pre- and within 3 hours post-dose on Days 1, 8, and 15 of Cycle 1, Day 1 of Cycle 2-4 of induction phase (1 cycle = 3 weeks)
Intervention | days (Mean) |
---|---|
Bevacizumab + Chemotherapy | 20.8 |
Overall Survival Duration
Overall survival was defined as the time between randomization and death due to any cause. Participants without an event were censored at the last time they were known to be alive. Median overall survival was estimated using Kaplan-Meier estimates and 95% CI for median was computed using the method of Brookmeyer and Crowley. (NCT00643565)
Timeframe: Screening up to approximately 10.75 years (assessed at screening, Cycles 4, 7 of induction phase, Cycles 1, 4, 7, 10 of maintenance, then every 3 months for 1.5 years and thereafter every 6 months for 2.5 years)
Intervention | months (Median) |
---|---|
Chemotherapy | 24.02 |
Bevacizumab + Chemotherapy | 32.79 |
Percentage of Participants Who Died
(NCT00643565)
Timeframe: Screening up to approximately 10.75 years (assessed at screening, Cycles 4, 7 of induction phase, Cycles 1, 4, 7, 10 of maintenance, then every 3 months for 1.5 years and thereafter every 6 months for 2.5 years.
Intervention | percentage of participants (Number) |
---|---|
Chemotherapy | 50 |
Bevacizumab + Chemotherapy | 51.4 |
Percentage of Participants Who Experienced EFS Events Among Participants Who Had Objective Response
EFS events was described in Outcome Measure 1 and Outcome Measure 3. (NCT00643565)
Timeframe: Screening up to approximately 6.75 years
Intervention | percentage of participants (Number) |
---|---|
Chemotherapy | 40.7 |
Bevacizumab + Chemotherapy | 76.5 |
Percentage of Participants Who Experienced Event-Free Survival (EFS) Events as Per Independent Review Committee (IRC) Assessment
EFS events included tumor progression (IRC assessed), no evidence of response after 3 cycles of induction (derived from IRC assessment), second primary cancer, or death due to any cause. Data for participants who had not experienced an event by the time of clinical cut-off were censored at the date of the last disease assessment prior to the clinical cut-off date. Data for participants who did not have any post-baseline disease assessments were censored at the time of randomization. Tumor progression was defined using Response Evaluation Criteria in Solid Tumors version 1.0 (RECIST v1.0) as at least a 20% increase in the disease measurement, taking as reference the smallest disease measurement recorded since the start of treatment, or the appearance of one or more new lesions, or evidence of clinical progression and unequivocal progression of existing non-target lesions. (NCT00643565)
Timeframe: Screening up to approximately 6.75 years (assessed at screening, Cycles 4, 7 of induction phase, Cycles 1, 4, 7, 10 of maintenance, then every 3 months for 1.5 years and thereafter every 6 months for 2.5 years)
Intervention | percentage of participants (Number) |
---|---|
Chemotherapy | 52.5 |
Bevacizumab + Chemotherapy | 68.9 |
Percentage of Participants With Objective Response Prior to First Local Therapy Assessed by RECIST v1.0 Criteria
Objective response prior to first local therapy (surgery and/or radiotherapy) was defined as complete response (CR) or partial response (PR) determined on two consecutive occasions >/=4 weeks apart. Tumor response was assessed as per IRC using RECIST v1.0. CR was defined as disappearance of all target and non-target lesions. If immunocytology was available, no disease was to be detected by that methodology. PR was defined as at least a 30% decrease in the disease measurement, taking as reference the disease measurement done to confirm measurable disease at study entry. (NCT00643565)
Timeframe: Screening up to approximately 6.75 years
Intervention | percentage of participants (Number) |
---|---|
Chemotherapy | 36.0 |
Bevacizumab + Chemotherapy | 54.0 |
Volume of Distribution of Bevacizumab
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state. (NCT00643565)
Timeframe: Pre- and within 3 hours post-dose on Days 1, 8, and 15 of Cycle 1, Day 1 of Cycle 2-4 of induction phase (1 cycle = 3 weeks)
Intervention | mL (Mean) |
---|---|
Bevacizumab + Chemotherapy | 2070 |
Complete or Partial Response Rate
Tumor response by imaging. Complete Response (CR): Complete disappearance of the tumor. Partial Response (PR): At least 64% decrease in volume compared to the measurement obtained at study enrollment. Overall Response (OR)=CR+PR. (NCT00346164)
Timeframe: 13 weeks
Intervention | percentage of patients (Number) |
---|---|
Arm D | 33.1 |
Event Free Survival Probability Disease Extent
Probability of no relapse, secondary malignancy or death after 5 years since enrollment. (NCT00346164)
Timeframe: 5 years
Intervention | Probability (Number) |
---|---|
Non-metastatic | 0.7758 |
Metastatic | 0.1960 |
Event Free Survival Probability Histologic Grade
Probability of no relapse, secondary malignancy or death after 5 years since enrollment (NCT00346164)
Timeframe: 5 years
Intervention | Probability (Number) |
---|---|
Histologic Grade 1 | 0.9636 |
Histologic Grade 2 | 0.8505 |
Histologic Grade 3 | 0.6136 |
Incidence of Distant Metastasis
Percent of patients who had distant metastasis. (NCT00346164)
Timeframe: Up to 10 years
Intervention | Percentage of participants (Number) |
---|---|
Non-metastatic | 10.59 |
Metastatic | 60.87 |
Histologic Grade 1 | 0.00 |
Histologic Grade 2 | 5.06 |
Histologic Grade 3 | 23.38 |
Overall Survival Probability Disease Extent
Probability of survival after 5 years since enrollment. (NCT00346164)
Timeframe: 5 years
Intervention | Probability (Number) |
---|---|
Non-metastatic | 0.8752 |
Metastatic | 0.3153 |
Overall Survival Probability Extent of Resection of the Primary Tumor
Probability of survival after 5 years since enrollment. (NCT00346164)
Timeframe: 5 years
Intervention | Probability (Number) |
---|---|
Less Than Total Resection | 0.5975 |
Negative Margins | 0.9353 |
Positive Margins | 0.7764 |
Percent Tumor Necrosis
Percent tumor necrosis by pathology review. (NCT00346164)
Timeframe: 13 weeks
Intervention | percentage of tumor necrosis (Mean) |
---|---|
Arm D | 59.4 |
Probability for Event Free Survival.
Probability of no relapse, secondary malignancy or death after 5 years since enrollment. (NCT00346164)
Timeframe: 5 years
Intervention | Probability of EFS at 5 years (Number) |
---|---|
Arm A: No Adjuvant Treatment | 0.8984 |
Arm B: Low Risk; Adjuvant Radiotherapy | 0.7647 |
Arm C: Intermediate & High Risk; Adjuvant Chemoradiotherapy | 0.6079 |
Arm D: Intermediate & High Risk; Neoadjuvant Chemoradiotherapy | 0.4873 |
Toxicity Rate
Percentage of Arm D patients experiencing grade 4+ adverse events. (NCT00346164)
Timeframe: 13 weeks
Intervention | percentage of participants (Number) |
---|---|
Arm D | 3.06 |
Degree of Agreement in Histologic Grade Between Pediatric Oncology Group (POG) and Fédération Nationale Des Centres de Lutte Contre le Cancer (FNCLCC) Pathologic Grading Systems
POG and FNCLCC grades were determined by pathologists based on published standards. A higher grade is associated with a more severe disease. (NCT00346164)
Timeframe: At diagnosis
Intervention | Participants (Count of Participants) | ||
---|---|---|---|
Histologic grade 1 by POG | Histologic grade 2 by POG | Histologic grade 3 by POG | |
Histologic Grade 1 by FNCLCC | 46 | 24 | 9 |
Histologic Grade 2 by FNCLCC | 8 | 69 | 145 |
Histologic Grade 3 by FNCLCC | 1 | 0 | 240 |
Degree of Agreement in Histologic Grade Determined by the Enrolling Institution Versus by Central Pathology Reviewers
Histologic grades were determined by the central pathology reviewers and institutional pathologists based on published standards. A higher grade is associated with a more severe disease. (NCT00346164)
Timeframe: At Diagnosis
Intervention | Participants (Number) | ||
---|---|---|---|
Histologic grade 1 by central pathology reviewers | Histologic grade 2 by central pathology reviewers | Histologic grade 3 by central pathology reviewers | |
Histologic Grade 1 by Enrolling Institution | 38 | 4 | 3 |
Histologic Grade 2 by Enrolling Institution | 5 | 56 | 10 |
Histologic Grade 3 by Enrolling Institution | 1 | 9 | 268 |
6-month Progression - Free Survival
Percentage of participants survived for 6 months from the start of study treatment without progression of disease. Progression of the disease was associated with increasing symptoms, including pain from new or progressing lesions. Delay in disease progression generally represents a clinical benefit to the participant. (NCT00796120)
Timeframe: 6 months
Intervention | percentage of participants (Number) |
---|---|
Trabectedin | 66.7 |
Doxorubicin Plus Ifosfamide | 78.3 |
Duration of Response (DOR)
The DOR is defined as the time from date of first documentation of response (CR or PR, whichever comes first) to the date of documented PD or death. PR=at least 30% reduction in the sum of the longest dimensions (LD) of all target lesions in reference to the baseline sum LD, CR =Disappearance of all non-target lesions. (NCT00796120)
Timeframe: Up to 20 months
Intervention | days (Median) |
---|---|
Trabectedin | NA |
Doxorubicin Plus Ifosfamide | NA |
Overall Survival
Overall survival defined as time from the date of randomization to the date of death. For participants who were alive at the time of analysis, overall survival was censored at the last contact date. (NCT00796120)
Timeframe: Baseline up to End of Study (an average of 4 years)
Intervention | months (Median) |
---|---|
Trabectedin | 46.6 |
Doxorubicin Plus Ifosfamide | 33.5 |
Percentage of Participants With Objective Response
Tumor response was assessed according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Partial Response (PR)=at least 30% reduction in the sum of the longest dimensions (LD) of all target lesions in reference to the baseline sum LD, Complete Response (CR) =Disappearance of all non-target lesions. Percentage of participants with objective tumor response was determined by the number of participants with PR or CR divided by the total number of response-evaluable participants. (NCT00796120)
Timeframe: Every 6 weeks during first 9 months of the study and thereafter every 9 weeks up to 20 months
Intervention | percentage of participants (Number) |
---|---|
Trabectedin | 5.9 |
Doxorubicin Plus Ifosfamide | 27.0 |
Progression - Free Survival (PFS)
The PFS was assessed as median number of days from the date of randomization until the first documented sign of disease progression (increase in disease; radiographic, clinical, or both) or death due to any cause, whichever occurred earlier. (NCT00796120)
Timeframe: Every 6 weeks from randomization during the first 9 months and thereafter, every 9 weeks up to 20 months
Intervention | months (Median) |
---|---|
Trabectedin | 19.6 |
Doxorubicin Plus Ifosfamide | 8.3 |
Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0)
Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01755195)
Timeframe: Date treatment consent signed to date off study, approximately 86 months and 3 days.
Intervention | Participants (Count of Participants) |
---|---|
Cabozantinib | 53 |
Objective Response (Complete Response (CR)+Partial Response (PR) of Cabozantinib in Patients With Soft Tissue Sarcomas
Objective response was assessed by the Response Evaluation Criteria in Solid Tumors RECIST) v1.1. Complete Response is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. (NCT01755195)
Timeframe: Date treatment consent signed to date off study, approximately 86 months and 3 days.
Intervention | percentage of particpants (Number) |
---|---|
Cabozantinib | 11.1 |
Percentage of Participants With 6 Month Progression Free Survival (PFS)
Progression in participants with soft tissue sarcomas treated with cabozantinib was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Progression is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. The appearance of one or more new lesions is also considered progressions. (NCT01755195)
Timeframe: 6 months
Intervention | percentage of participants (Number) |
---|---|
Cabozantinib | 49.3 |
Mean Change From Baseline in Levels of Circulating Hepatocyte Growth Factor (HGF)
Blood samples were collected before treatment on the first day of cycles 1 and 2 to determine circulating levels of HGF. HGF protein content (in picograms; pg) in blood plasma (in milliliters; mL) was measured for each sample with a two-site immunoassay and the difference from before to after treatment for each patient was reported. A change in this biomarker from the baseline value has not been linked to clinical outcomes; that is, it is neither a good or a bad outcome. (NCT01755195)
Timeframe: Baseline to Cycle 1 Day 1 and baseline to Cycle 2 Day 1
Intervention | pg/mL (Mean) | |
---|---|---|
Baseline to Cycle 1 Day 1 | Baseline to Cycle 2 Day 1 | |
Cabozantinib | -51.3 | 344.8 |
Mean Change From Baseline in Levels of Circulating Soluble Mesenchymal Epithelial Transition Factor (sMET)
Blood samples were collected before treatment on the first day of cycles 1 and 2 to determine circulating levels of soluble MET (sMET). sMET protein content (in nanograms; ng) in blood plasma (in milliliters; mL) was measured for each sample with a two-site immunoassay and the difference from before to after treatment for each patient was reported. A change in this biomarker from the baseline value has not been linked to clinical outcomes; that is, it is neither a good or a bad outcome. (NCT01755195)
Timeframe: Baseline to Cycle 1 Day 1 and baseline to Cycle 2 Day 1
Intervention | ng/mL (Mean) | |
---|---|---|
Baseline to Cycle 1 Day 1 | Baseline to Cycle 2 Day1 | |
Cabozantinib | -6.1 | 16.4 |
Mean Change From Baseline in Levels of Circulating Soluble Vascular Endothelial Growth Factor Receptor 2 (sVEGFR-2)
Blood samples were collected before treatment on the first day of cycles 1 and 2 to determine circulating levels of soluble VEGFR2 (sVEGFR-2). sVEGFR-2 protein content (in nanograms; ng) in blood plasma (in milliliters; mL) was measured for each sample with a two-site immunoassay and the difference from before to after treatment for each patient was reported. A change in this biomarker from the baseline value has not been linked to clinical outcomes; that is, it is neither a good or a bad outcome.. (NCT01755195)
Timeframe: Baseline to Cycle 1 Day 1 and baseline to Cycle 2 Day 1
Intervention | ng/mL (Mean) | |
---|---|---|
Baseline to Cycle 1 Day 1 | Baseline to Cycle 2 Day 1 | |
Cabozantinib | -1.0 | -10.9 |
Mean Change From Baseline in Levels of Circulating Vascular Endothelial Growth Factor A (VEGF-A)
Blood samples were collected before treatment on the first day of cycles 1 and 2 to determine circulating levels of VEGF-A. VEGF-A protein content (in picograms; pg) in blood plasma (in milliliters; mL) was measured for each sample with a two-site immunoassay and the difference from before to after treatment for each patient was reported. A change in this biomarker from the baseline value has not been linked to clinical outcomes; that is, it is neither a good or a bad outcome. (NCT01755195)
Timeframe: Baseline to Cycle 1 Day 1 and baseline to Cycle 2 Day 1
Intervention | pg/mL (Mean) | |
---|---|---|
Baseline to Cycle 1 Day 1 | Baseline to Cycle 2 Day 1 | |
Cabozantinib | 5.6 | 32.5 |
Overall Survival
(NCT00802880)
Timeframe: Until completion of follow-up or patient death (estimated to be 1 year)
Intervention | months (Median) |
---|---|
Dacarbazine | 8.09 |
Rate of Nausea/Emesis (Any Grade)
Approximately 18 weeks (NCT00802880)
Timeframe: Completion of 6 cycles of treatment (18 weeks)
Intervention | percentage of participants (Number) |
---|---|
Dacarbazine | 22.5 |
Rate of Neutropenia (Grade 3/4)
"Grade 3 neutropenia = absolute neutrophil count of <1000 - 500/mm^3~Grade 4 neutropenia = absolute neutrophil count of <500/mm^3" (NCT00802880)
Timeframe: Completion of 6 cycles of treatment (18 weeks)
Intervention | percentage of participants (Number) |
---|---|
Dacarbazine | 7.5 |
Time to Progression (TTP)
-Progression - At least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. (NCT00802880)
Timeframe: Until completion of follow-up (estimated to be 1 year)
Intervention | months (Median) |
---|---|
Dacarbazine | 2.07 |
Best Anatomical Tumor Response
"Complete response (CR): disappearance of all target lesions, disappearance of all non-target lesions, normalization of tumor level marker~Partial response (PR): at least 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD, persistence of one or more non-target lesion and/or maintenance of tumor marker level above the upper limits of normal~Stable disease (SD): neither sufficient shrinkage in target lesions to qualify for PR nor sufficient increase to qualify for progressive disease taking as references the smallest sum LD since the treatment started, persistence of one or more non-target lesion and/or maintenance of tumor marker level above the normal limits of normal~Progressive disease (PD): at least 20% increase in the sum of the LD of target lesions and/or appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions" (NCT00802880)
Timeframe: After completion of 3 cycles
Intervention | participants (Number) | |||
---|---|---|---|---|
Complete response | Partial response | Stable disease | Progressive disease | |
Dacarbazine | 0 | 2 | 22 | 30 |
Comparison of the SUV at up to 3 Tumor Sites
(NCT00802880)
Timeframe: Baseline and after every three cycles of treatment (up to 1 year)
Intervention | standard uptake value (Mean) | ||||
---|---|---|---|---|---|
Baseline | End of cycle 3 | End of cycle 6 | End of cycle 9 | End of cycle 12 | |
Dacarbazine | 7.42 | 7.57 | 7.7 | 6.89 | 7.48 |
Correlate Overall Survival With Best Anatomic Response
(NCT00802880)
Timeframe: Completion of follow-up (estimated to be 1 year)
Intervention | months (Median) | ||
---|---|---|---|
Partial response | Stable disease | Progressive disease | |
Dacarbazine | 18.16 | 14.77 | 7.96 |
Correlate Overall Survival With Best Metabolic Response
(NCT00802880)
Timeframe: Completion of follow-up (estimated to be 1 year)
Intervention | months (Median) | ||
---|---|---|---|
Partial metabolic response | Stable metabolic disease | Progressive metabolic disease | |
Dacarbazine | 18.16 | 18.59 | 8.75 |
Correlate the Time to Progression With Best Anatomic Response
-Progression - At least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. (NCT00802880)
Timeframe: Completion of follow-up (estimated to be 1 year)
Intervention | months (Median) | ||
---|---|---|---|
Partial response | Stable disease | Progressive disease | |
Dacarbazine | NA | 4.14 | 1.97 |
Correlate the Tumor Metabolic Response Rate With the Tumor Anatomic Response Rate
(NCT00802880)
Timeframe: After completion of 3 cycles
Intervention | participants (Number) | |||
---|---|---|---|---|
PR | SD | PD | Total | |
Partial Metabolic Response | 1 | 2 | 1 | 4 |
Progressive Metabolic Disease | 1 | 8 | 24 | 33 |
Stable Metabolic Disease | 0 | 10 | 2 | 12 |
Total | 2 | 20 | 27 | 49 |
Correlate Time to Progression With Best Metabolic Response
-Progression - At least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. (NCT00802880)
Timeframe: Completion of follow-up (estimated to be 1 year)
Intervention | months (Median) | ||
---|---|---|---|
Partial metabolic response | Stable metabolic disease | Progressive metabolic disease | |
Dacarbazine | 3.95 | 5.30 | 2.07 |
Overall Disease Control Rate
(NCT00802880)
Timeframe: 12 months
Intervention | participants (Number) | |||
---|---|---|---|---|
Complete response | Partial response | Stable disease | Progressive disease | |
Dacarbazine | 0 | 0 | 5 | 1 |
Overall Tumor Metabolic Response
"Complete metabolic response (CMR)-complete resolution of all metabolically active target and non-target lesions, and no interval development of new lesions.~Partial metabolic response (PMR)~Target lesions: 20% or greater decrease in maximum SUV from baseline. No unequivocal metabolic progression of non-target disease, and no unequivocal new lesions.~Non-target lesions: decrease in total number of non-target lesions, without complete resolution of metabolically active disease, or unequivocal decrease in degree of FDG activity within >50% of the lesions. No unequivocal new lesions.~Stable metabolic disease (SMD): does not qualify for CMR, PMR, or PMD.~Progressive metabolic disease (PMD):~Unequivocal development of one more new metabolically active lesions~Target lesion: 20% or greater increase in maximum SUV from baseline.~Non-target lesions: unequivocal increase in FDG activity" (NCT00802880)
Timeframe: After completion of 3 cycles
Intervention | participants (Number) | |||
---|---|---|---|---|
CMR | PMR | SMD | PMD | |
Dacarbazine | 0 | 4 | 13 | 34 |
Reviews
73 reviews available for ifosfamide and Sarcoma, Epithelioid
Article | Year |
---|---|
Established and Experimental Systemic Treatment Options for Advanced Liposarcoma.
Topics: Doxorubicin; Humans; Ifosfamide; Liposarcoma; Sarcoma; Trabectedin | 2022 |
Hyperthermia in the treatment of high-risk soft tissue sarcomas: a systematic review.
Topics: Combined Modality Therapy; Humans; Hyperthermia, Induced; Ifosfamide; Sarcoma; Soft Tissue Neoplasms | 2023 |
Effect of anthracyclines/ifosfamide-based adjuvant chemotherapy for soft tissue sarcoma: a conventional and network Meta-analysis.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem | 2021 |
What is the standard indication of adjuvant or neoadjuvant chemotherapy in localized soft-tissue sarcoma?
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Tri | 2021 |
Selection of Patients With Localized Extremity Soft Tissue Sarcoma for Treatment With Perioperative Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; D | 2018 |
[Multimodal treatment of sarcomas: standards and new aspects in pharmacological and radio-oncological treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; H | 2019 |
Soft tissue sarcoma: an update on systemic treatment options for patients with advanced disease.
Topics: Antineoplastic Agents; Dioxoles; Doxorubicin; Evidence-Based Medicine; Humans; Ifosfamide; Indazoles | 2014 |
Evaluation of the stability profile of anticancer drugs: A review of Ifosfamide and Mesna regimen for the treatment of metastatic soft tissue sarcoma.
Topics: Antineoplastic Agents; Drug Stability; Humans; Ifosfamide; Mesna; Sarcoma | 2016 |
Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Cyclophosphamide; Humans; Ifosfamid | 2015 |
First-line treatment in advanced or metastatic disease: one size fits all or adapted to specific histiotypes?
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, | 2016 |
Trabectedin for the treatment of soft tissue sarcomas.
Topics: Animals; Anthracyclines; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Clinical Trials a | 2016 |
Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study).
Topics: Alkylating Agents; Antineoplastic Agents; Cyclophosphamide; Female; Humans; Ifosfamide; Male; Random | 2017 |
[Pleural epithelioid sarcoma: about a case and review of the literature].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fatal Outcome; Female; Humans; I | 2016 |
Chemotherapeutic management of soft tissue sarcoma.
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Chemotherap | 2008 |
Multidisciplinary management of metastatic sarcoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality | 2008 |
Encephalopathy after high-dose Ifosfamide: a retrospective cohort study and review of the literature.
Topics: Adult; Albumins; Antineoplastic Agents, Alkylating; Bilirubin; Brain Diseases; Cohort Studies; Enzym | 2008 |
Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Tr
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Epid | 2010 |
Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Tr
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Epid | 2010 |
Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Tr
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Epid | 2010 |
Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Tr
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Epid | 2010 |
Palifosfamide, a bifunctional alkylator for the treatment of sarcomas.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Clinical Trials as Topic; Drug Evaluation, Preclinic | 2010 |
Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients.
Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Cyclophosphamide; Humans; Ifosfamide; Sarc | 2010 |
[Chemotherapy options for patients with advanced soft-tissue sarcoma beyond anthracyclines].
Topics: Antineoplastic Agents; Dacarbazine; Deoxycytidine; Dioxoles; Docetaxel; Doxorubicin; Gemcitabine; Hu | 2010 |
Spontaneous pneumothorax during chemotherapy: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drainage; Humans; Ifosfamide; Mal | 2010 |
Metastatic soft tissue sarcoma chemotherapy: an opportunity for personalized medicine.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Doxorubici | 2011 |
Cervical sarcoma botryoides and ovarian Sertoli-Leydig cell tumor: a case report and review of literature.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Humans; I | 2012 |
Systemic management strategies for metastatic soft tissue sarcoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dioxoles; Doxo | 2011 |
Malignant primary cardiac tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cardiac Surgical Procedures; | 2012 |
Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Cyclophosphamide; Humans; Ifosfamid | 2012 |
Ifosfamide in the treatment of malignant epithelial ovarian tumors.
Topics: Antineoplastic Agents, Alkylating; Carcinoma; Female; Humans; Ifosfamide; Ovarian Neoplasms; Sarcoma | 2003 |
Ifosfamide with regional hyperthermia in soft-tissue sarcomas.
Topics: Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Humans; Hyperthermia, Induced; Ifosfamide | 2003 |
Ifosfamide in the adjuvant therapy of soft tissue sarcomas.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2003 |
[Soft tissue sarcoma: postoperative chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Cyclophos | 2004 |
[Current strategy of chemotherapy for reflactory bone and soft tissue sarcomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Carboplatin; Cisplatin; | 2004 |
Emerging treatments for soft tissue sarcoma of adults.
Topics: Adult; Antineoplastic Agents; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Ther | 2004 |
On the apparent failure of adjuvant pelvic radiotherapy to improve survival for women with uterine sarcomas confined to the uterus.
Topics: Abdominal Neoplasms; Antineoplastic Agents; Brachytherapy; Chemotherapy, Adjuvant; Combined Modality | 2005 |
Advances in chemotherapy for patients with extremity soft tissue sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Dose-Response Rela | 2006 |
Emerging drugs for the treatment of soft tissue sarcomas.
Topics: Antineoplastic Agents; Benzamides; Dacarbazine; Doxorubicin; Gastrointestinal Stromal Tumors; Humans | 2007 |
The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas.
Topics: Adult; Antineoplastic Agents; Clinical Trials as Topic; Disease Progression; Doxorubicin; Drug Thera | 2007 |
Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Humans; Ifosfam | 2008 |
Ifosfamide: European perspective.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Administrat | 1982 |
Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clini | 1995 |
Preoperative therapy for soft tissue sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials a | 1995 |
New drugs for the treatment of sarcomas.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Chemotherapy, A | 1995 |
The use of ifosfamide, carboplatin, and etoposide in children with solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Etoposide; Humans; Ifosfamide; L | 1995 |
[Chemotherapy for soft tissue sarcoma--current concepts and review].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Doxorubicin; Humans; Ifosfam | 1993 |
Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience.
Topics: Acetylcysteine; Bone Neoplasms; Fluid Therapy; Humans; Ifosfamide; Mesna; Randomized Controlled Tria | 1993 |
Perspectives on anthracyclines plus ifosfamide in advanced soft tissue sarcomas.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase | 1993 |
Ifosfamide in the treatment of soft tissue sarcomas.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, | 1996 |
High-dose ifosfamide in the treatment of sarcomas of soft tissues and bone.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; C | 1996 |
Ongoing clinical studies of ifosfamide for pediatric cancer in the United States.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Proto | 1996 |
[Locally developed sarcoma of the thoracic wall].
Topics: Antineoplastic Combined Chemotherapy Protocols; Back; Chemotherapy, Adjuvant; Combined Modality Ther | 1996 |
Infusional chemotherapy combined with recombinant human granulocyte colony stimulating factor: advantages and limitations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials as Topic; Doxorubicin; Dr | 1997 |
Problems and controversies in the management of childhood sarcomas.
Topics: Amputation, Surgical; Antineoplastic Agents; Child; Child, Preschool; Doxorubicin; Humans; Ifosfamid | 1996 |
[Adjuvant chemotherapy of soft tissue sarcoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Doxorubicin; Fo | 1997 |
Chemotherapy in soft tissue sarcoma. The Scandinavian Sarcoma Group experience.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; | 1999 |
The treatment of distant metastases in soft tissue sarcoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality | 1999 |
Sustained response of sarcomatoid renal-cell carcinoma to MAID chemotherapy: case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Dacarbazine; Doxorubicin; Hum | 2001 |
[High-dose chemotherapy in soft tissue sarcomas of adults].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase I as | 2001 |
Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Child, Preschool; Combined Mo | 2001 |
Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Clin | 2001 |
Current trials and new aspects in soft tissue sarcoma of adults.
Topics: Adult; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Combined Modality Therapy; Europe; | 2002 |
Primary soft tissue sarcoma of the breast.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Doxorub | 2001 |
Experience with ifosfamide in the EORTC Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Europe; Humans; Ifosfamide; Sarcoma; | 1992 |
The clinical management of soft tissue sarcomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Doxorubicin; Humans; Ifosfam | 1992 |
Chemotherapy of advanced sarcomas of bone and soft tissue.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topic; Dacarbazin | 1992 |
Gynecologic Oncology Group studies with ifosfamide.
Topics: Adenocarcinoma; Carcinoma; Clinical Trials, Phase II as Topic; Endometrial Neoplasms; Female; Genita | 1992 |
Doxorubicin (or epidoxorubicin) combined with ifosfamide in the treatment of adult advanced soft tissue sarcomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Epirubicin; Humans; Ifosfamide; Sarcoma | 1992 |
Megatherapy for soft tissue sarcomas. EBMT experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyclophosphamide; Dacti | 1991 |
Ifosfamide in paediatric oncology: tried but not tested?
Topics: Child; Cyclophosphamide; Evaluation Studies as Topic; Humans; Ifosfamide; Neoplasms; Prognosis; Sarc | 1990 |
The role of ifosfamide in the treatment of adult soft tissue sarcomas, Ewing's sarcoma, and osteosarcoma: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Ifosfamide; Osteosarcoma; Sarcoma; Sarcoma, | 1990 |
The role of ifosfamide in the treatment of sarcomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Humans; Ifosfamide; Osteosarcoma; Sarcoma; Sa | 1989 |
Chemotherapy of advanced soft-tissue sarcomas.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Dru | 1988 |
Ifosfamide.
Topics: Breast Neoplasms; Drug Evaluation, Preclinical; Female; Humans; Ifosfamide; Lung Neoplasms; Lymphoma | 1988 |
The treatment of soft tissue sarcomas with focus on chemotherapy: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; | 1986 |
Ifosfamide--pharmacology, safety and therapeutic potential.
Topics: Animals; Biotransformation; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Evalu | 1985 |
Trials
187 trials available for ifosfamide and Sarcoma, Epithelioid
Article | Year |
---|---|
Pemetrexed plus cisplatin in patients with previously treated advanced sarcoma: a multicenter, single-arm, phase II trial.
Topics: Cisplatin; Humans; Ifosfamide; Pemetrexed; Sarcoma; Soft Tissue Neoplasms | 2021 |
Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Humans; Ifosfamide; N | 2022 |
Metastatic Rhabdomyosarcoma: Results of the European
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Dactinomycin; Disease-Free | 2022 |
Metastatic Rhabdomyosarcoma: Results of the European
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Dactinomycin; Disease-Free | 2022 |
Metastatic Rhabdomyosarcoma: Results of the European
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Dactinomycin; Disease-Free | 2022 |
Metastatic Rhabdomyosarcoma: Results of the European
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Dactinomycin; Disease-Free | 2022 |
Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Doxorubicin; Febrile Neutr | 2022 |
Pegylated Liposomal Doxorubicin Combined with Ifosfamide for Treating Advanced or Metastatic Soft-tissue Sarcoma: A Prospective, Single-arm Phase II Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Humans; Ifosfamide; Neoplasms, Second P | 2022 |
Value of peri-operative chemotherapy in patients with CINSARC high-risk localized grade 1 or 2 soft tissue sarcoma: study protocol of the target selection phase III CHIC-STS trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Doxorubicin; Hum | 2020 |
Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Deox | 2021 |
Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-
Topics: Adult; Aged; Female; Humans; Ifosfamide; Indoles; Male; Medical Futility; Middle Aged; Neoplasm Stag | 2021 |
Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Doxorubicin; Female; Follow-U | 2017 |
Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2018 |
Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Fema | 2018 |
Neoadjuvant Interdigitated Chemoradiotherapy Using Mesna, Doxorubicin, and Ifosfamide for Large, High-grade, Soft Tissue Sarcomas of the Extremity: Improved Efficacy and Reduced Toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arm; Chemoradiotherapy; Doxorubicin; Fe | 2019 |
Long-term renal function and hypertension in adult survivors of childhood sarcoma: Single center experience.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Body Mass Index; Child; Child, Preschool; Cros | 2018 |
The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dox | 2019 |
Clinical features and outcomes of young patients with epithelioid sarcoma: an analysis from the Children's Oncology Group and the European paediatric soft tissue Sarcoma Study Group prospective clinical trials.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined | 2019 |
Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Dose- | 2013 |
Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Line, Tumor; Cell Prol | 2014 |
Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Bone Neoplasms; E | 2013 |
Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Bone Neoplasms; E | 2013 |
Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Bone Neoplasms; E | 2013 |
Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Bone Neoplasms; E | 2013 |
Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: a phase I-II study from the Italian Sarcoma Group.
Topics: Aged; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Feasibility Studies; Humans; Ifosfamid | 2014 |
Chemotherapy, Irradiation, and Surgery for Function-preserving Curative Therapy of Primary Extremity Soft Tissue Sarcomas: Initial Treatment With I-MAP and Inhalation GM-CSF During Preoperative Irradiation and Postoperatively.
Topics: Administration, Inhalation; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2016 |
Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Drug Adm | 2014 |
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free | 2014 |
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free | 2014 |
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free | 2014 |
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free | 2014 |
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free | 2014 |
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free | 2014 |
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free | 2014 |
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free | 2014 |
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free | 2014 |
Excellent local control with IOERT and postoperative EBRT in high grade extremity sarcoma: results from a subgroup analysis of a prospective trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemothe | 2014 |
A randomized phase II/III trial of perioperative chemotherapy with adriamycin plus ifosfamide versus gemcitabine plus docetaxel for high-grade soft tissue sarcoma: Japan Clinical Oncology Group Study JCOG1306.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; D | 2014 |
Non-pegylated liposomal doxorubicin plus ifosfamide in metastatic soft tissue sarcoma: results from a phase-II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Doxorubicin; Dru | 2015 |
Perioperative chemotherapy with ifosfamide and doxorubicin for high-grade soft tissue sarcomas in the extremities (JCOG0304).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Doxorubicin; Dr | 2015 |
Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Cisplatin; Disease-Free Survival; Double-Blind Metho | 2015 |
A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; | 2015 |
Feasibility of Preoperative Chemotherapy With or Without Radiation Therapy in Localized Soft Tissue Sarcomas of Limbs and Superficial Trunk in the Italian Sarcoma Group/Grupo Español de Investigación en Sarcomas Randomized Clinical Trial: Three Versus Fiv
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2015 |
Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship | 2009 |
Preoperative and postoperative chemotherapy with ifosfamide and adriamycin for adult high-grade soft-tissue sarcomas in the extremities: Japan Clinical Oncology Group Study JCOG0304.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Doxorubicin; Extremiti | 2009 |
Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined | 2009 |
Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dise | 2009 |
Phase I study of non-pegylated liposomal doxorubicin in combination with ifosfamide in adult patients with metastatic soft tissue sarcomas.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; H | 2010 |
Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Administration S | 2010 |
Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combined Modality | 2009 |
Comparison of radiological and pathohistological response to neoadjuvant chemotherapy combined with regional hyperthermia (RHT) and study of response dependence on the applied thermal parameters in patients with soft tissue sarcomas (STS).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Com | 2009 |
Comparison of radiological and pathohistological response to neoadjuvant chemotherapy combined with regional hyperthermia (RHT) and study of response dependence on the applied thermal parameters in patients with soft tissue sarcomas (STS).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Com | 2009 |
Comparison of radiological and pathohistological response to neoadjuvant chemotherapy combined with regional hyperthermia (RHT) and study of response dependence on the applied thermal parameters in patients with soft tissue sarcomas (STS).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Com | 2009 |
Comparison of radiological and pathohistological response to neoadjuvant chemotherapy combined with regional hyperthermia (RHT) and study of response dependence on the applied thermal parameters in patients with soft tissue sarcomas (STS).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Com | 2009 |
Consolidation with high-dose chemotherapy and stem cell support for responding patients with metastatic soft tissue sarcomas: prospective, single-institutional phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Doxorubicin; Hemat | 2010 |
Prediction of chemotherapy outcome in patients with metastatic soft tissue sarcomas based on dynamic FDG PET (dPET) and a multiparameter analysis.
Topics: Discriminant Analysis; Doxorubicin; Drug Therapy, Combination; Fluorodeoxyglucose F18; Follow-Up Stu | 2010 |
Impact of dynamic 18F-FDG PET on the early prediction of therapy outcome in patients with high-risk soft-tissue sarcomas after neoadjuvant chemotherapy: a feasibility study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Discriminant Analysis; Doxorubicin; Etoposide; Feasi | 2010 |
Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2010 |
Intensified adjuvant IFADIC chemotherapy in combination with radiotherapy versus radiotherapy alone for soft tissue sarcoma: long-term follow-up of a prospective randomized feasibility trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Doxorubi | 2010 |
Optimizing clinical care in patients with advanced soft tissue sarcoma: a phase II study of a new schedule of high-dose continuous infusion ifosfamide and doxorubicin combination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu | 2011 |
High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modal | 2012 |
Doxorubicin and ifosfamide for high-grade sarcoma during pregnancy.
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Sc | 2012 |
Adjuvant therapy for resectable high-risk soft tissue sarcoma: feasibility and efficacy of a sandwich chemoradiotherapy strategy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Chemoradiotherapy, Adjuvant; D | 2012 |
A phase II study evaluating neo-/adjuvant EIA chemotherapy, surgical resection and radiotherapy in high-risk soft tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modali | 2011 |
Long-term follow-up of patients treated with neoadjuvant chemotherapy and radiotherapy for large, extremity soft tissue sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuva | 2012 |
Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplas | 2012 |
Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatr
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Dactinomycin; | 2012 |
Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dox | 2012 |
Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: a 10-year single institution retrospective study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemothe | 2013 |
A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group.
Topics: Adult; Aged; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Do | 2013 |
Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Doxorubicin; Et | 2002 |
Adjuvant epirubicin with or without Ifosfamide for adult soft-tissue sarcoma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2002 |
Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Disease Progression; Dose-Response Relationship, Dru | 2002 |
[Preliminary result of advanced soft tissue sarcoma treated by MAID regimen].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Fem | 2002 |
Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cyclophosp | 2003 |
A Systemic Hyperthermia Oncologic Working Group trial. Ifosfamide, carboplatin, and etoposide combined with 41.8 degrees C whole-body hyperthermia for metastatic soft tissue sarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Th | 2003 |
Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Dox | 2003 |
Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cohort Studies | 2003 |
Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Cross-Over Studies; Female; Hu | 2003 |
Late effects surveillance system for sarcoma patients.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Cisplatin; Doxorubicin; Feasibili | 2004 |
Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 2004 |
Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Th | 2004 |
Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Presch | 2005 |
Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemothe | 2004 |
Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma.
Topics: Adolescent; Adult; Aged; Anemia; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Ant | 2005 |
High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Disease-Free Survival; | 2004 |
The IVADo regimen--a pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma: a pilot study of behalf of the European pediatric Soft tissue sarcoma Study Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dactinom | 2005 |
Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Doxoru | 2005 |
Alternating sequential chemotherapy with high-dose ifosfamide and doxorubicin/cyclophosphamide for adult non-small round cell soft tissue sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; | 2005 |
Ifosfamide/liposomal daunorubicin is a well tolerated and active first-line chemotherapy regimen in advanced soft tissue sarcoma: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Disease Progression; Drug | 2005 |
Soft tissue sarcoma or malignant mesenchymal tumors in the first year of life: experience of the International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Committee.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphami | 2005 |
Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514.
Topics: Adult; Aged; Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2006 |
Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514.
Topics: Adult; Aged; Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2006 |
Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514.
Topics: Adult; Aged; Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2006 |
Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514.
Topics: Adult; Aged; Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2006 |
Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Doxorubicin; Femal | 2006 |
Phase I trial and pharmacokinetic analysis of ifosfamide in cats with sarcomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Area Under Curve; Cat Diseases; Cats; Dose-Response Rela | 2006 |
Results of a phase II clinical trial on the use of ifosfamide for treatment of cats with vaccine-associated sarcomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Cat Diseases; Cats; Drug Administration Schedule; Female | 2006 |
Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Combined M | 2006 |
Concurrent radiochemotherapy of locally recurrent or advanced sarcomas of the uterus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dose-Respons | 2006 |
Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas.
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; | 2007 |
Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS).
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Doce | 2006 |
Full-dose ifosfamide can be safely administered to outpatients.
Topics: Adolescent; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool | 2008 |
Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, | 2006 |
Noninvasive magnetic resonance thermography of soft tissue sarcomas during regional hyperthermia: correlation with response and direct thermometry.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Temperature; Chemotherapy, Adjuvant; Combined M | 2006 |
Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, | 2006 |
Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Etopo | 2006 |
Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma.
Topics: Antineoplastic Agents, Alkylating; Area Under Curve; Breath Tests; Cytochrome P-450 CYP3A; Cytochrom | 2007 |
Experience of the use of trabectedin (ET-743, Yondelis) in 21 patients with pre-treated advanced sarcoma from a single centre.
Topics: Adolescent; Adult; Anthracyclines; Antineoplastic Agents, Alkylating; Dioxoles; Disease Progression; | 2007 |
Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dose-Respon | 2007 |
Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cyclophosphami | 2008 |
Early prediction of therapy outcome in patients with high-risk soft tissue sarcoma using positron emission tomography.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposide; Female; Fluorodeoxygl | 2008 |
Histologic response of dose-intense chemotherapy with preoperative hypofractionated radiotherapy for patients with high-risk soft tissue sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dose Fractio | 2008 |
Ifosfamide: European perspective.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Administrat | 1982 |
[Preliminary evaluation of the effectiveness of holoxan in the treatment of malignant soft tissue and bone neoplasms].
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Neoplasms; Child; Child, Preschool; Clinical Trials a | 1981 |
[Chemotherapy in advanced sarcomas (author's transl)].
Topics: Cisplatin; Doxorubicin; Drug Therapy, Combination; Humans; Ifosfamide; Lung Neoplasms; Sarcoma; Vinc | 1981 |
High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Dacarbazine; Doxorubici | 1995 |
Feasibility and compliance of epirubicin plus ambulatory continuous infusion ifosfamide at escalating doses in advanced soft tissue sarcomas: a phase I study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Feasibility Studies; Humans; Ifosfamide; | 1995 |
Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and response.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cyclophosphamide; Dact | 1995 |
Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Double-Blind Met | 1995 |
Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Digesti | 1995 |
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio | 1995 |
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio | 1995 |
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio | 1995 |
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio | 1995 |
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio | 1995 |
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio | 1995 |
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio | 1995 |
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio | 1995 |
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio | 1995 |
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio | 1995 |
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio | 1995 |
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio | 1995 |
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio | 1995 |
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio | 1995 |
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio | 1995 |
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio | 1995 |
Phase I study of escalating doses of paclitaxel (Taxol) with fixed doses of ifosfamide, carboplatin, and etoposide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinom | 1995 |
Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 1995 |
Ifosfamide and etoposide in the treatment of advanced soft tissue sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Gastrointestinal Neo | 1994 |
Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor.
Topics: Acute Kidney Injury; Adolescent; Adult; Chemotherapy, Adjuvant; Child; Child, Preschool; Creatinine; | 1994 |
[Value of neoadjuvant radiochemotherapy in undifferentiated soft tissue sarcomas].
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemothe | 1994 |
Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas.
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; | 1993 |
Epirubicin and ifosfamide in advanced soft tissue sarcomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Feasibility Stu | 1993 |
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases | 1993 |
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases | 1993 |
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases | 1993 |
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases | 1993 |
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases | 1993 |
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases | 1993 |
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases | 1993 |
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases | 1993 |
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases | 1993 |
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neo | 1993 |
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neo | 1993 |
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neo | 1993 |
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neo | 1993 |
Phase II evaluation of doxorubicin, ifosfamide, and dacarbazine plus amphotericin B in the treatment of metastatic soft tissue sarcomas. A pilot study.
Topics: Adolescent; Adult; Amphotericin B; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxo | 1993 |
Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group.
Topics: Adolescent; Adult; Aged; Chi-Square Distribution; Cyclophosphamide; Female; Humans; Ifosfamide; Leuk | 1993 |
Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administr | 1993 |
Preoperative doxorubicin plus ifosfamide in primary soft-tissue sarcomas of the extremities.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arm; Ch | 1993 |
Phase II trial of ifosfamide and cisplatin in the treatment of metastatic sarcomas: a Southwest Oncology Group study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cispl | 1993 |
Efficacy of ifosfamide in combination with doxorubicin for the treatment of metastatic soft-tissue sarcoma. The Eastern Cooperative Oncology Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Administration S | 1993 |
Epirubicin and ifosfamide in advanced soft tissue sarcoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Epirubici | 1993 |
Chemotherapy administration and data collection in an EORTC collaborative group--can we trust the results?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Data Collection; Doxorubicin; Granulocyte-Mac | 1993 |
Accelerated epirubicin-ifosfamide-dacarbazine regimen in patients with adult soft tissue sarcomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response | 1996 |
High-dose ifosfamide in the treatment of advanced soft tissue sarcomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dose-Response Relationship, Drug; Female; Humans; If | 1996 |
Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics.
Topics: Acute Disease; Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Chronic Disea | 1996 |
GM-CSF did not allow doxorubicin dose escalation in the MAID regimen: a phase I trial. A Southwest Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Dacarbazine; Doxorubicin; Granulocyte-M | 1996 |
Phenobarbital administration does not affect high-dose ifosfamide pharmacokinetics in humans.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Area Under Curve; Chromatography, High Pressur | 1996 |
Ifosfamide, carboplatin and etoposide (ICE) combined with 41.8 degrees C whole body hyperthermia in patients with refractory sarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Th | 1996 |
[High-dose ifosfamide in the treatment of patients with soft tissue sarcoma].
Topics: Adult; Antineoplastic Agents, Alkylating; Drug Administration Schedule; Female; Humans; Ifosfamide; | 1996 |
Optimization of chemotherapy administration for clinical 41.8 degrees C whole body hyperthermia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Temperature; Breast Neoplasms; Carboplatin; Car | 1997 |
[High dose ifosfamide at 15 g/m2/cycle: a feasibility study in 10 patients].
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Clonazepam; Dose-Response Relations | 1997 |
High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Dose-Response Relationsh | 1997 |
Can molgramostim enhance the antitumor effects of cytotoxic drugs in patients with advanced sarcomas?
Topics: Adult; Antineoplastic Agents; Cisplatin; Doxorubicin; Drug Synergism; Granulocyte-Macrophage Colony- | 1997 |
A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; Granu | 1997 |
Ifosfamide and continuous infusion etoposide in advanced adult soft tissue sarcoma. A Scandinavian Sarcoma Group Phase II Study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Th | 1997 |
Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Drug Administration Schedule; Female; Granulocyte Co | 1997 |
A pilot study of vincristine, ifosfamide, and doxorubicin in the treatment of pediatric non-rhabdomyosarcoma soft tissue sarcomas.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Child; Child, Pr | 1998 |
Increased systemic toxicity of sarcoma chemotherapy due to combination with the P-glycoprotein inhibitor cyclosporin.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Membe | 1998 |
The pharmacokinetics and metabolism of ifosfamide during bolus and infusional administration: a randomized cross-over study.
Topics: Adult; Aged; Antineoplastic Agents; Biotransformation; Cross-Over Studies; Cyclophosphamide; Dexamet | 1998 |
Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Filgras | 1998 |
High-dose-intensity combination chemotherapy for advanced sarcomas: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Dacarbazine; Doxorubicin; | 1998 |
Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Doxo | 1998 |
Treatment of advanced refractory sarcomas with ifosfamide and etoposide combination chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Ifosfamide; | 1998 |
Activity of doxorubicin after high-dose ifosfamide in adult patients with advanced soft tissue sarcoma: a study of the Spanish Group for Research on Sarcomas (GEIS).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Ifosfamide | 1998 |
Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS)
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Female; Granulocyte-Macrophage Colony-Stimulating Fa | 1998 |
Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dose-Respon | 1998 |
High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible?
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Feasib | 1998 |
Dose-intensive first-line chemotherapy with epirubicin and continuous infusion ifosfamide in adult patients with advanced soft tissue sarcomas: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Epirubici | 1999 |
Phase I-II trial of intensification of the MAID regimen with support of lenograstim (rHuG-CSF) in patients with advanced soft-tissue sarcoma (STS).
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Do | 1999 |
Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK).
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Dose-Response Relationship, Drug; | 1999 |
Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modali | 1999 |
Very intensive, short-term chemotherapy for children and adolescents with metastatic sarcomas.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Child; Child, Preschool; Cyc | 2000 |
Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Female; Follow-Up Studies; Humans | 2000 |
Prospective randomized comparison of morning versus night daily single subcutaneous administration of granulocyte-macrophage-colony stimulating factor in patients with soft tissue or bone sarcoma.
Topics: Adult; Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Bone Neoplasms; Chi-Square Distribu | 2000 |
Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM.
Topics: Adult; Aged; Algorithms; Antineoplastic Agents, Alkylating; Area Under Curve; Computer Simulation; F | 2000 |
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the Europe
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu | 2000 |
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the Europe
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu | 2000 |
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the Europe
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu | 2000 |
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the Europe
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu | 2000 |
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the Europe
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu | 2000 |
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the Europe
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu | 2000 |
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the Europe
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu | 2000 |
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the Europe
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu | 2000 |
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the Europe
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu | 2000 |
The efficacy of a combination of etoposide, ifosfamide, and cisplatin in the treatment of patients with soft tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule | 2000 |
Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Doxorubicin; Drug Therapy, Combination; | 2000 |
Radiologist review versus group peer review of claimed responses in a phase II study on high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the EORTC Soft Tissue and Bone Sarcoma Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Humans; Ifosfamide; Middle Aged; Peer Re | 2000 |
High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combin | 2000 |
Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy, C | 2000 |
A phase I trial of AUC-directed carboplatin with infusional doxorubicin and ifosfamide plus G-CSF in patients with advanced gynecologic malignancies.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; | 2000 |
Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dis | 2001 |
A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule.
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemot | 2001 |
A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Com | 2001 |
Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults: long-term results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cohort Studies; | 2001 |
Treatment of primary, recurrent or inadequately resected high-risk soft-tissue sarcomas (STS) of adults: results of a phase II pilot study (RHT-95) of neoadjuvant chemotherapy combined with regional hyperthermia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cohort Studies; | 2001 |
Ifosfamide and epirubicin combination in untreated sarcomas: two treatment schedules.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, | 2001 |
Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Child; Child, Preschool; Disease Pro | 2001 |
Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide and metabolites after a 72-h continuous infusion in patients with soft tissue sarcoma.
Topics: Adult; Aged; Algorithms; Antineoplastic Agents, Alkylating; Cyclophosphamide; Female; Humans; Ifosfa | 2001 |
Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 2002 |
Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Dose-Response Rela | 2002 |
Current trials and new aspects in soft tissue sarcoma of adults.
Topics: Adult; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Combined Modality Therapy; Europe; | 2002 |
[Clinical experience with the cytostatic drug ifosfamide].
Topics: Adolescent; Adult; Aged; Bleomycin; Carcinoma; Clinical Trials as Topic; Cyclophosphamide; Drug Ther | 1977 |
Experience with ifosfamide in the EORTC Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Europe; Humans; Ifosfamide; Sarcoma; | 1992 |
Ifosfamide, vincristine, doxorubicin and dacarbazine in adult patients with advanced soft-tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Drug Administ | 1992 |
Doxorubicin (or epidoxorubicin) combined with ifosfamide in the treatment of adult advanced soft tissue sarcomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Epirubicin; Humans; Ifosfamide; Sarcoma | 1992 |
Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evaluation; Female; G | 1991 |
A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Com | 1991 |
Dana-Farber Cancer Institute studies in advanced sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation | 1990 |
Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Child; Chil | 1990 |
Ifosfamide in soft tissue sarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Dactinomycin; Doxorubicin; Etoposide; | 1990 |
Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Clinical Trials as Topic; Female; Hematuria; Human | 1989 |
Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bra | 1989 |
Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Hematopoiesis; Humans; Ifosfamide; Mult | 1989 |
Doxorubicin, ifosfamide, and dacarbazine (AID) with mesna uroprotection for advanced untreated sarcoma: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Doxorubic | 1986 |
Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas.
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Drug Evaluation; Female; Humans; Ifosfamide; Infections; | 1986 |
The treatment of soft tissue sarcomas with focus on chemotherapy: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; | 1986 |
Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas.
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Drug Evaluation; Female; Humans; Ifosfamide; Male; Middle | 1987 |
Ifosfamide--pharmacology, safety and therapeutic potential.
Topics: Animals; Biotransformation; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Evalu | 1985 |
Other Studies
242 other studies available for ifosfamide and Sarcoma, Epithelioid
Article | Year |
---|---|
There is more to soft tissue sarcomas than just grade and size.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Ifosfamide; Sarcoma; Soft Tissue Neoplasms | 2022 |
The role of Ifosfamide-doxorubicin chemotherapy in histology-specific, high grade, locally advanced soft tissue sarcoma, a 14-year experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Humans; Ifosfamide; Retrospectiv | 2021 |
Doxorubicin Combined With Ifosfamide for Sarcoma Induces Muscle Atrophy and Sleep Disruption.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Doxorubicin | 2021 |
Standardization of evaluation method and prognostic significance of histological response to preoperative chemotherapy in high-grade non-round cell soft tissue sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Doxorubicin; Dr | 2022 |
Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Doxorubicin; Humans; Ifosf | 2022 |
The role of perioperative chemotherapy in primary high-grade extremity soft tissue sarcoma: a risk-stratified analysis using PERSARC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Extremities; Humans; Ifosfamide; Retrospective Studi | 2022 |
Management of elderly patients with bone and soft tissue sarcomas: JCOG Bone and Soft Tissue Tumor Study Group.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Doxorubicin; Humans; Ifosfamid | 2022 |
Pregnancy outcomes related to the treatment of sarcomas with anthracyclines and/or ifosfamide during pregnancy.
Topics: Adolescent; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc | 2022 |
First-line chemotherapy in advanced intra-abdominal well-differentiated/dedifferentiated liposarcoma: An EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; | 2022 |
Prediction of the therapeutic efficacy of epirubicin combined with ifosfamide in patients with lung metastases from soft tissue sarcoma based on contrast-enhanced CT radiomics features.
Topics: Epirubicin; Humans; Ifosfamide; Lung Neoplasms; Retrospective Studies; Sarcoma; Soft Tissue Neoplasm | 2022 |
Rare presentation in a rare case of pancreatic extraosseous Ewing's sarcoma: A case report.
Topics: Adolescent; Cyclophosphamide; Dysuria; Epirubicin; Etoposide; Flank Pain; Humans; Ifosfamide; Male; | 2022 |
Rare presentation in a rare case of pancreatic extraosseous Ewing's sarcoma: A case report.
Topics: Adolescent; Cyclophosphamide; Dysuria; Epirubicin; Etoposide; Flank Pain; Humans; Ifosfamide; Male; | 2022 |
Rare presentation in a rare case of pancreatic extraosseous Ewing's sarcoma: A case report.
Topics: Adolescent; Cyclophosphamide; Dysuria; Epirubicin; Etoposide; Flank Pain; Humans; Ifosfamide; Male; | 2022 |
Rare presentation in a rare case of pancreatic extraosseous Ewing's sarcoma: A case report.
Topics: Adolescent; Cyclophosphamide; Dysuria; Epirubicin; Etoposide; Flank Pain; Humans; Ifosfamide; Male; | 2022 |
Epirubicin, cisplatin plus ifosfamide versus standard chemotherapeutic regimens for advanced/unresectable primary thoracic sarcomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Humans; Ifosfamide; Prospecti | 2023 |
Epirubicin, cisplatin plus ifosfamide versus standard chemotherapeutic regimens for advanced/unresectable primary thoracic sarcomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Humans; Ifosfamide; Prospecti | 2023 |
Epirubicin, cisplatin plus ifosfamide versus standard chemotherapeutic regimens for advanced/unresectable primary thoracic sarcomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Humans; Ifosfamide; Prospecti | 2023 |
Epirubicin, cisplatin plus ifosfamide versus standard chemotherapeutic regimens for advanced/unresectable primary thoracic sarcomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Humans; Ifosfamide; Prospecti | 2023 |
Strategies for the Treatment of Infantile Soft Tissue Sarcomas With BCOR Alterations.
Topics: Biomarkers, Tumor; Carboplatin; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Ifosfamide; Infant | 2023 |
Population pharmacokinetic analysis reveals no impact of aprepitant on the pharmacokinetics of ifosfamide, 2-dechloroifosfamide, and 3-dechloroifosfamide.
Topics: Antiemetics; Aprepitant; Humans; Ifosfamide; Retrospective Studies; Sarcoma | 2023 |
Efficacy of second and third lines of treatment in advanced soft tissue sarcomas: a real-world study.
Topics: Dacarbazine; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Retrospective Studies; Sarcoma; Soft Ti | 2023 |
Perspectives of Cell Sensitivity/Resistance Assay in Soft Tissue Sarcomas Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Humans; Ifosfamide; Sarcoma; Soft Tissu | 2023 |
Sarcomas and old age: few options for such a large patient population.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycy | 2019 |
Which goals should we pursue in each line of treatment for advanced soft tissue sarcoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Doxorubicin | 2019 |
Feasibility of Treating Adults with Ewing or Ewing-Like Sarcoma with Interval-Compressed Vincristine, Doxorubicin, and Cyclophosphamide Alternating with Ifosfamide and Etoposide.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cyclophosp | 2020 |
Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Dacarbazine; Doxorubicin; Female; Humans; Ifosfamide | 2020 |
Doxorubicin and Olaratumab Versus Doxorubicin, Ifosfamide, and Mesna for Treatment of Advanced Soft Tissue Sarcomas.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antineoplastic Combined Chemothera | 2020 |
Use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Pediatric Sarcoma for Maximal Oncologic Control.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cisplatin; Cystectomy; Cytoreducti | 2020 |
Reply to Deleterious effect of ifosfamide in leiomyosarcoma: Convergence of weak signals.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Humans; Ifosfamide; Leiomy | 2020 |
Deleterious effect of ifosfamide in leiomyosarcoma: Convergence of weak signals.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Humans; Ifosfamide; Leiomy | 2020 |
Epithelioid Hyalinizing Sarcoma With MGA-NUTM1 Fusion.
Topics: Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Helix Transcription Factors; Cyclop | 2020 |
Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia).
Topics: Adenosarcoma; Anthracyclines; Antineoplastic Agents; Chemotherapy, Adjuvant; Consensus; Dacarbazine; | 2020 |
Modern Management of High-risk Soft Tissue Sarcoma With Neoadjuvant Chemoradiation: A Single-center Experience.
Topics: Adolescent; Adult; Aged; Disease-Free Survival; Female; Humans; Ifosfamide; Kaplan-Meier Estimate; M | 2021 |
Incidence of ifosfamide induced encephalopathy in patients receiving concomitant fosaprepitant.
Topics: Adult; Brain Diseases; Humans; Ifosfamide; Incidence; Morpholines; Retrospective Studies; Sarcoma | 2021 |
Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy.
Topics: Adolescent; Adult; Adult Survivors of Child Adverse Events; Aged; Antineoplastic Agents; Bone Neopla | 2017 |
Long-term Follow-up and Post-relapse Outcome of Patients with Localized Retroperitoneal Sarcoma Treated in the Italian Sarcoma Group-Soft Tissue Sarcoma (ISG-STS) Protocol 0303.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Female; Follow-Up Studies; Humans | 2017 |
Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents, Alkylating; Antineoplastic Co | 2018 |
Long-term Outcomes With Ifosfamide-based Hypofractionated Preoperative Chemoradiotherapy for Extremity Soft Tissue Sarcomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemorad | 2018 |
The Value of Neoadjuvant Chemotherapy in Localized High-Risk Soft-Tissue Sarcoma of the Extremities and Trunk.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Extremities; | 2018 |
Efficacy of mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) in patients with advanced pulmonary pleomorphic carcinoma.
Topics: Adult; Aged; Dacarbazine; Doxorubicin; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Midd | 2018 |
ASO Author Reflections: Chemoradiation for High-Risk Soft Tissue Sarcomas.
Topics: Chemoradiotherapy; Epirubicin; Humans; Ifosfamide; Sarcoma; Soft Tissue Neoplasms | 2018 |
Olaratumab combined with doxorubicin and ifosfamide overcomes individual doxorubicin and olaratumab resistance of an undifferentiated soft-tissue sarcoma in a PDOX mouse model.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Disease Models, Ani | 2019 |
(Neo)adjuvant chemotherapy and interdigitated split-course hyperfractionated radiation in high risk soft tissue sarcoma - Results from a large single-institution series.
Topics: Adult; Aged; Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy | 2019 |
Effect of concurrent chemotherapy and hyperthermia on outcome of preoperative radiotherapy of high-risk soft tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Combined Modal | 2013 |
Chemotherapy influences the pseudocapsule composition in soft tissue sarcomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; | 2014 |
Successful treatment of recurrent pediatric inflammatory myofibroblastic tumor in a single patient with a novel chemotherapeutic regimen containing celecoxib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Child; Humans; Ifosfamide; Lung Neoplasms | 2013 |
Patterns of local recurrence and dose fractionation of adjuvant radiation therapy in 462 patients with soft tissue sarcoma of extremity and trunk wall.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemothera | 2013 |
Embryonal sarcoma of the liver.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chil | 2013 |
Comparison of efficacy and toxicity of first line chemotherapy with or without epirubicin for patients with advanced stage soft tissue sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisp | 2013 |
Targeted imaging of α(v)β(3) expressing sarcoma tumor cells in vivo in pre-operative setting using near infrared: a potential tool to reduce incomplete surgical resection.
Topics: Animals; Diagnostic Imaging; Humans; Ifosfamide; Integrin alphaVbeta3; Lung Neoplasms; Preoperative | 2014 |
Risk-stratified patients with resectable soft tissue sarcoma benefit from epirubicin-based adjuvant chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease-Free Survival; | 2014 |
Neoadjuvant treatment with preoperative radiotherapy for extremity soft tissue sarcomas: long-term results from a single institution in Turkey.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplas | 2014 |
An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center.
Topics: Antineoplastic Agents, Alkylating; Brain Diseases; Cancer Care Facilities; Cisplatin; Female; Humans | 2015 |
[End-stage renal disease after sarcoma therapy - case 3/2014].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Diagnosis, Differential | 2014 |
The Impact of Perioperative Chemotherapy Timing in Conjunction With Postoperative External-Beam Radiation Therapy on Extremity Soft-Tissue Sarcomas Outcome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemorad | 2016 |
Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma.
Topics: Adenoviridae; Animals; Antibiotics, Antineoplastic; Cell Line, Tumor; Cell Survival; Combined Modali | 2015 |
Undifferentiated sarcoma of the orbit with angiomyxoid features.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; Female; Huma | 2014 |
Trabectedin clinical cases: use according to indication in diverse clinical scenarios.
Topics: Anthracyclines; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; C | 2015 |
[Systemic therapy of soft tissue sarcomas].
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Ad | 2015 |
Multivariate Markov models for the conditional probability of toxicity in phase II trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biometry; Calibration; Clinic | 2016 |
Successful Ifosfamide Rechallenge in Soft-Tissue Sarcoma.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Cohort Studies; Databases, Factual; Disease | 2018 |
Adjuvant chemotherapy for soft tissue sarcomas: a 10-year mono-institutional experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2016 |
Successful treatment of primary intracranial sarcoma with the ICE chemotherapy regimen and focal radiation in children.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2016 |
Effective local control of advanced soft tissue sarcoma with neoadjuvant chemoradiotherapy and surgery: A single institutional experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Doxorubici | 2016 |
Severe toxicity of chemotherapy against advanced soft tissue sarcoma in Werner's syndrome: Ifosfamide-induced encephalopathy with central diabetes insipidus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Diabetes Insipidus, Neurogenic; Doxo | 2016 |
Singapore Cancer Network (SCAN) Guidelines for the Initial Evaluation, Diagnosis, and Management of Extremity Soft Tissue Sarcoma and Osteosarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Neoplasms; Chemotherapy, Adjuvan | 2015 |
Combination of Cisplatin, Ifosfamide, and Adriamycin as Neoadjuvant Chemotherapy for Extremity Soft Tissue Sarcoma: A Report of Twenty-Eight Patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin | 2016 |
Primary proximal epithelioid sarcoma of the lung successfully treated with pneumonectomy and adjuvant chemotherapy.
Topics: Adult; Chemotherapy, Adjuvant; Doxorubicin; Hemoptysis; HIV Infections; Humans; Ifosfamide; Lung Neo | 2016 |
Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma.
Topics: Adult; Aged; Carcinoma; Carcinosarcoma; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Human | 2016 |
A successful case of an anaplastic meningioma treated with chemotherapy for soft tissue sarcomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child, Preschool; Doxorubicin; Huma | 2016 |
Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropeni | 2017 |
Efficacy analysis of the aprepitant-combined antiemetic prophylaxis for non-round cell soft-tissue sarcoma patients received adriamycin and ifosfamide therapy.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Do | 2016 |
Dramatic Reduction in Tumor Size During 5 Months of Pazopanib Therapy in Combination With Ifosfamide, Carboplatin, and Etoposide in an Early Infant With Progressive Soft Tissue Sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Ifosfamide; Indazole | 2017 |
VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2017 |
The risk of postoperative complications and functional impairment after multimodality treatment for limb and trunk wall soft-tissue sarcoma: Long term results from a monocentric series.
Topics: Abdominal Wall; Activities of Daily Living; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplast | 2017 |
Undifferentiated sarcoma of the maxillary sinus: report of a rare case in an adult.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Fatal Outc | 2009 |
Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant.
Topics: Antidotes; Antiemetics; Antineoplastic Agents, Alkylating; Aprepitant; Delirium; Female; Humans; Ifo | 2008 |
Childhood undifferentiated embryonal liver sarcoma: clinical features and immunohistochemistry analysis.
Topics: Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protoc | 2008 |
Testicular function of survivors of childhood cancer: a comparative study between ifosfamide- and cyclophosphamide-based regimens.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Biomarkers; Child; Cyclophosphamide; Dose-Resp | 2009 |
FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Deoxycytidine; Doxorubicin; Female; Fluorodeoxyglucose F18; Follow-U | 2009 |
Primary tumor necrosis predicts distant control in locally advanced soft-tissue sarcomas after preoperative concurrent chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Doxo | 2010 |
Late effects surveillance system after childhood cancer in Germany, austria and parts of Switzerland--update 2009.
Topics: Adolescent; Aftercare; Antineoplastic Combined Chemotherapy Protocols; Austria; Bone Neoplasms; Card | 2009 |
Aprepitant-associated ifosfamide neurotoxicity.
Topics: Adult; Antidepressive Agents; Antineoplastic Agents, Alkylating; Aprepitant; Case-Control Studies; F | 2010 |
[Positron emission tomography as a tool for early prediction of therapy outcome in soft tissue sarcoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Doxorubicin; Etoposide; | 2009 |
Should patients with high-risk soft tissue sarcoma receive adjuvant chemotherapy?
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Mod | 2009 |
Long-term evaluation of Ifosfamide-related nephrotoxicity in children.
Topics: Antineoplastic Agents, Alkylating; Child; Follow-Up Studies; Humans; Ifosfamide; Kidney; Kidney Dise | 2009 |
Stroke due to undifferentiated aortic intimal sarcoma with disseminated metastatic lesions.
Topics: Antineoplastic Agents; Aorta; Chemotherapy, Adjuvant; Combined Modality Therapy; Doxorubicin; Echoca | 2009 |
Undifferentiated sarcoma of the thyroid in a child.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dactinomycin; | 2010 |
Ifosfamide encephalopathy associated with chemotherapy for musculoskeletal sarcomas: incidence, severity, and risk factors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Cisplatin; Dose-R | 2010 |
Bevacizumab in combination with sequential high-dose chemotherapy in solid cancer, a feasibility study.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera | 2010 |
[Lung metastases of epithelioid sarcoma revealed by bilateral spontaneous pneumothorax: a pathological diagnosis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Doxorubicin; Drainage; Fatal Outc | 2010 |
Extraskeletal Ewing's sarcoma family of tumours in adults: analysis of 57 patients from a single institution.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dactin | 2010 |
Ifosfamide-induced encephalopathy in patients with uterine sarcoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Female; Humans; Ifosfamide; Methylene Blue; Middle Aged; Ne | 2010 |
Definitive radiotherapy and single-agent radiosensitizing ifosfamide in patients with localized, irresectable soft tissue sarcoma: a retrospective analysis.
Topics: Adult; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Female; Follow-Up Studies; Huma | 2010 |
Prolonged 14-day continuous infusion of high-dose ifosfamide with an external portable pump: feasibility and efficacy in refractory pediatric sarcoma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Female; Humans; Ifosfamide; | 2010 |
Continuously improving ifosfamide/mesna: a winning combination.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Humans; Ifosfamide; Mesna; Sarcoma | 2010 |
Large primary cardiac sarcoma on the left ventricular free wall: is total excision contraindicated?
Topics: Aged; Antineoplastic Agents, Alkylating; Cardiac Surgical Procedures; Cardiac Tamponade; Chemotherap | 2010 |
Five-year results from a Scandinavian sarcoma group study (SSG XIII) of adjuvant chemotherapy combined with accelerated radiotherapy in high-risk soft tissue sarcoma of extremities and trunk wall.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Doxorubicin; Ex | 2011 |
Role of palliative chemotherapy in advanced epithelioid sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Fema | 2012 |
Determinants of toxicity, patterns of failure, and outcome among adult patients with soft tissue sarcomas of the extremity and superficial trunk treated with greater than conventional doses of perioperative high-dose-rate brachytherapy and external beam r
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Chemo | 2011 |
Ifosfamide nephropathy in patients with sarcoma.
Topics: Adolescent; Adult; Age Distribution; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Coh | 2011 |
High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Disease-Free Survival; Female; Human | 2011 |
Stromal sarcoma of the breast with lung metastases showing a clinical complete response to doxorubicin plus ifosfamide treatment: report of a case.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Doxorubicin; Female; Humans; Ifosfamide; Lung Neopla | 2011 |
A case of intimal sarcoma of the pulmonary artery successfully treated with chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Doxorubicin; Female; Humans; | 2012 |
Neoadjuvant and adjuvant chemotherapy with modified mesna, adriamycin, ifosfamide, and dacarbazine (MAID) regimen for adult high-grade non-small round cell soft tissue sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Di | 2013 |
Modified vaccinia virus Ankara delivers a robust surrogate marker for immune monitoring to sarcoma cells even if cells are being exposed to chemotherapy and heat treatment.
Topics: Antigen Presentation; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Green Fluo | 2012 |
Maintenance therapy in the treatment of sarcoma.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Disease-Free Survival; Doxorubicin; Humans; Ifosfam | 2011 |
Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Epi | 2013 |
Spindle cell rhabdomyosarcoma of the prostate.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dactinomycin; Doxorubicin; Humans; Ifosfamide; Magne | 2013 |
Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma.
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents; Epirubicin; Female; Granulocyte Colony-S | 2013 |
Salvage chemotherapy for advanced sarcoma patients: a single-institution experience survey.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dacarbazine; D | 2002 |
Cancer-related thrombotic microangiopathy secondary to Von Willebrand factor-cleaving protease deficiency.
Topics: ADAM Proteins; ADAMTS13 Protein; Adenocarcinoma; Anemia, Hemolytic; Antineoplastic Combined Chemothe | 2002 |
Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modali | 2002 |
[Continuous-infusion high dose ifosfamide as salvage treatment for pre-treated soft tissue sarcoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Dose-Response Relationship, Drug; Female | 2002 |
High-grade extremity soft tissue sarcomas: factors predictive of local recurrence and its effect on morbidity and mortality.
Topics: Amputation, Surgical; Antineoplastic Agents; Antineoplastic Protocols; Combined Modality Therapy; Do | 2003 |
High-grade extremity soft tissue sarcomas: factors predictive of local recurrence and its effect on morbidity and mortality.
Topics: Amputation, Surgical; Antineoplastic Agents; Antineoplastic Protocols; Combined Modality Therapy; Do | 2003 |
High-grade extremity soft tissue sarcomas: factors predictive of local recurrence and its effect on morbidity and mortality.
Topics: Amputation, Surgical; Antineoplastic Agents; Antineoplastic Protocols; Combined Modality Therapy; Do | 2003 |
High-grade extremity soft tissue sarcomas: factors predictive of local recurrence and its effect on morbidity and mortality.
Topics: Amputation, Surgical; Antineoplastic Agents; Antineoplastic Protocols; Combined Modality Therapy; Do | 2003 |
Gastrointestinal stromal tumors: should they be treated with the same systemic chemotherapy as other soft tissue sarcomas?
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Gastrointestinal Neopla | 2003 |
Chemotherapy of soft tissue sarcoma--a clinical evaluation of treatment over ten years.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dacarbazin | 2003 |
Use of sarcoma-based chemotherapy in a case of congenital mesoblastic nephroma with liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposide; Humans; Ifosfamide; Infant; | 2003 |
Has "MAID" made it in the management of high-risk soft-tissue sarcoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Doxorubicin; Ex | 2003 |
Alveolar soft part sarcoma in Japan: multi-institutional study of 57 patients from the Japanese Musculoskeletal Oncology Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisp | 2003 |
Extended total sacrectomy and reconstruction for sacral tumor.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combi | 2004 |
Influence of age upon Ifosfamide-induced nephrotoxicity.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Do | 2004 |
Salvage surgical resection after high-dose ifosfamide (HDIF) based regimens in advanced soft tissue sarcoma (ASTS): a potential positive selection bias--a study of the Spanish group for research on sarcomas (GEIS).
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Bias; Clinical Trials, | 2004 |
Sarcomas of the head and neck. Results from the treatment of 25 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2005 |
Successful treatment of pulmonary artery sarcoma by a two-drug combination chemotherapy consisting of ifosfamide and epirubicin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Humans; Ifosfamide; Progno | 2005 |
Doxorubicin and ifosfamide-mesna in advanced and recurrent uterine sarcomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Ifosfamide; Mesn | 2005 |
Decision-theoretic designs for dose-finding clinical trials with multiple outcomes.
Topics: Algorithms; Anti-HIV Agents; Antineoplastic Agents, Alkylating; Child, Preschool; Clinical Trials, P | 2006 |
Multimodal treatment using surgery, radiotherapy, and chemotherapy in a patient with a perivascular epithelioid cell tumor of the uterus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Doxorubicin; Epith | 2005 |
Preoperative chemotherapy and split-course radiation therapy for patients with localized soft tissue sarcomas: home run, base hit, or strike out?
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; | 2006 |
Langerhans cell sarcoma.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Disease-Free Survival; Doxoru | 2006 |
Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System.
Topics: Abdomen; Adolescent; Age Factors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemoth | 2007 |
Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: a report from the late effects surveillance system.
Topics: Adolescent; Antineoplastic Agents; Carboplatin; Child; Child, Preschool; Cisplatin; Creatinine; Fema | 2007 |
Mediastinal follicular dendritic cell sarcoma involving bone marrow: a case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; Dendritic Cells, Fol | 2006 |
[A case of the treatment in an adult with hepatic undifferentiated (embryonal) sarcoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Dactinomycin; Doxorubicin; Female; Humans; Ifosfamid | 2007 |
Thyroid function in paediatric and young adult patients after sarcoma therapy: a report from the Late Effects Surveillance System.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Dactinomycin; F | 2007 |
Anthracycline-based adjuvant chemotherapy in early-stage uterine sarcomas: long-term results of a single institution experience.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 2007 |
Prognosis of radiation-induced bone sarcoma is similar to primary osteosarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combin | 2007 |
Ifosfamide-related encephalopathy in elderly patients : report of five cases and review of the literature.
Topics: Abdominal Neoplasms; Aged; Antidotes; Antineoplastic Agents, Alkylating; Antineoplastic Combined Che | 2007 |
Does ifosfamide affect gonadal function?
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Female; Humans; Ifosf | 2008 |
[Responses of 109 adult soft tissue sarcoma patients to chemotherapy].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemothe | 2007 |
F-18 FDG PET and PET/CT evaluation of response to chemotherapy in bone and soft tissue sarcomas.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Female; Fluorodeoxyglucose F18 | 2008 |
Mediastinal sarcoma with deviated tracheal anatomy.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Doxorubicin; Female; Humans; Ifosfam | 2008 |
Histologic alterations from neoadjuvant chemotherapy in high-grade extremity soft tissue sarcoma: clinicopathological correlation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Disease-Free Surviva | 2008 |
Experimental basis and clinical experience with non-cross-resistant combinations in solid tumours.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bro | 1984 |
High-dose ifosfamide by infusion with mesna in advanced soft tissue sarcoma.
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Female; Humans; Ifosfamide; Male; Mercaptoethanol; Mesna; | 1983 |
High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma.
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; Human | 1983 |
Ifosfamide in combination chemotherapy for sarcomas and testicular carcinomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; | 1983 |
Treatment of advanced, high-grade soft-tissue sarcoma with ifosfamide and continuous-infusion etoposide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Etoposide; Female; F | 1995 |
Comparison of continuous infusion and bolus administration of ifosfamide in children.
Topics: Adolescent; Child; Child, Preschool; Female; Humans; Ifosfamide; Infant; Infusion Pumps; Infusions, | 1995 |
Mesna, doxorubicin, ifosfamide, and dacarbazine chemotherapy for ovarian mixed müllerian sarcoma: report of four cases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Combined Modality Therapy; Da | 1995 |
The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion.
Topics: Adolescent; Child; Child, Preschool; Chromatography, Thin Layer; Female; Half-Life; Humans; Ifosfami | 1995 |
[Peri-operative chemotherapy during resection of pulmonary metastases of sarcoma].
Topics: Adult; Combined Modality Therapy; Female; Humans; Ifosfamide; Infusions, Intravenous; Intraoperative | 1994 |
Ifosfamide and carboplatin combined with 41.8 degrees C whole-body hyperthermia in patients with refractory sarcoma and malignant teratoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Combine | 1994 |
Depletion of total cysteine, glutathione, and homocysteine in plasma by ifosfamide/mesna therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; C | 1994 |
Renal function in children and adolescents following 72 g/m2 of ifosfamide.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Female; Glomerular Filtrat | 1994 |
Discussion: the Satellite Symposium on "Ifosfamide in the treatment of sarcomas" of the 6th European Conference on Clinical Oncology and Cancer Nursing, Firenze, October 27, 1991.
Topics: Humans; Ifosfamide; Sarcoma | 1993 |
Validity and usefulness of human tumor models established by intratibial cell inoculation in nude rats.
Topics: Animals; Bone Neoplasms; Cell Line; Doxorubicin; Female; Femur; Ifosfamide; Male; Melanoma, Amelanot | 1994 |
Ifosfamide-induced hyperpigmentation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Etoposide; Female; Humans; | 1994 |
Selection of large and objectively measurable target lesions in EORTC phase II trials: impact on recruitment and response rate. EORTC Soft Tissue and Bone Sarcoma Group (STBSG).
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Doxorubicin; Gra | 1993 |
[Intensive chemotherapy for alveolar soft part sarcoma with lung metastasis in a child].
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cisplatin; Cyclophosphamide; Dactinomycin; Do | 1993 |
Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children.
Topics: Adolescent; Child; Child, Preschool; Drug Administration Schedule; Female; Humans; Ifosfamide; Infan | 1993 |
Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Grou
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Disea | 1993 |
Determination of the urinary excretion of ifosfamide and its phosphorated metabolites by phosphorus-31 nuclear magnetic resonance spectroscopy.
Topics: Adult; Aged; Humans; Ifosfamide; Magnetic Resonance Spectroscopy; Middle Aged; Phosphorus; Phosphory | 1993 |
[Toxic effects of ifosfamide in the treatment of bone and soft tissue sarcomas].
Topics: Administration, Intravesical; Adolescent; Adult; Aluminum Hydroxide; Bone Neoplasms; Child, Preschoo | 1993 |
Treatment results obtained in metastatic soft-tissue sarcoma with a combination of doxorubicin and dacarbazine or doxorubicin and ifosfamide.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; F | 1993 |
Ifosfamide combination regimens for soft-tissue sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposide; Fem | 1993 |
Ifosfamide in the treatment of soft-tissue sarcomas: experience at the West German Tumor Center, Essen.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Dru | 1993 |
A pilot study of rapidly alternating epirubicin/dacarbazine and ifosfamide as first-line therapy for metastatic soft-tissue sarcoma in adults.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedu | 1993 |
Ifosfamide plus epirubicin at escalating doses in the treatment of locally advanced and/or metastatic sarcomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone | 1993 |
Preoperative systemic etoposide/ifosfamide/doxorubicin chemotherapy combined with regional hyperthermia in high-risk sarcoma: a pilot study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1993 |
The use of recombinant human granulocyte-macrophage colony-stimulating factor with combination chemotherapy in the treatment of advanced adult soft-tissue sarcomas: early results from the EORTC Soft-Tissue and Bone Sarcoma Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Doxorubicin; Fema | 1993 |
A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; beta 2-Microglobulin; Child; Child, Preschool; | 1995 |
High-dose ifosfamide by infusion with Mesna in advanced refractory sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Doxorubicin; Female; | 1996 |
Ifosfamide in sarcomas: is it a schedule-dependent drug?
Topics: Doxorubicin; Drug Administration Schedule; Humans; Ifosfamide; Sarcoma | 1996 |
Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agen | 1996 |
[Ifosfamide in pediatric malignancy--experiences in the Northern Israel Oncology Center].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; C | 1996 |
The use of combined chemotherapy for the treatment of advanced sarcoma of the uterus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; C | 1996 |
Increasing 4'-epidoxorubicin and fixed ifosfamide doses plus granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a pilot study.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemo | 1997 |
Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis.
Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Breast Neoplasms; Carcinoma, Transitional Cell; D | 1997 |
Treatment of childhood post-irradiation sarcoma of bone in cancer survivors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; | 1997 |
The use of a systemic therapy checklist improves the quality of data acquisition and recording in multicentre trials. A study of the EORTC Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Data Collection; Doxorubicin; Granul | 1997 |
[The effects of high-dose ifosfamide in the treatment of bone and soft tissue sarcomas].
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Drug Administration Sch | 1997 |
Treatment of children with relapsed soft tissue sarcoma: report of the German CESS/CWS REZ 91 trial.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 1998 |
Toxicity of chemotherapeutical protocols in the treatment of uterine sarcomas (Vincristine, actinomycin D, Cyclophosphamide VAC versus ifosfamide).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Ad | 1998 |
[Chemotherapy for pulmonary metastases of soft tissue sarcoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Administra | 1998 |
Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Cyclophos | 1998 |
High-dose ifosfamide for soft tissue sarcomas: set the scene, or senescence?
Topics: Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Dose-Response Relationship, Drug; Human | 1998 |
Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biot | 1998 |
Treatment of intermediate risk rhabdomyosarcoma and undifferentiated sarcoma with alternating cycles of vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclopho | 1998 |
Treatment of soft-tissue sarcomas: high-dose ifosfamide or combination of ifosfamide and etoposide?
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 1999 |
Advanced soft tissue sarcoma: how many more trials with anthracyclines and ifosfamide?
Topics: Antibiotics, Antineoplastic; Humans; Ifosfamide; Randomized Controlled Trials as Topic; Sarcoma | 1999 |
Ifosfamide: new idications-new dose strength. Limited evidence of effectiveness.
Topics: Adult; Antineoplastic Agents, Alkylating; Breast Neoplasms; Child; Clinical Trials as Topic; Cycloph | 1998 |
Radiation therapy for consolidation of metastatic or recurrent sarcomas in children treated with intensive chemotherapy and stem cell rescue. A feasibility study.
Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow | 1999 |
[Neoadjuvant radiochemotherapy in soft tissue sarcomas. Optimization of local functional tumor control].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modali | 1999 |
Comments on: Should patients with advanced soft tissue sarcomas be treated with chemotherapy? Arbiter: Van Hoesel, Q.G.C.M. Eur J Cancer 1998, 34(7), 964-965.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Ifosfamide; Sarcoma | 1999 |
Role of the combination of ifosfamide and etoposide in the treatment of soft tissue sarcomas.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 1999 |
Efficacy of docetaxel in the second-line treatment of locally advanced or metastatic soft tissue sarcoma after failure of chemotherapy with anthracycline or ifosfamide.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, | 1999 |
A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Div | 1999 |
Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Co | 2000 |
Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2000 |
Nephrotoxicity of ifosfamide, carboplatin and etoposide (ICE) alone or combined with extracorporeal or radiant-heat-induced whole-body hyperthermia.
Topics: Adolescent; Adult; Aged; Albuminuria; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phyt | 2000 |
Assessment of systemic toxicity in children receiving chemotherapy with cyclosporine for sarcoma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplasti | 2000 |
Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Female; Humans; Ifosfamide; | 2000 |
Impact of neoadjuvant chemotherapy on postoperative morbidity in soft tissue sarcomas.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy | 2000 |
Large, deep, high-grade extremity sarcomas: treating tumors of the flexor fossae.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Combined Modality Therapy; Dose Fractionatio | 1999 |
Treatment comparisons based on two-dimensional safety and efficacy alternatives in oncology trials.
Topics: Antineoplastic Agents, Alkylating; Biometry; Clinical Trials as Topic; Humans; Ifosfamide; Leukemia, | 1999 |
Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; C | 2001 |
Adult testicular sarcoma: presentation, evaluation, and treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Humans; Ifosfamide; Male; Middle Aged; | 2002 |
Alterations in intestinal permeability following the intensified polydrug-chemotherapy IFADIC (ifosfamide, Adriamycin, dacarbazine).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Female; Human | 2002 |
Systemic therapy for advanced soft-tissue sarcomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Doxorubicin; G | 2002 |
The oncogenic effect of immunosuppressive (cytotoxic) agents in (NZB x NZW) mice. II. Emergence of tumors in young animals treated with azathioprine and ifosfamide, including a histologic assessment of the neoplasms.
Topics: Animals; Azathioprine; Carcinogens; Carcinoma; Cyclophosphamide; Female; Hyperplasia; Ifosfamide; Ly | 1979 |
High dose chemotherapy with ABMT in soft tissue sarcomas: a report of 22 cases.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chil | 1992 |
Epirubicin/dacarbazine rapidly alternated with ifosfamide in the treatment of metastatic soft tissue sarcomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Epirubicin; Fe | 1992 |
A new approach to the study of ifosfamide metabolism by the analysis of human body fluids with 31P nuclear magnetic resonance spectroscopy.
Topics: Body Fluids; Humans; Ifosfamide; Magnetic Resonance Spectroscopy; Sarcoma; Soft Tissue Neoplasms | 1992 |
Extra-uterine endometrial stromal sarcoma with DNA flow cytometric analysis.
Topics: Adult; Colonic Neoplasms; DNA; Doxorubicin; Endometriosis; Female; Flow Cytometry; Follow-Up Studies | 1992 |
Epirubicin plus ifosfamide and dacarbazine (EID) in advanced soft tissue sarcomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Epirubicin; Follow-U | 1992 |
Clinical pharmacokinetics of ifosfamide in combination with N-acetylcysteine.
Topics: Acetylcysteine; Agranulocytosis; Bone Marrow; Humans; Ifosfamide; Sarcoma | 1992 |
Ifosfamide vs cyclophosphamide in cancer therapy.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cyclophosphamide; Female; Genital Neoplasms, | 1991 |
Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report.
Topics: Acute Kidney Injury; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Presc | 1991 |
Local hyperthermia enhances cyclophosphamide, ifosfamide and cis-diamminedichloroplatinum cytotoxicity on human-derived breast carcinoma and sarcoma xenografts in nude mice.
Topics: Animals; Body Temperature; Breast Neoplasms; Cisplatin; Combined Modality Therapy; Cyclophosphamide; | 1992 |
Improvement of local control by regional hyperthermia combined with systemic chemotherapy (ifosfamide plus etoposide) in advanced sarcomas: updated report on 65 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chi | 1991 |
Mesna, doxorubicin, ifosfamide, dacarbazine (MAID) regimen for adults with advanced sarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Ther | 1990 |
Interstitial pneumonitis associated with ifosfamide therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Female; Humans; Ifosfamide | 1990 |
Early phase II Gynecologic Oncology Group experience with ifosfamide/mesna in gynecologic malignancies.
Topics: Antineoplastic Agents; Carcinoma; Drug Evaluation; Female; Humans; Ifosfamide; Mercaptoethanol; Mesn | 1990 |
Ifosfamide plus etoposide combined with regional hyperthermia in patients with locally advanced sarcomas: a phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Co | 1990 |
Bioavailability of subcutaneous ifosfamide and feasibility of continuous outpatient application in cancer patients.
Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Drug | 1990 |
Chemotherapy of metastatic soft tissue sarcoma with a combination of adriamycin and DTIC or adriamycin and ifosfamide.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Dos | 1990 |
Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evaluatio | 1990 |
Epirubicin and ifosfamide in patients with refractory breast cancer and other metastatic solid tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance; Epirubicin; Femal | 1990 |
Primary chemosensitivity and secondary drug resistance of xenografted soft part sarcomas.
Topics: Animals; Bleomycin; Doxorubicin; Drug Resistance; Female; Histiocytoma, Benign Fibrous; Humans; Ifos | 1989 |
Clinical studies of ifosfamide/mesna at St Jude Children's Research Hospital, 1983-1988.
Topics: Adolescent; Child; Child, Preschool; Drug Evaluation; Humans; Ifosfamide; Infant; Mercaptoethanol; M | 1989 |
Mesna: continuous or bolus infusion?
Topics: Drug Administration Schedule; Humans; Ifosfamide; Infusions, Intravenous; Injections, Intravenous; M | 1989 |
Phase II study of ifosfamide-etoposide-mesna in adults with advanced nonosseous sarcomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Etoposide; | 1989 |
Characterization and chemotherapy of human soft tissue sarcoma (STS) lines grown in nude mice.
Topics: Animals; Cyclophosphamide; Doxorubicin; Female; Fibrosarcoma; Histiocytoma, Benign Fibrous; Humans; | 1989 |
Combination chemotherapy with doxorubicin, dacarbazine, and ifosfamide in advanced adult soft tissue sarcoma. Canadian Sarcoma Group--National Cancer Institute of Canada Clinical Trials Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; F | 1989 |
Ifosfamide/mesa and encephalopathy.
Topics: Brain Diseases; Carcinoma, Small Cell; Cyclophosphamide; Female; Humans; Ifosfamide; Lung Neoplasms; | 1985 |
Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma.
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Pre | 1986 |
Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Child; Comb | 1987 |
Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Child; Comb | 1987 |
Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Child; Comb | 1987 |
Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Child; Comb | 1987 |
A phase II study of ifosfamide/mesna with doxorubicin for adult soft tissue sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Doxorubicin; Drug Ev | 1988 |
A phase I-II study of ifosfamide in combination with adriamycin in the treatment of adult soft tissue sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evaluatio | 1988 |
[Results of whole lung irradiation and chemotherapy in comparison with partial lung irradiation in metastasizing, undifferentiated soft tissue sarcomas].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 1988 |
Ifosfamide: an old drug recently rediscovered.
Topics: Cyclophosphamide; Drug Evaluation; Female; Humans; Ifosfamide; Male; Neoplasms; Sarcoma; Soft Tissue | 1988 |
Phase II study of ifosfamide + adriamycin in advanced soft tissue sarcoma in adults. A preliminary analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evaluatio | 1986 |
Alternatives to CYVADIC combination therapy of soft tissue sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dacarbazin | 1986 |
The role of ifosfamide in paediatric soft tissue sarcomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Dactinomycin; Drug Evaluation; Humans; Ifosfa | 1986 |
A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people.
Topics: Adolescent; Adult; Bone Neoplasms; Child; Child, Preschool; Cyclophosphamide; Drug Evaluation; Femal | 1986 |
Alternatives to CYVADIC-combination therapy of soft tissue sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dacarbazin | 1985 |
Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cystitis; Drug | 1985 |